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ABSTRACT 
FACULTY OF MEDICINE, HEALTH AND LIFE SCIENCES 
SCHOOL OF BIOLOGICAL SCIENCES 
Doctor of Philosophy 
 
DECONTAMINATION OF PRIONS, PRION ASSOCIATED AMYLOID AND 
INFECTIVITY FROM SURGICAL STAINLESS STEEL – IMPLICATIONS  
FOR THE RISK OF IATROGENIC TRANSMISSION OF CJD 
By Robert Howlin 
 
The physicochemical nature of the infectious agent in prion diseases creates a 
significant challenge for decontamination services. It has been shown to be both resistant to 
standard methods of decontamination, used to inactivate viruses and bacteria, and to associate 
avidly with surgical stainless steel. Moreover, the pathophysiology of the variant, iatrogenic 
and sporadic forms of Creutzfeldt Jakob Disease (CJD) suggests deposition of the infectious 
agent across a wide range of extraneural, lymphoid tissues, as well as in the skeletal muscle 
and blood. Coupled with the potential for asymptomatic carriers, there is a significant risk of 
iatrogenic transmission of CJD through both neurosurgical procedures and standard surgery.  
This PhD study was undertaken in order to improve methods of instrument 
decontamination and to evaluate prion detection techniques and their applicability for the 
assessment of prion inactivation and removal. The project has provided relevant, critical 
assessment of hospital decontamination procedures, in addition to guidance on how working 
protocols should be improved to provide a cleaner and safer end product for the patient. 
Moreover, laboratory studies have been performed to evaluate current methods of prion 
decontamination in the context of hospital procedures for instrument reprocessing. Challenges 
faced by sterile service departments, such as soil drying and surface degradation, have been 
addressed and their impact on the risk of iatrogenic transmission of prions has been 
investigated. Critically, the use of a fluorescent amyloid fluorophore for the detection of prion 
associated amyloid as a marker for disease permitted the investigation of the role of amyloid 
in infectious disease under denaturing conditions. Correlation of this detection technique with 
the identification of PrP
res by Western blot and infectious disease suggested that, whilst 
fluorescent detection of prion associated amyloid was more sensitive than Western blot, PrP
res 
detection was more specific relative to infectivity. Improved fluorophores, with greater 
sensitivity, have been evaluated which will enhance in situ detection of prions in the future.    iii 
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PBS  Phosphate Buffered Saline 
PET  Positron emission tomography 
PK  Proteinase K 
PMCA  Protein Misfolding Cyclic Amplification 
PRNP  Prion protein gene 
PrP
27 30  Prion Protein 27 30 fragment 
PrP
c  cellular Prion Protein 
PrP
res  Pathological conformer of the prion protein 
R/H/L  Arginine/Histidine/Leucine 
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Rec.MoPrP  Recombinant Mouse Prion Protein 
SAF  Scrapie Associated Fibrils   xviii 
sCJD  sporadic Creutzfeldt Jakob Disease 
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ThT  Thioflavin T 
TME  Transmissible Mink Encephalopathy 
TSE  Transmissible Spongiform Encephalopathy 
UK  United Kingdom 
vCJD  variant Creutzfeldt Jakob Disease 
VHP  Vaporised Hydrogen Peroxide 
VRQ  Valine/Arginine/Glutamine 
VV  Valine Valine homozygous 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     1   
 
 
 
 
 
 
 
 
CHAPTER 1 
 
 
 
INTRODUCTION TO PRION DISEASES 
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1.1. INTRODUCTION 
 
  Transmissible spongiform encephalopathies (TSEs) or prion diseases are a 
collection of severe and uniformly terminal neurodegenerative disorders affecting many 
mammalian species (Table 1). The central concept behind prion disease propagation and 
pathogenesis is the posttranslational conversion of the normal, host encoded cellular 
protein, PrP
c, to an abnormal isoform PrP
res as set out by the protein only hypothesis 
(Prusiner, 1982; Prusiner, 1998). This transition involves conformational changes in the 
absence of covalent modification, conferring PrP
res with partial resistance to proteolytic 
degradation and detergent insolubility (McKinley et al., 1983; Weissmann, 2004). The 
protein only hypothesis states that it is the pathological conformer PrP
res, devoid of nucleic 
acid, that is responsible for and potentially the sole component of transmissible disease.  
 
 
1.2. THE PRIONOPATHIES AND THEIR EPIDEMIOLOGY 
 
Although relatively rare when compared to neurological disorders such as 
Alzheimer’s and Parkinson’s disease, Creutzfeldt Jakob disease (CJD) is the most common 
human TSE (Prusiner, 1998). Aetiologically, human prion diseases can be grouped into 
three categories: sporadic, acquired and inherited (Collinge, 1999). The majority of cases 
(~ 85 %) are sporadic, with sporadic CJD the most prevelant. Countries carrying out 
surveillance report a 0.6 – 1.2 x 10
6 incidence rate, with equal occurrence in males and 
females (Ladogana et al., 2005). Cases with a genetic predisposition, inherited as an 
autosomal dominant trait, such as fatal familial insomnia (FFI) or familial CJD (fCJD) 
account for around 15 % of the total reported cases. Acquired cases, including kuru, 
variant and iatrogenic forms of CJD (vCJD and iCJD, respectively) are thought to be 
relatively infrequent in the general population (Wadsworth et al., 2008a).  
Sporadic CJD was the first classified prionopathy. Described in 1921 by German 
neurologists Hans Gerhard Creutzfeldt and Alfons Maria Jakob, they reported the case of a 
22 year old woman presenting with dementia, tremors, spasticity, ataxia and possibly 
myoclonus (Belay, 1999). To this date the aetiology of sCJD remains unclear with no 
exogenous or endogenous causes identified.  
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Kuru represents the only human epidemic of a prionopathy to date. The disease was 
isolated within the Forè linguistic group of the Eastern Highlands of Papua New Guinea and, 
to a lesser extent, neighbouring tribal groups into which the Forè intermarried (Gajdusek & 
Zigas, 1957; Will, 2003). Molecular and neuropathological data from transmission studies 
suggest that kuru originated from the chance transumption of an individual with sCJD and was 
propagated through cannibalistic mortuary feasts, undertaken as a mark of respect and 
mourning (Wadsworth et al., 2008b; Whitfield et al., 2008). In mortuary rituals, the 
consumption of internal organs, including the brain, was undertaken by the women and 
children but rarely by males older than six or eight, which would explain the grouping of 
disease primarily in the young tribal women and children (Whitfield et al., 2008). In excess of 
2,700 cases of kuru have been identified since 1957 within a total population of 36,000 people 
(Will, 2003). There is no evidence of vertical transmission of disease as children born after the 
cessation of endocannibalism in 1956 and those born after 1959 to mothers incubating the 
disease were unaffected (Collinge et al., 2006). 
Kuru represented the first demonstration of the transmission of a prionopathy by the 
oral route but was not the last (Gajdusek et al., 1966; Gajdusek et al., 1967). The large scale 
epidemic of bovine spongiform encephalopathy (BSE) throughout the United Kingdom in the 
late eighties and nineties cost the British government four billion pounds. An estimated 
180,000 cattle were confirmed as carriers of the disease and slaughtered, with a further one to 
three million likely to have been infected but destroyed before showing symptoms (Smith & 
Bradley, 2003). The peak of the outbreak came in 1992 when 37,280 cases were confirmed 
and others documented in twenty four countries worldwide (data from World Organisation for 
Animal Health). The initial cause of the BSE epidemic is unknown but was propagated in 
British cattle by the use of BSE contaminated meat and bone meal (MBM), a high protein 
supplement feed produced by the rendering of waste material from mixed species. The 
termination of MBM feed in cattle farming had a dramatic effect on the rate of BSE incidence 
suggesting that, unlike scrapie which is endemic in UK herds, BSE transmission does not 
occur horizontally.  
As a result of the noted similarity of neuropathological lesions in BSE and scrapie 
several hypotheses suggest that BSE arose from the survival of scrapie or BSE adapted scrapie 
to the MBM rendering process, although studies have demonstrated inactivation of the 
infectious agent in BSE and scrapie under rendering procedures (Taylor et al., 1995; Taylor et 
al., 1997; Wells et al., 1987). Moreover, whilst transmission of BSE to sheep has been 
successful through oral challenge, the BSE strain is biologically and molecularly distinct from     5   
scrapie strains (Bruce, 2003; Foster et al., 1994). In addition, under the confines of this 
hypothesis, it is unclear why BSE did not present in UK cattle prior to 1985 given that MBM 
has been used in cattle farming since the 1920s and that scrapie has been endemic in the UK 
over several hundred years. However, it has been noted that, in addition to the expansion of 
the UK sheep population, which may have increased the general incidence of scrapie, 
rendering procedures had been altered in the late 1970s and early 1980s, corresponding with 
the known incubation period of BSE (~ 5 years) and its emergence in 1985 (Wilesmith et al., 
1988; Wilesmith et al., 1991). Alternatively, it is plausible that BSE originated sporadically at 
an initially low frequency, although there is no direct evidence to support this theory. 
In 1996 a new variant form of CJD (vCJD) was classified, confirming BSE as a 
zoonosis and creating widespread public health concern (Will et al., 1996). Biochemical and 
histopathological data confirmed that vCJD was manifested in humans as a result of the 
transmission of BSE prions through consumption of infected meat products (Figure 1) (Bruce 
et al., 1997; Collinge et al., 1996; Hill et al., 1997).  
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Reviews of archival material have been unable to isolate a case with a 
neuropathological appearance similar to vCJD prior to 1996 (Budka et al., 2002). For 
example, variant CJD can be separated pathologically from kuru by a markedly increased 
prion protein load in all areas of the central nervous system (CNS) such as frontal cortex, basal 
ganglia, thalamus and cerebellar molecular layers, with the exception of the cerebellar 
granular layer (McLean, 2008). In areas such as the basis pontex, spinal gray matter and 
substantia gelatinosa where levels of prion protein deposition are low in vCJD, they remain 
substantially increased relative to kuru. Studies on the transmission characteristics and 
neuropathology of vCJD have also highlighted distinct similarities between BSE and vCJD but 
not sCJD in transgenic mice expressing the bovine prion protein (Scott et al., 1999). Variant 
CJD can be distinguished from sporadic CJD by a number of characteristics, primarily age of 
death; an average of 28 years old in vCJD relative to 65 years old in sCJD (Murray et al., 
2008). Moreover, the disease duration is typically longer in vCJD (13 months against 4 
months in sCJD) and, whilst there is an overlap in characteristics, vCJD cases are typically 
clinically homogenous relative to sCJD which is classically more contrasting (Spencer et al., 
2002). In vCJD early clinical course is largely dominated by psychiatric symptoms such as 
anxiety, insomnia or withdrawal within the first 4 months. In contrast, neurological symptoms 
such as headache, tiredness, sleep or appetite disturbance, depression, altered personality and 
nervousness often predate the main illness in sCJD (Kubler et al., 2003). However, this is 
complicated by the fact that approximately 12 % of sporadic CJD patients are reported for 
epidemiology studies based on psychiatric evaluation  and around 35 % of vCJD cases have 
been reported with neurological symptoms, primarily memory loss and constant pain (Collins 
et al., 2004a; Kubler et al., 2003; Spencer et al., 2002). Moreover, with regards to patient age, 
seven cases of sCJD have been reported in teenagers in the United States of America and 
Canada, as well as France, Germany, Poland and two in the United Kingdom (Berman et al., 
1988; Brown et al., 1985; Kulczycki et al., 1991; Monreal et al., 1981; Murray et al., 2008; 
Petzold et al., 2004). Conversley, the first documented case of vCJD in Japan was diagnosed 
recently in a 48 year old male (Shinde et al., 2009) 
  In 2008 there were 25 reported cases of BSE in the United Kingdom (data from World 
Organisation for Animal Health) and a decline in total cases of between 25 – 45 % a year has 
been observed since 1992 (Smith & Bradley, 2003). To date, 164 cases of vCJD have been 
reported, with a further 4 cases still alive but diagnosed clinically without neuropathological 
examination (data from UK Creutzfeldt Jakob Disease Surveillance Unit). The peak incidence     8   
was in 2000 when 28 cases were identified and recorded numbers have decreased year on year 
since then with 5 cases in 2005, 2006 and 2007 and only a single case reported in 2008.  
However, as the incidence of BSE and vCJD decline, chronic wasting disease (CWD) 
continues to undergo a dramatic spread in both game farmed and wild cervid populations in 
North America. Previously this disease has been demonstrated in Rocky Mountain elk (Cervus 
elaphus nelsoni), mule deer (Odocoileus hemionus), white tailed deer (Odocoileus 
virginianus) and Shira’s moose (Alces alces shirasi) in North America, Canada and Korea 
(Baeten et al., 2007; Kim et al., 2005; Spraker et al., 1997). However, international 
surveillance remains limited, with the exception of a testing program in Germany (Schettler et 
al., 2006). This is of particular concern given that CWD demonstrates a particularly high rate 
of transmission, with a >10 % incidence in several wild deer populations in the states of 
Colorado and Wyoming (Manson et al., 2006). Moreover, up to 79 % of a captive population 
have previously demonstrated subclinical incubation of CWD in the absence of symptoms 
upon clinical presentation of a single individual (Keane et al., 2008). Chronic wasting disease 
also represents a particularly difficult disease to control, particularly in wild cervid 
populations, without impacting significantly on the surrounding ecosystem. Whilst the 
mechanism of pathogenesis is unknown, epidemiological evidence has suggested a horizontal 
mode of transmission through direct animal to animal contact or through oral exposure to 
prion infected blood, urine, saliva, faeces or fatty tissue (Safar et al., 2008; Race et al., 2009). 
However, evidence suggests that infectivity in fatty tissues, urine and saliva is low, as 
demonstrated by a lack of detectable PrP
res by the Western blot method, in addition to 
incomplete transmission and prologued incubation times in experiments involving transgenic 
mice expressing the cervid PrP gene (Race et al., 2009; Haley et al., 2009). It also remains 
unclear as to the extent of inter species transmission of CWD. Studies have demonstrated the 
presence of CWD infectivity in skeletal muscle and, as a result, there can be no doubt that 
predators or scavengers have been exposed to the disease, in addition to humans given the 
extent of hunting and venison consumption in North America (Angers et al., 2006). However, 
analysis of 812 tissue samples from mammalian scavengers in the CWD affected area of 
Wisconsin suggests that cross species transmission is rare, with none of the samples positive 
for PrP
res as confirmed by Western blot (Jennelle et al., 2009). The transmission of CWD to 
humans is also considered unlikely (Raymond et al., 2000). Twenty seven patients have 
presented with CJD and admitted to regular consumption of venison although no molecular, 
biochemical or histopathological data indicates the emergence of a new prion disease (Belay et 
al., 2004; Kong et al., 2005). Given the environmental contamination as a precursor to CWD     9   
transmission, it can also be expected that domestic ruminants may be exposed to CWD if areas 
of grazing overlap. Importantly, however, CWD has not been successfully transmitted to 
species other than to those within the cervidae family through oral inoculation. Moreover, 
sheep and cattle indicate a poor susceptibility through intra cerebral (i.c.) inoculation in the 
case of mule deer CWD (Hamir et al., 2005; Hamir et al., 2006). Howoever, other studies 
have demonstrated highly successful transmission of white tailed deer CWD to cattle and, 
conversely, BSE to European red deer (Cervus elaphus elaphus) through i.c. inoculation with 
clinical signs and pathology similar to CWD (Dagleish et al., 2008; Hamir et al., 2007).  
  In addition to current concerns surrounding CWD, atypical forms of BSE and scrapie 
have recently been identified which should halt any urges to relax surveillance measures 
despite the hazards surrounding classical BSE (cBSE) having been perceived to have passed.  
Atypical scrapie (Nor 98) was first identified in the United Kingdom in 2002, although 
retrospective analysis has identified a single case in 1989 (Benestad et al., 2003; Bruce et al., 
2007). Initially considered a different form of classical scrapie, Nor 98 is now known to be 
clearly distinguishable from classical scrapie and BSE. Accumulation of the prion protein is 
observed primarily in the cerebellum and cerebral cortex rather than the brain stem targeted in 
classical scrapie (Gavier Widen et al., 2004). Western blot analysis also demonstrates an 
additional small molecular weight (10 12 kDa) prion protein fragment following digestion by 
proteinase K, including a C  and N terminal truncated form of the prion protein (Gavier 
Widen et al., 2004; Klingeborn et al., 2006). Following the beginning of large scale 
surveillance of prion diseases in small ruminants, the incidence rate of Nor 98 has increased in 
a large number of European countries, in addition to the Falklands Islands and North America 
(Benestad et al., 2008; Buschmann et al., 2004; DeBosschere et al., 2004; Epstein et al., 2005; 
Gavier Widen et al., 2004; Onnasch et al., 2004; Orge et al., 2004; Seuberlich et al., 2007).  
Atypical BSE exists in two forms, identified recently in Europe and North America as 
a consequence of cBSE testing (Biacabe et al., 2004;Casalone et al., 2004). These forms are 
designated bovine amyloidotic spongiform encephalopathy (BASE, also known as BSE L) 
and BSE H; so called because of the higher and lower electrophoretic positions of the prion 
protein isoforms. The cause of these subtypes of BSE is unknown but they may represent a 
form of sporadic BSE. Of particular concern is BASE which, in addition to a different 
molecular profile of the prion protein, also demonstrates amyloid plaque deposition and is 
largely asymptomatic (Comoy et al., 2008; Kong et al., 2008). Serial passages of BASE into 
nontransgenic mice resulted in a neuropathological and molecular disease phenotype identical 
to cBSE infected mice suggesting an intrinsic capability of BASE to evolve towards the     10   
classical strain of disease (Capobianco et al., 2007). Although yet to be clarified, this 
potentially suggests sporadic generation of a cattle strain of prions which may have mutated 
through passage in an intermediary host, such as sheep, with the end product a bovine stable 
form of classical BSE. 
Most recently, a new prionopathy has been described in 11 patients previously 
diagnosed with sporadic CJD. Designated proteinase sensitive prionopathy (PSPr), it 
represents a novel, relatively rare form of human prion disease and is thought to account for   
3 % of all sCJD cases (Gambetti et al., 2008). The authors of the study identifying PSPr 
concede that it may be even more prevalent as some cases may be classified as non 
Alzheimer’s dementia. Clinically it is characterised by a relatively short disease duration 
(mean: 20 months) and a rather non specific phenotype involving progressive dementia and 
ataxia, with a number of cases also displaying Parkinsonism, consisting of tremors, rigidity, 
hypokinesia and postural instability. It can be further distinguished from known prionopathies 
based on the type of spongiform degeneration, the immunostaining pattern and the presence of 
prion associated amyloid microplaques in the cerebellum, cerebrum and, less frequently, in the 
white matter. However, of particular interest is the detection of an abnormal form of the prion 
protein which, in several brain regions, was almost exclusively sensitive to degradation by the 
protease proteinase K (PK). Detectable protease resistant PrP or PrP
res produced a distinct 
electrophoretic profile, clearly distinguishing PSPr from sporadic CJD and sporadic fatal 
familial insomnia (sFI) (Gambetti et al., 2008). Whilst investigations into the transmissibility 
of PSPr are underway, this new disease, coupled with atypical forms and recent studies into 
existing diseases, expands the entire nature of what is known regarding prion diseases. 
 
 
1.3. PRNP AND THE CELLULAR PRION PROTEIN 
 
The prion protein gene (PRNP) is a small single copy gene found on the short arm of 
chromosome 20 in humans and 2 in mice (Collinge, 1997).   In humans, wild type PRNP 
consists  of  two  exons  (three  in  mice),  one  of  which  is  short  and  untranslated,  the  other 
considerably larger incorporating the 759 nucleotide open reading frame (ORF) for the prion 
protein (Collinge, 1997; Gacia et al., 2006).  
The  cellular  prion  protein  (PrP
c)  is  highly  conserved  among  mammals  (Collinge, 
2001). It is present in a wide range of tissues including the heart and skeletal muscle. High 
levels of expression are observed in the CNS and at varying concentrations on cells of the     11   
lymphohaematopoietic  system.  These  include  haematopoietic  stem  cells,  dendritic  cells, 
follicular  dendritic  cells,  monocytes,  macrophages,  microglia,  granulocytes,  lymphocytes 
(both T and B cells), erythrocytes, platelets, CD34
+ and several groups of lymphoid precursors 
(Burthem et al., 2001; Dodelet & Cashman, 1998; Isaacs et al., 2006; Li et al., 2001; Liu et 
al., 2001; Zhang et al., 2006). In the CNS, particularly elevated levels of this protein and its 
mRNA  are  found  in  neocortical  and  hippocampal  neurons,  spinal  motor  neurons  and 
cerebellar
 Purkinje cells, with particularly wide subcellular distribution observed throughout 
cytoplasmic organelles, central and nerve muscle synapses, in addition to secretory granules of 
epithelial cells (Fournier et al., 2000; Harris, 1999; Sales et al., 1998). PrP
c possesses a half 
life in the body of around six hours. During much of this time it associates with specialized 
membrane domains enriched with cholesterol and glycosphingolipids known as lipid rafts, 
following which it is transferred to clathrin coated pits where it is subjected to endocytosis and 
recycling (DeMarco & Daggett, 2005; Taylor & Hooper, 2006; Westergard et al., 2007). 
Encoded  by  PRNP,  the  human  PrP
c  protein  is  synthesised  as  a  253  amino  acid 
polypeptide chain (Collinge, 1997; Collins et al., 2004b). After targeting to the endoplasmic 
reticulum, the first 22 amino acids are cleaved on initiation of translation and an initial core 
glycan is added to one or both of the glycosylation sites available (Asn 181 and Asn 197) 
(DeMarco & Daggett, 2005; Zahn et al., 2000). A disulfide bond is then formed between the 
cysteine residues 179 and 214 providing structural stability to the C terminus followed by 
addition of a C terminal glycosylphosphatidylinositol (GPI) anchor attached at residue 230 
(Ronga  et  al.,  2006).  Following  further  structural  alterations  to  the  glycans  in  the  Golgi 
apparatus, PrP
c is inserted into the plasma membrane (Figure 2).  
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Figure 2 Orientation of PrP
c following insertion into the cellular membrane showing the 
flexible N terminus and globular C terminus with the GPI anchor attached at residue 230 and 
glycans at residues 181 and 197. Adapted from Pinheiro, 2006. 
 
Although structural studies have yet to provide a precise, high resolution structure of 
PrP, nuclear magnetic resonance (NMR) studies have shown that, common to all species, the 
prion protein possesses a globular C terminus domain. This region of the protein includes 
three α helical regions: H1 consisting of residues 143 153, H2 encompassing residues 171 192 
and H3 of residues 199 226, the latter two of which are linked by the disulphide bond and two 
N linked  glycosylation  sites  (Norstrom  &  Mastrianni,  2006).  Western  blot  analysis 
demonstrates three major PrP bands corresponding to the occupation of either two, one or zero 
glycosylation  sites.  Glycosylation  is  thought  to  be  important  as  a  signal  for  correct 
intracellular trafficking and possibly for targeting of PrP
c to specific sites within the CNS 
(DeArmond et al., 1997; DeArmond et al., 1999). Two short antiparallel β strands consisting 
of residues 128 130 and 160 162 are also contained within the C terminal domain (Figure 3).  
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Figure 3 Proposed 3D structure of the C terminus of the human prion protein, residues 125 
230 indicating the glycosylphosphatidylinositol (GPI) anchor, Helix 1, 2 and 3, β strands 1 
and 2 and occupation of the two N linked glycosylation sites at residues 181 and 197. Adapted 
from Collinge, 2005.  
 
PrP
c also possesses a flexible, unstructured N terminus which spans residues 23 124, 
encompassing a highly conserved octapeptide repeat (OR) region located between residues 51 
and 95 (Collinge, 2005; Zidar et al., 2008). It is mutations in the OR region, leading to the 
accumulation of additional repeats, which are associated with forms of inherited prion disease, 
potentially involving inhibition of microtubule polymerization along the pathway to cell death 
(Dong et al., 2008). The N terminal region also contains a polybasic N terminal motif KKRP 
(residues 23 26) which is critical for endocytosis through interaction with the transmembrane 
adapter protein (Taylor et al., 2005). Deletion of the polybasic region results in accumulation 
of  PrP
c  within  the  cellular  membrane.  Also  within  the  N terminal  domain  is  a  residue 
sequence  of  amino  acids  104 135  comprising  a  short  stop  transfer  effector  (STE),  a 
hydrophilic  sequence  (residues  104 111)  and  residues  112 135  designated  a  putative 
transmembrane segment (TM) for its hydrophobic nature. The TM segment contains a sorting     14   
signal which, in addition to or in conjunction with signals from the GPI anchor, has been 
implicated  in  the  correct  trafficking  of  PrP
c  to  lipid  rafts  in  the  basolateral  membrane  of 
polarised cells (Kaneko et al., 1997). As a result, the AV3 mutation which alters the TM 
region is known to misroute the cellular prion protein to the apical membrane (Sorgato & 
Bertoli, 2006). The final structure of PrP
c consists of around 3 % β structure and 42 % α 
helices (Pan et al., 1993). 
 
1.3.1. The Normal Physiological Function(s) of PrP
c 
 
Several  physiological  functions  for  PrP
c  have  been  suggested  but,  as  of  yet,  none 
confirmed  or  completely  defined.  This  is  somewhat  surprising  given  that  PRNP  was  first 
decoded in 1985 and the physiology of a prion protein knockout mouse homozygous for PrP 
null alleles (PRNP
0/0) was described in 1992 (Basler et al., 1986; Bueler et al., 1992). This is 
largely a result of the fact that PRNP
0/0 mice appear to behave and develop normally showing 
no overt phenotype (Bueler et al., 1992). The only immediately evident alteration in normal 
physiology is a resistance to prion disease. Inoculation of PRNP
0/0 mice with scrapie brain 
homogenate does not elicit a disease phenotype and no subclinical replication of the infectious 
agent is detected (Bueler et al., 1993; Sailer et al., 1994; Weissmann et al., 1994). However, 
subtle  alterations  in  synaptic  physiology,  more  specifically  in  GABAA  mediated  synaptic 
inhibition, abnormal circadian rhythms and sleep patterns, in addition to deficits in spatial 
learning and long term potentiation, have since been described (Collinge, 1997; Criado et al., 
2005; Manson et al., 1995; Tobler et al., 1996). The molecular bases of these changes remain 
undefined and, as a consequence, the changes may be a result of the variability in genetic 
background of laboratory murine strains.  
Importantly,  PRNP
0/0  murine  models  and  several  PRNP
0/0  neural  cell  lines  have 
demonstrated an increased susceptibility to oxidative stress (Brown et al., 1997; Brown et al., 
2002; Choi et al., 2007; Klamt et al., 2001; Wong et al., 2001). This has led to the suggestion 
of a neuroprotective role for the cellular prion protein. The over expression of PrP
c in cultured 
neurons, some mammalian cell lines and a yeast system has been shown to rescue cells from 
apoptosis whereby the N terminal domain is largely implicated (arra Mehrpour et al., 2004; 
Dupiereux et al., 2008; Kuwahara et al., 1999; Li & Harris, 2005; Sorgato & Bertoli, 2006). 
Critically, the octapeptide repeat region has been demonstrated to possess a pivotal role in 
neuroprotection. Divalent copper ions bind to the N terminal region of the protein in the OR 
which consists of four tandem repeats possessing the 8 amino acid sequence Proline Histidine     15   
Glycine Glycine Glycine Tryptophan Glycine Glutamine (PHGGGWGQ) (Del et al., 2007). 
These repeats can bind up to four Cu
2+ ions with a high affinity in the fmol/L and  mol/L 
range. The stoichiometry of Cu
2+ binding to the octapeptide repeats has been demonstrated to 
be heavily buffer and pH dependent with two copper ions bindings to the OR region at pH 6 
and four at pH 7.4 (Whittal et al., 2000). Consequently, PrP
c may function as Cu
2+ transporter, 
conveying ions to Cu
+ specific intracellular trafficking proteins or transferring the divalent 
ions from the extracellular space to the endosome.  
The  ability  of  PrP
c  to  bind  Cu
2+  would  imply  a  potential  to  inhibit  the  oxidative 
properties of copper through prevention of the ions interaction with water and the generation 
of radicals such as hydroxyl. Importantly, in the presence of copper the N terminal region 
reverts  from  an  unstructured  to  a  more  structured  state  which  may  confer  antioxidant 
properties to the protein in a similar manner to superoxide dismutase (SOD) (Collins et al., 
2004b). As such PrP
c may be either directly involved in detoxifying reactive oxygen species 
(ROS)  or  indirectly  through  the  upregulation  of  other  proteins  such  as  Cu Zn  SOD 
(Westergard et al., 2007). Whilst this is an enticing hypothesis, PrP
c has not demonstrated 
contributions to SOD activity in vivo although concerns over the biological availability of 
copper bound PrP
c under experimental conditions have been raised (Haigh & Brown, 2006; 
Hutter  et  al.,  2003).  Interestingly,  studies  have  suggested  that  copper  toxicity  may  occur 
through mechanisms which are dependent and also independent of oxidative stress, the latter 
also inhibited by expression of the cellular prion protein (Haigh & Brown, 2006). 
The hypothesis of a neuroprotective role has been supported by data demonstrating an 
increased mortality in PRNP
0/0 mice subjected to several in vivo models of chemically induced 
seizure,  a  likely  consequence  of  hyper excitability  leading  to  excitotoxicity  (Walz  et  al., 
1999). Neuronal excitability and excitotoxic neuronal cell death are features of glutamate 
activated N methyl D aspartate (NMDA) receptor activity and PRNP
0/0 mice exhibit increased 
and prolonged NMDA evoked currents through an increase in functional NMDA receptors 
containing the NR2D subunit (Khosravani et al., 2008; Mody & MacDonald, 1995). Normal 
functionality can be rescued through over expression of exogenous PrP
c and, as such, has led 
to the conclusion that PrP
c may mediate its neuroprotective role by virtue of its ability to 
inhibit the NR2D subunit, thus preventing glutamate excitotoxicity. It has also been noted that 
PrP
c is upregulated during the early stages of focal cerebral ischemia, potentially as an early 
adaptive response, with the extent of upregulation dependent on lesion severity (Weise et al., 
2004).  Critically,  PRNP
0/0  mice  have  demonstrated  increased  neuronal  damage  following 
ischemic stroke. The mice display an increased infarct size of up to 200 % relative to wild     16   
type  mice,  which  can  be  protected  against  following  over expression  of  PrP
c  through 
adenovirus mediated gene targeting in rodent models (McLennan et al., 2004; Shyu et al., 
2005;  Spudich  et  al.,  2005).  Further  studies  have  suggested  that  the  anti apoptotic 
phosphatdylinositol  3 kinase/Akt  pathway  may  be  impaired  (Weise  et  al.,  2006).  This 
consequently results in reduced post ischemic phospho Akt expression leading to enhanced 
post ischemic caspase 3 activation and increased neuronal injury following a simulation of 
transient and permanent cerebral ischemia. Transgenic mice lacking the octapeptide region 
(C4/  mice) which are subjected to controlled ischemia display an infarct size identical to 
PRNP knockout mice and three times larger than wild type mice (Mitteregger et al., 2007). 
Functionality can not be rescued in the knockout mice through introduction of C4/  suggesting 
that the N terminal OR region plays a crucial role in PrP
c physiology and protection against 
oxidative stress.  
Another function of the OR region appears to be linked to the sequence similarity with 
the Bcl 2 homology domain 2 (Sorgato & Bertoli, 2006). Bcl 2 is an anti apoptotic factor 
capable of rescuing neurons from death through its direct interaction with Bax (Kurschner & 
Morgan, 1995). Interestingly, both Bcl 2 or PrP
c over expression has been shown to overcome 
serum  deprivation induced  toxicity  in  PRNP
0/0  neuronal  cells  (Kuwahara  et  al.,  1999). 
Subsequent studies were able to abolish the protective role exerted by PrP
c in Bax mediated 
cell injury through removal of the octapeptide repeat region (Bounhar et al., 2001). However, 
the difference in cell location of PrP
c and Bcl 2 suggests rather than interacting directly with 
Bax, PrP
c may influence a pathway such as the Ca
2+ metabolism of the mitochondria which 
involves  Bax.  Mitochondrial  permeability  transition,  which  is  affected  by  both  Bax  and 
misregulation of Ca
2+ metabolism, has been demonstrated to trigger the activation of caspases 
and subsequently lead to apoptosis (Sorgato & Bertoli, 2006). Later studies have observed 
mitochondrial  irregulation  in  neuronal  cultures  devoid  of  PrP
c  (Miele  et  al.,  2002). 
Importantly,  transgenic  mice  expressing  a  deletion  of  the  flexible  N terminal  tail  of  PrP
c 
between residues 32 134 (thereby encompassing the OR region) develop ataxia, degeneration 
of cerebellar granule cells and demonstrate vacuolation of white matter in the brain and spinal 
cord leading to death within 3 months (Li et al., 2007a). Deletion of a 21 amino acid sequence 
of  residues  105 125  outside  the  OR  region  in  the  N terminal  region  also  shows  severe 
neurodegeneration but fatality is observed at 1 week following birth (Li et al., 2007b). While 
Bax deletion is shown to delay the onset of clinical illness and slow apoptosis, it offers no 
protection against white matter degeneration in Tg 32 134 mice. Subsequent Bax deletion in 
the Tg 105 125 mice has no affect on neuropathology or clinical phenotype suggesting that a     17   
Bax  related  pathway  mediates  initial  neurotoxic  actions  of  Tg  32 134  but  that 
neurodegeneration induced by Tg 105 125 involves Bax independent pathways.  
The theory that PrP
c may not possess any inherent, direct biological activity itself but 
may modify the functionality of other proteins has led to extensive efforts to classify PrP
c 
binding proteins or receptor candidates. However, it is not clear whether any of the PrP
c 
receptor proteins identified thus far possess an in vivo functional pathway in which the cellular 
prion protein is involved. PrP
c has been shown to bind with the carboxy terminal decapeptide 
region  of  the  laminin  γ 1  chain  of  the  37 kDa/67 kDa  laminin  receptor,  an  interaction 
important for both neuronal adhesion and extension and maintenance of neurites, as well as 
the neural cell adhesion molecule (NCAM) (Graner et al., 2000; Santuccione et al., 2005). 
Both cis and trans interactions between NCAM and PrP
c at the neuronal surface allow for 
recruitment of NCAM into lipid rafts therefore allowing the downstream activation of fyn 
kinase, an enzyme involved in NCAM mediated neurite outgrowth. This has been shown to be 
ablated in NCAM deficient and PrP
c–deficient neurons and also by PrP
c antibodies indicating 
a  potential  involvement  of  the  cellular  prion  protein  in  nervous  system  development. 
Transgenic mice lacking the central domain comprising the charge cluster (residues 95 110) 
and  the  hydrophobic  core  (residues  112 134)  demonstrate  potent  neurotoxic  effects  with 
widespread central and peripheral neuropathy with myelin damage rather than neuronal loss 
the primary cause of lethality (Baumann et al., 2007). Consequently, rather than inducing an 
entirely different disease, this form of PrP
c appears to aggravate symptoms caused by the loss 
of wild type PrP
c function suggesting myelin integrity represents an important physiological 
role for which residues 94 134 are important. It is also postulated that since laminin is known 
to be abundant in the hippocampus, a region of the brain whose known role is in memory and 
function, that PrP
c may have a function in memory formation. This is consistent with the 
observed defects in spatial learning and long term potentiation and the increased excitability of 
hippocampal neurons in PRNP
0/0 knockout mice, in addition to the subcellular localisation of 
PrP
c  at  the  synapses  (Colling  et  al.,  1996;  Colling  et  al.,  1997;  Fournier  et  al.,  2000). 
Interestingly, it has been demonstrated that infusion of mice with anti PrP
c antibodies impairs 
short  and long term memory retention (Coitinho et al., 2003; Martins & Brentani, 2002). This 
has also been observed in PRNP
0/0 and PRNP
+/+ mice which exhibit significant impairment, 
not  only  in  memory,  but  also  in  locomotor  activity  and  an  increase  in  anxiety related 
responses suggesting a role in age related behavioural defects (Rial et al., 2009).  
  The interaction, either directly or indirectly, of PrP
c with the heat shock protein 60 
(Hsp 60) has raised the questions of whether PrP
c may participate in Hsp 60 dependent signal     18   
transduction, which has been demonstrated to contribute to the establishment of a Brucella 
abortus infection, a gram negative bacterium which replicates within macrophages vacuoles 
(Watarai  et  al.,  2003).  Cellular  prion  protein–knockout  macrophages  have  demonstrated  a 
decreased internalization of B. abortus as a consequence of disruption of the receptor ligand 
interaction between macrophage PrP
c and the Hsp60 of B. abortus. Further studies have also 
given weight to the suggestion that PrP
c may have a role in signal transduction. Glockshuber 
et al (1998) noted that  the C terminal domain of PrP
c possesses similarities to membrane 
anchored  signal  peptidases.  Tyrosine 128  and  Histidine 177  of  PrP
c  were  demonstrated  to 
align  precisely  with  the  active  site  residues  within  the  catalytic  domain  of  the  rat  signal 
peptidase. Critically, however, this has not been demonstrated functionally. In addition, the 
cross linking  of  the  cellular  prion  protein  with  F(Ab)2  antibody  fragments  activates  intra 
cellular tyrosine kinase in a calveolin 1 dependent binding mechanism in the 1C11 cell line, 
particularly in neurites (Mouillet Richard et al., 2000). However no further studies have been 
able to verify or reproduce this signal transduction event in other cell lines. 
Given the wide cellular expression on cells of the lymphohaematopoietic system it is 
also  conceivable  that  PrP
c  may  be  involved  in  aspects  of  immunological  response  or 
neuroinflammation. There is data to support this theory and PrP
c has been implicated in T cell 
activation,  macrophage  phagocytosis  and  T  cell dendritic  cell  interaction  (Ballerini  et  al., 
2006; de Almeida et al., 2005; Mabbott et al., 1997). Moreover, there is evidence to suggest 
PrP
c may be involved in T cell mediated neuroinflammation as a more aggressive disease 
onset  and  prolonged  neuroinflammation  was  observed  in  a  PRNP
0/0   T  cell  mouse  model 
during  the  course  of  experimental  autoimmune  encephalomyelitis  (Tsutsui  et  al.,  2008). 
Cellular prion protein expression on haematopoietic stem cells (HSCs) has also demonstrated 
that  HSCs  from  PRNP
0/0 bone  marrow  in  lethally  irradiated  mice  exhibit  impaired  self 
renewal following serial transplantation (Zhang et al., 2006).  
 
 
1.4. THE PATHOLOGICAL PRION PROTEIN 
 
It is widely accepted that the precursor to prion disease is a post translational process, 
occurring after PrP
c has been inserted into the plasma membrane whereby the cellular prion 
protein is converted into a pathological conformer known as PrP
sc or PrP
res which is only 
detectable in prion disease states. This conversion can be initiated by mutations (sCJD) or     19   
interaction of the cellular and pathogenic isoform of the prion protein (iCJD and vCJD). No 
transfer of genetic material is required for this transformation to occur (Scott, 2006).  
Key to the understanding of the mechanism of disease is the concept that the primary 
amino acid sequences of
 both PrP
c and PrP
res are identical and that PrP
res generation is a result 
of  post translational  modifications  in  conformational  structure  with  no  changes  in  mRNA 
transcript levels (Aguzzi & Heppner, 2000; Collinge, 2005; Collins et al., 2004b; Hosszu et 
al., 2005). The structural alteration results in an increase in β sheet content of the protein from 
3 %, to 43 %, accompanied by a small decrease in α helix from 42 % to 30 % (Table 2). The 
disulphide bond linking H2 and H3 between residues 179 214 is thought to be maintained in 
the PrP
res structure although contrasting data on this fact exists (Caughey & Lansbury, 2003; 
Turk et al., 1988). Consequently a profound change in physicochemical property of the prion 
protein is observed with PrP
res demonstrating extreme resistance to heat, radiation and various 
enzymes. Treatment with the protease proteinase K produces a proteolytically resistant core, 
with the loss of residues 23 to ~89 (Prusiner et al., 1983). Designated PrP
27 30, due to its 
molecular weight in kilodaltons (kDa), this N terminally truncated form of PrP
res retains its 
high β sheet content and is proposed to be fully infectious, with the ability to assemble into 
prion rods which have the properties of amyloid fibrils (Baskakov et al., 2002a; McKinley et 
al., 1983; McKinley et al., 1991a; Pan et al., 1993). The pathological form of the prion protein 
is also highly insoluble in non denaturing solvents and, supposedly, neurotoxic although the 
direct role of PrP
res in disease remains unclear (Prusiner, 1998).  
 
Table 2 Secondary structure, in relation to α helix and β sheet content, of the  
known isoforms of PrP. 
Isoform  α helix (%)  β sheet (%) 
PrP
c  42  3 
PrP
res  30  43 
PrP 
27 30  21  54 
 
1.4.1. The Site of PrP
res Conversion 
 
The specific site of the conversion process is difficult to ascertain. The pathological 
form of the prion protein is poorly immunoreactive unless treated with denaturing substances 
which  result  in  disruption  to  cellular  morphology  (Harris,  1999).  Expression  of  PrP
c  is 
necessary  for  neuronal  damage  and  scrapie  propagation  within  the  CNS  (Brandner  et  al., 
1996). Cellular prion protein depleted neurons adjacent to an infected PRNP
+/+ graft do not     20   
incur damage, implying that interaction of PrP
c with PrP
res at the cell surface is necessary for 
disease pathogenesis. Consequently, misfolding may occur at the cell surface with several 
studies  suggesting  that  the  lipid  rafts  into  which  PrP
c  is  inserted  following  synthesis  and 
trafficking  to  the  cell  surface  play  an  important  role  in  the  conversion  process  (Pinheiro, 
2006). Recombinant transmembrane forms of PrP
c not associated with lipid rafts prevent the 
development of PrP
res (Kaneko et al., 1997). In addition, cholesterol depletion redistributes 
PrP
c outside of the lipid rafts and decreases PrP
res formation in cell lines (Bate et al., 2004; 
Taraboulos et al., 1995). However, it is known that PrP
res accumulates intracellularly thus 
suggesting that while interaction occurs at the cell surface, conversion occurs within the cell 
following endocytosis (Taraboulos et al., 1990). It is important to note that conversion in vitro 
is  frequently  observed  within  a  pH  range  of  4 7,  such  as  may  be  encountered  within  the 
endosomal compartment (Borchelt et al., 1992). Electron microscopic evidence and studies 
using  scrapie  infected  neuroblastoma  (ScN2a)  and  hamster  brain  (ScHaB)  cells  suggest 
conversion may occur along the endocytic pathway or within late endosome like organelles or 
lysosomes, some of which contain acid phosphatase (Arnold et al., 1995; Mayer et al., 1992; 
McKinley et al., 1991b; Taraboulos et al., 1992). However, as PrP
res is not degraded within 
the  lysosomes,  beyond  truncation  of  the  N terminus,  it  is  logical  to  suggest  that  PrP
res 
formation must occur prior to contact with lysosomal proteases (Caughey et al., 1991). 
 
1.4.2. Important Molecular Structures in the Conversion of PrP
c to PrP
res 
 
A  precise  tertiary  structure  of  PrP
res  or  PrP
27 30  remains  undetermined  due  to  their 
insolubility  and  propensity  to  form  large,  heterogeneous  aggregates  which  are  difficult  to 
analyse by high resolution methods. Consequently, isolation of specific residues involved in 
the  conversion  process,  through  interaction  with  PrP
res  or  which  undergo  misfolding 
themselves,  is  considerably  difficult  and  often  relies  on  fragment  peptide  studies  from  a 
variety of species, analysed in a variety of cellular or animal models.  
Conflicting data exists over the role of the N terminal domain in misfolding and prion 
replication.  The  fact  that  the  N terminal  residues  23 89  are  removed  upon  proteinase  K 
treatment to produce PrP
27 30 would appear to suggest that these residues are not critical for 
prion  replication.  Indeed,  the  N terminal  region  encompassing  residues  23 89  has  been 
demonstrated to be superfluous for prion replication in murine neuroblastoma cells (Fischer et 
al., 1996; Rogers et al., 1993). However, a further deletion of the first 113 residues of the N 
terminus  has  been  demonstrated  to  reduce  PrP
res  formation  and,  in  addition,  produced  an     21   
altered  protease  resistant  product  as  identified  by  the  presence  of  additional  protease  K 
cleavage sites (Lawson et al., 2001). However, the location of membrane bound PrP
c would 
appear to suggest that the N terminus could potentially interact with PrP
res (Figure 2) (Martins 
et al., 2002). Moreover, residues 89 175 (including the final 35 residues of the N terminus) 
have  been  suggested  to  be  able  to  adopt  a  β helical  formation  (Govaerts  et  al.,  2004).  A 
synthetic  peptide  of  residues  109 122  has  also  been  shown  to  acquire  a  β sheet  structure 
(Gasset et al., 1992). Another peptide consisting of residues 106 126, thereby encompassing 
the N terminal residues of the TM region and its hydrophobic core AGAAAAGA consisting 
of residues 112 119, has demonstrated formation of prion associated amyloid plaques, similar 
in structure to those found in CJD and GSS brains and toxicity in primary brain cells (De et 
al., 1994; Forloni et al., 1993; Jobling et al., 1999; Tagliavini et al., 1993). Cellular prion 
protein mutants lacking the TM domain or part of it are not converted to PrP
res (Muramoto et 
al., 1996). As a generalisation it would appear that the N terminal up to and including residue 
89 is not required for conversion with the remaining residues (90 124) possessing the potential 
to convert to a β sheet structure and be actively involved in the conversion process to some 
extent. However, Cu
2+ has demonstrated in vitro inhibition of conversion of PrP
c into amyloid 
fibrils suggesting a complex role for copper in prion pathogenesis, mediated by the N terminus 
and the OR region (Bocharova et al., 2005b). Cells expressing PrP
c with deletion of the OR 
region do not produce PrP
res (Sakudo et al., 2008). Moreover, N terminal deletion mutations of 
recombinant  PrP  (recPrP)  of  residues  51 90  and  32 121  decrease  pressure  stability  and 
increase thermal lability of the protein. These effects are exacerbated as the N terminal is 
shortened and the process is not reversible suggesting that this region may affect stability and 
the 3D organisation of recombinant murine PrP (Cordeiro et al., 2005). This may be a result of 
the loss of residues 88 and 98 which data suggests may play a prominent role in nucleation 
(Sun et al., 2007).  
A significant body of data supports the notion that the C terminus undergoes structural 
transition,  retaining  infectivity  and  protease  resistance  (Sorgato  &  Bertoli,  2006). 
Recombinant  murine  PrP  (rec.MoPrP)  of  residues  89 230  containing  neither  the  N linked 
glycans nor the GPI anchor elicits a disease phenotype suggesting these structures are not 
required  for  infectivity  (Legname  et  al.,  2004).  However,  it  is  unknown  whether  these 
structures may influence the efficiency of PrP
res formation (Collinge et al., 1996). Subsequent 
studies have suggested several loci within the C terminal domain which may be involved in β 
structure propagation. A proposed model based on the electron crystallography of prion rods 
isolated from rodent brain material suggests that H2 and H3 remain intact and linked by the     22   
disulphide bond
 (Norstrom & Mastrianni, 2006). Conversely, the N terminal to H2 segment 
encompassing residues 89 175 (thereby including H1) has been suggested to be able to adopt a 
β helical formation and appears to rearrange into a left handed β helix structure where H1 
protrudes  out  as  a  loop  adjacent  to  neighbouring  prion  molecules  (Govaerts  et  al.,  2004; 
Norstrom & Mastrianni, 2006; Wille et al., 2002). Whether H1 undergoes rearrangement itself 
is  disputed  (Watzlawik  et  al.,  2006).  However,  it  has  previously  been  postulated  that  the 
central domain, specifically residues 96 167, is involved in the interaction with PrP
res (Telling 
et  al.,  1995).  Consequently,  H1  appears  to  be  in  an  ideal  position  to  influence  prion 
replication. C  and N terminal neighbouring residues of H1 have been demonstrated to be 
important in the conversion process (Kocisko et al., 1995). Interestingly, H1 is an unusually 
hydrophilic α helix structure where most of the charges are situated on the outer face of the 
helix away from the globular domain. Prion molecules lacking H1 are resistant to conversion 
in cell lines which have been chronically infected with prions (Vorberg et al., 2001). However, 
it  is  unclear  whether  this  may  be  a  result  of  an  interference  with  protein  trafficking  and 
complex glycosylation which are known to affect the misfolding process. Neutralization of the 
charges in the N terminal residues of 143 146 but not the C terminal residues 147 151 of H1 
permits the conversion to PrP
res whilst complete reversal of charge orientation leads to the 
production of a PrP
c molecule unable to undergo conversion (Norstrom & Mastrianni, 2006). 
Importantly,  the  charge  substitutions  did  not  alter  the  secondary  structure  or  the  protein 
expression levels on the cell surface.  
Studies  involving  monomeric  sheep  PrP
c  have  identified  further  loci  which  may 
participate in the β sheet transition. The first involves residues 129 131, which form part of 
the  intra molecular  β sheet  with  residues  161 163.  Deletion  of  the  beta strands  has  been 
shown to inhibit PrP
res formation (Vorberg et al., 2001). In contrast to other studies described 
above, the second is thought to involve residues 188 204, involving the C terminal residues of 
H2 and the first six residues of H3, which modelling has suggested has the capacity to act as 
an α helix to β sheet switch (Haire et al., 2004). Critically, this has been demonstrated in other 
studies  which  indicate  that  residues  172 224,  including  H2  and  H3,  may  adopt  a  β sheet 
conformation, potentially  as part of an intermediate structure (Dima  & Thirumalai, 2004). 
Significantly,  it  has  been  suggested  that  structural  change  involving  the  H2  region  could 
potentially promote β sheet mediated transition (Tizzano et al., 2005). The first three turns of 
H2  are  closely  associated  with  H3  whereby  the  glycosyl  moiety  on  the  Asn 181  residue 
provides efficient stabilisation of the region. However, residues 190 195 situated apart from     23   
the last helix and H3 and could facilitate further transition to a β sheet structure and hence 
aggregation (Ronga et al., 2006).  
 
1.4.3. Evidence for an Auxiliary factor in Prion Conversion 
 
Several studies suggest that a co factor may be involved in the misfolding of PrP
c to 
PrP
res. Cell based or animal systems demonstrate maintenance of infectivity and the successful 
conversion of PrP
c to PrP
res (Fichet et al., 2004; Ma & Lindquist, 2002). However, conversion 
in a cell free system is significantly harder to achieve, requiring chemical denaturants and high 
temperatures  under  non physiological  conditions  (Baskakov,  2007b;  Caughey  et  al.,  1995; 
Legname et al., 2004). Critically, studies have demonstrated that a broad variety of proteins 
which  are  unrelated  to  human  disease  can  be  refolded  into  β sheet  rich,  amyloid like 
conformations under induced conditions which destabilise their native state (Chiti et al., 1999; 
Chiti et al., 2000; Gross et al., 1999; Ramirez Alvarado et al., 2000). As a result it would 
appear  that  the  ability  to  form  a  β sheet  rich  amyloid  structure  is  not  a  protein specific 
property unique to individual proteins but may be a general feature of polypeptide chains 
(Guijarro et al., 1998). The accompanying infectivity surrounding PrP
res is therefore likely to 
be an intrinsic property of the protein itself and efficient conversion achievable only within a 
cellular environment.  
Telling et al., (1995) investigated the mechanism behind the conversion process in 
transgenic mice expressing either human (TgHuPrP) or chimeric prion protein genes. Upon 
inoculation with brain extracts from fCJD or sCJD human patients, TgHuPrP
 mice were 
resistant to human prions and susceptibility was restored upon ablation of the murine PrP 
gene. In contrast, chimeric mice were fully susceptible to human prions, arguing that a 
species specific macromolecule was involved, designated protein X. It is hypothesised that 
protein X forms a binary complex with PrP
c through interaction with prion residues between 
96 197 (Telling et al., 1995).  
The designation of protein X as a protein is misleading. The possibility that the 
auxiliary factor is a cholesterol, glycosphingolipid, phospholipid or the membrane surface 
itself can not be excluded (Kaneko et al., 1997). As a consequence of the fact that conversion 
is likely to require at least partial unfolding of PrP
c, protein X may encompass a cofactor 
which either destabilises the native state or stabilises the transition state (Baskakov, 2007b). 
Suggested molecules have included double stranded DNA, RNA and the zwitterionic 
phospholipid palmitoyl oleoyl phosphatidylglycerol (POPG) (Adler et al., 2003; Cordeiro et     24   
al., 2001; Critchley et al., 2004; Deleault et al., 2003; Re et al., 2008). Interestingly, a pH 
dependent association between the lipid membrane and PrP
c has also been recognised which 
suggests that the native structure of PrP
c is maintained at a neutral pH with unfolding and 
oligomerisation occurring at pH 5 suggesting that membrane association may have a 
stabilising effect on the prion protein (Re et al., 2008). 
 
1.4.4. Mechanism(s) of PrP
res Misfolding 
 
Two current theories are suggested to explain the mechanism behind the generation of 
PrP
res: a “refolding” or template directed model or the nucleation polymerisation/“seeding” 
model. In the former, the conversion of PrP
c to PrP
res is kinetically controlled, whereby the 
interaction  of  PrP
res  with  PrP
c  overcomes  a  high  activation  energy  barrier  preventing 
spontaneous conversion. This induces the conformational change and subsequent replication 
occurs through dimerisation (Cohen et al., 1994; Roostaee et al., 2009). The latter model 
suggests a reversible, thermodynamic equilibrium state between PrP
c and PrP
res balanced in 
favour of PrP
c (Jarrett & Lansbury, Jr., 1993). Stabilisation of the PrP
res conformational form 
can only be achieved following interaction with an aggregated PrP
res containing structure or 
“seed”  through  a  nucleation dependent  polymerization  process  thus  recruiting  monomeric 
PrP
res molecules into amyloid fibers. Fragmentation of the amyloid increases the number of 
seeds for further recruitment and replication of PrP
res (Figure 4). 
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Figure  4  Diagrammatic  representation  for  the  suggested  models  of  the  conformational 
conversion  of  PrP
c  to  PrP
res.  a)  The  “refolding”  or  template directed  model  and  b)  The 
“seeding” or nucleation polymerisation model. Taken from Aguzzi & Polymenidou, 2004. 
 
Cell free conversion studies have demonstrated that aggregates of PrP
res are capable of 
initiating conversion of PrP
c to its pathological isoform (Bessen et al., 1997; Kocisko et al., 
1996). Importantly, the protein misfolding cyclic amplification (PMCA) technique functions 
on the basis of a seeding mechanism. Conceptually analogous to the polymerase chain reaction 
(PCR),  PMCA  amplifies  minute  concentrations  of  existing  PrP
res  through  incubation  with 
excess  PrP
c.  Sonication  is  used  to  fragment  the  generated  aggregates  to  produce  smaller 
seeding units which undergo further rounds of amplification in the presence of PrP
c thereby 
augmenting the initial PrP
res signal (Castilla et al., 2005a; Castilla et al., 2005b; Saa et al., 
2006a).  Generation  of  infectivity  has  been  achieved  using  this  technique  from  an  initial    
1x10
 12 dilution of scrapie brain homogenate (Saa et al., 2006b). In addition, data has indicated 
that the β sheet rich isoform of recombinant murine PrP is thermodynamically more stable 
than  the  native  α helical  state  and  that  transition  is  indeed  separated  by  a  large  energetic 
barrier (Baskakov et al., 2001; Baskakov et al., 2002b). Refolding of the C terminus is also 
thought to be rapid (170  s) further suggesting a nucleation elongation mechanism (Wildegger 
et  al.,  1999).  However,  one  caveat  of  the  nucleation polymerisation  model  is  that  if  a 
thermodynamic  equilibrium  between  PrP
c  and  PrP
res  exists,  albeit  in  favour  of  the  PrP
c     26   
conformation,  monomeric  PrP
res  could  not  represent  the  infectious  agent  as  it  would  be 
ubiquitous.  
 
1.4.5. Aggregation, Fragmentation and Replication of PrP
res 
 
Following misfolding of the native cellular prion into the predominantly anti parallel 
β sheet secondary structure of PrP
res, the prion protein readily polymerises into insoluble 
fibrous protein aggregates known as amyloid fibres with characteristic green birefringence 
upon fluorescent labelling with Congo red dye under polarised light (Prusiner et al., 1983). 
Fibrils are known to be ordered such that the β strands lie perpendicular to the fibrillar axis, 
with approximately 4.8 Å between two neighbouring strands (Baskakov, 2007a). Moreover, 
whilst the 3D orientation of PrP
res within an amyloid fibre has not been described, it is 
predicted that a single PrP
res molecule occupies approximately 1.2 nm of a fibres length 
(Anderson et al., 2006). An immunoconformational assay published by Novitskaya et al., 
(2006) suggests that once in a fibrillar structure, region 159 174 and 224 230 of the PrP 
globular domain are buried within the structure and resistant to denaturation. Residues 132 
156 were only accessible under partially denaturing conditions and residues 95 105 towards 
the N terminal are solvent accessible. Critically, however, electron microscopy and 3D 
reconstruction suggests that amyloid fibrils display a range of assemblies (Figure 5). Fibres 
have been shown to differ in their number and the packing arrangement of protofibrils, in 
addition to helical twists within and between fibrils (Jimenez et al., 2001; Jimenez et al., 
2002). This has also been demonstrated by Anderson et al., (2006) whereby full length murine 
prion fibrils varied with respect to the number of constitutive filaments and the style in which 
they were assembled as visualised in vitro by atomic force microscopy (AFM). Fibrillar 
morphology changed even within individual filaments suggesting multiple mechanisms of 
assembly that are inter convertible and thermodynamically equivalent. The morphology of 
fibrils obtained in vitro was similar to scrapie associated fibrils (SAF) obtained from scrapie 
infected brains (Anderson et al., 2006). Higher order amyloid plaque morphology is known to 
vary between diseases as a consequence. Kuru plaques characteristically consist of a stellate 
core with few or no dystrophic neurites (Hainfellner et al., 1995; Liberski, 2004). In GSS, 
multicentric plaques consisting of numerous different sizes and shapes are a typical feature in 
the CNS (Liberski & Budka, 1995).  
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Figure 5 Variation in size distribution and ultrastructure of prion associated amyloid fibrils 
formed from recombinant prion protein analysed in parallel by Thioflavin T fluorescence 
microscopy (left panels) and electron microscopy (right panels). (A,B) scale bars = 1  m; (C) 
scale bar = 10  m. Figure taken from Bocharova et al., 2005a. 
 
Subsequent to the elucidation of the involvement of several sequences of PrP
c in the 
conversion to the PrP
res structural state, certain sequences also appear to be important for 
amyloid formation. The loss of the N terminal residues 23 89 results in smaller, less ordered 
aggregates relative to the full length protein, suggesting that the N terminal may mediate high 
order aggregation (Frankenfield et al., 2005).   
The GPI anchor can also impact prion polymerization in several ways. The anchor can 
alter the specific orientation of the cellular prion protein in the plasma membrane and 
therefore increase effective concentration (Breydo et al., 2007). The GPI anchor may also 
impose important steric constraints on the packing arrangement of PrP into a fibrillar structure. 
Whilst it is known that GPI anchorless PrP
res does not reduce prion infectivity it is unclear 
whether a lack of GPI anchor in the cellular form of the prion protein leads to the formation of     28   
fibrils that are arranged in a different manner and hence potentially non infectious. The 
addition of a hydrophobic moiety known as N myristoylamidomaleimidyl mimics the GPI 
anchor when attached to the C terminal (Breydo et al., 2007).  Whilst this addition does not 
alter the structure of PrP it decreases fibrilisation and prohibits assembly of filaments into 
higher order fibrils by preventing their lateral association. This confirms that the C terminus is 
involved in formation of the cross β structure but, in addition, may also assist in the formation 
of an interface between the filaments. Subsequent studies have shown that GPI deficient PrP
c 
produces an accumulation of PK resistant PrP
res deposits whereby the PrP
res was also 
anchorless. These deposits were infectious towards wild type mice suggesting that the GPI 
anchor is not required to generate infectivity (Chesebro et al., 2005; Lewis et al., 2006a). It is 
however unclear whether the GPI anchor is required for generation of infectivity in cases 
where there is an absence of a seed mediated conversion, for example in sCJD.  
Studies into amyloidosis in prion diseases appear to also be in favour of the nucleated 
elongation reaction of prion propagation and the thermodynamic conversion model (Figure 4) 
(Baskakov et al., 2004; Harris & True, 2006). Observations into the conformational changes 
and oligomerisation process associated with PrP
27 30 and fragment 90 231 demonstrated a 
rapid (<1 min) conversion to β sheet dimers (Post et al., 1998). This was followed by the 
appearance of larger oligomers after 20 mins with protease resistant aggregates forming after 
several hours. Critically this study did not appear to require a cooperative, template assisted 
step. However, polymerization of the amyloidogenic yeast prion Sup35 demonstrates rapid 
polymerization through monomer addition (Collins et al., 2004a). This appeared to occur in 
the absence of observable intermediates suggesting that prion associated amyloid formation 
occurs separate to, and perhaps in competition with, the formation of oligomeric 
intermediates.  
Interestingly, it appears that while amyloid formation appears reminiscent of other 
protein polymerization events, such as actin and tubulin, it does not appear to be completely 
described by simple polymerization models (Ross et al., 2003; Thirumalai et al., 2003). 
Further studies to observe the fibrilisation of recombinant PrP displayed several kinetic 
features that can not be explain by either model (Baskakov, 2007a). These include a dramatic 
effect of reaction volume on the length of the lag phase, a volume dependent threshold effect 
and highly cooperative sigmoidal kinetics of the polymerization process, all of which are 
consistent with the mechanisms of branched chain reactions (Baskakov, 2007a; Collins et al., 
2004a). Branched chain reactions progress through nucleation, monomer addition and are 
accompanied by multiplication of active centres. Presumably this occurs as a result of fibril     29   
fragmentation which is considered to be an essential step in prion replication through the 
multiplication of active centres (Baskakov, 2007a). Several studies have indicated a reverse 
correlation between disease incubation period and the conformational stability of synthetic 
prions (Legname et al., 2005; Legname et al., 2006). Studies with AFM investigating the 
growth and divisions rates of three strains of Sup53 prions and their in vivo phenotypes have 
demonstrated that high fibrillar conformational stability correlated with the slowest aggregate 
growth rate (Tanaka et al., 2006). However, this was shown to be compensated for by an 
increase in brittleness of aggregates, thereby generating new seeds. Short fibrils or their 
fragments generated through fibril fragmentation can be found in substantial quantities during 
the initial stages of prion conversion and also at the final stages of elongation (Sun et al., 
2008).  
 
 
1.5. THE INFECTIOUS AGENT  
 
  There is now available a substantial body of evidence which supports the protein only 
hypothesis (Castilla et al., 2005a; Collinge, 2001; Prusiner, 1986; Prusiner et al., 1993; Sailer 
et al., 1994; Weissmann et al., 1994). The pathological conformer of the prion protein can be 
co purified with infectivity and the concentration of the prion protein has previously been 
demonstrated to be proportional to the infectivity titre (Gabizon et al., 1989). Infectivity can 
be reduced by protein denaturants and antibodies targeted to the prion protein but is not 
affected by procedures that normally destroy nucleic acids (Alper et al., 1967). Moreover, no 
virus or nucleic acids have been consistently associated with the infectious agent and all 
inherited cases of TSE are linked to PRNP mutations (Meyer et al., 1991; Prusiner, 1998; 
Safar et al., 2005). In addition, conversion of PrP
c to PrP
res has been achieved with infectivity 
generated in vitro, which is considered final proof of the prion hypothesis (Castilla et al., 
2005a; Deleault et al., 2003; Kocisko et al., 1994; Kocisko et al., 1995; Legname et al., 2005).  
  However, prion disease pathology and a clinical disease phenotype may exist in both 
animals and humans in the absence of detectable prion associated amyloid and/or PrP
res 
(Piccardo et al., 2007). Whilst several genetically distinct forms of GSS, vCJD and iCJD are 
regularly associated with amyloid deposition and the formation of plaques, several prion 
diseases demonstrate little, or often no, higher order amyloid formation (DeArmond & 
Prusiner, 1995; DeArmond, 2004; Will et al., 1996). The majority of sCJD cases (with the 
exception of the newly classified PSPr) and BSE represent two such diseases where no prion     30   
associated amyloid deposition occurs (Capobianco et al., 2007; Gambetti et al., 2008; Murray 
et al., 2008). Conversely, nearly all forms of TSE are associated with accumulation of PrP
res 
(with the exception of several cases of FFI) and PrP peptides comprising the hydrophobic 
domain have been demonstrated to be toxic to cultured neurons (Dupiereux et al., 2006; 
Gambetti et al., 1995). However, an apparent uncoupling of PrP
res and infectivity has been 
observed in lethal scrapie like disease in mice over expressing mutant transgenes, in wild type 
mice inoculated with BSE or FFI and in transgenic mice homozygous for a mutation at 
residues 101, replacing a proline with a leucine (Barron et al., 2007; Collinge et al., 1995; 
Lasmezas et al., 1997; Manuelidis et al., 1997; Telling et al., 1996). Barron et al., (2007) 
demonstrated prion infected mice with the P101L mutation exhibited characteristic 
vacuolation when inoculated with hamster 263K scrapie or human GSS. This disease was 
shown to be transmissible to 101L mice with an incubation time of 100 160 days. However, 
immunoblot analysis demonstrated low and sometimes non existent PrP
res. Despite the 
acknowledgment that high titres of infectivity can not necessarily be expected in animals 
which display such short incubation periods of disease, subsequent studies demonstrated titres 
of 10
7   10
9 IU/g to be present in the brain, with low or no detectable PrP
res. In another study, 
isolated gut loops inoculated with scrapie were transferred into the gut of 2 3 month old 
Suffolk lambs with the ARQ/ARQ genotype to investigate the mechanisms of intestinal 
transport of scrapie infection and early pathogenesis (Jeffrey et al., 2006). Detection of PrP
res 
in villous lacteals and in sub mucosal lymphatics was possible 15 210 minutes post challenge 
in the gut and, up to 24 hours post challenge, PrP
res was also detected in association with 
dendritic like cells in draining lymph nodes. Surprisingly however, at        1 month post 
infection (p.i.), de novo generated, inoculum associated PrP
res was found in the Peyer’s 
patches, distinct from that observed during the early phase which was not visible with 
immunochemistry prior to 30 days p.i. Two sheep which were allowed to develop clinical 
disease showed subsequent accumulation and pathogenesis of disease identical to those seen in 
natural scrapie. 
Within the confines of the prion hypothesis, it is possible that in many of these studies 
infectivity associates with levels of PrP
res below immunohistochemical detection thresholds. 
No data has been presented using the highly sensitive PMCA method to amplify levels of 
PrP
res in these tissues. However, the PMCA technique has demonstrated de novo generation of 
PrP
res in the absence of a pre existing prion seed. The generated material transmitted disease to 
wild type hamsters producing a new disease phenotype with unique clinical, 
neuropathological and biochemical characteristics (Barria et al., 2009). The isolation of PrP
res     31   
in PSPr would also suggest that infectivity can associate with a protease sensitive isoform of 
PrP
res, which could potentially exist in other natural and laboratory strains but be removed 
through the aggressive immunohistochemical treatments used to degrade PrP
c prior to 
antibody detection. However, knockout of neuronal PrP
c during established brain infection 
results in complete reversal of early pathology and behavioural deficits, preventing neuronal 
loss and clinical disease (Mallucci et al., 2003; Mallucci et al., 2007). This occurs despite 
continuous production and replication of PrP
res in the brain which eventually reach similar 
levels to those observed at end stage disease in wild type mice.  
  The fact that infectious disease and PrP
res can exist separate from one another suggests 
that, whilst PrP
res is likely to be a major component of the infectious agent, it may not be 
responsible for CNS pathology. As a result, the most neurotoxic entity may not be PrP
res but 
another form of the prion protein. The fact that chronic deposition of PrP
res is not toxic in 
PRNP knockout mice is consistent with the hypothesis that an oligomeric product formed 
during PrP
res production and higher order growth may represent the toxic agent (Brandner et 
al., 1996; Bueler et al., 1993; Merlini & Bellotti, 2003).  
There is growing evidence to suggest that pre fibrillar, soluble oligomeric 
intermediates represent the infectious agent in GSS and several other amyloidoses such as 
Alzheimer’s disease (Cleary et al., 2005; Kayed et al., 2003; Kirkitadze et al., 2002). In vivo, 
56 kDa dodecameric assemblies of Aβ 1 42 have demonstrated an association with memory 
deficiencies in a murine model of Aβ, resulting in transient memory impairment following 
inoculation into rat brain (Lesne et al., 2006). This was proposed to occur independently of 
plaque formation or neuronal loss. In a zebra fish embryo model, the expression of polyQ 
expanded fragments of Huntington (Htt) results in their accumulation as large, SDS insoluble 
cell inclusions whilst apoptotic cells are devoid of visible aggregates (Schiffer et al., 2007). 
Interestingly, anti prion compounds were able to prevent the formation of insoluble aggregates 
but did not suppress abnormal embryo morphology or cell death suggesting upstream soluble 
Htt assemblies are the toxic culprit.  
In prion disease, there is contrasting evidence surrounding the relationship between 
infectivity and PrP particle size. Oligomeric PrP has been shown to be highly infectious both 
in vitro and in vivo (Redecke et al., 2007; Silveira et al., 2005). Infectivity and converting 
activity has been shown to peak at a particulate size of 17 27 nm (300 600 kDa) (Silveira et 
al., 2005). In larger fibrils, the ability to demonstrate infection and stimulate PrP
c to PrP
res 
conversion was found to be lower and virtually absent in oligomers of ≤5 PrP molecules. This 
suggests non fibrillar particles of 14 28 PrP molecules are more efficient initiators of prion     32   
disease. Conversely, however, recombinant amyloid fibrils have demonstrated the potential to 
transmit  prion  disease  (Legname  et  al.,  2004).  Mature  amyloid  fibrils  produced  from  full 
length  recombinant  PrP  have  been  shown  to  be  highly  toxic  to  cultured  cells,  primary 
hippocampal and cerebella neurons in a time and dose dependent manner (Novitskaya et al., 
2007). However, the lethal effects were comparable with those exhibited by small, soluble β 
oligomers, suggesting that, in vitro at least, both amyloid and oligomeric intermediates are 
neurotoxic.  
Critically, kinetic data has suggested that the β oligomer is not on the pathway to 
amyloid formation and therefore may not represent an intermediate structure but an alternative 
product of misfolding. This is supported by data from recombinant PrP demonstrating 
formation of two distinct β sheet rich isoforms, a β oligomer and amyloid fibrils (Baskakov et 
al., 2004). Preferences for the formation of an oligomer or amyloid can be dictated by 
experimental conditions (Baskakov et al., 2002b). An acidic pH, similar to that found in 
endocytic vesicles, favours an oligomeric form of PrP, with neutral pH forming amyloid. The 
kinetics of fibril formation at different pH values suggest that the formation of the oligomeric 
isoform is not on the kinetic pathway to fibrillar formation. Therefore it is likely that there are 
multiple routes of conversion and misfolding occurring in distinct, competitive reactions. 
Strain variation or altered misfolding environments presumably dictate which conversion 
pathway is favoured. This may be a consequence of the intrinsic ability of PrP to adopt 
different abnormal conformations under pathological conditions (Baskakov et al., 2004). 
 
 
1.6. PRION DISEASE PATHOGENESIS 
 
The  clinical  presentation  of  prion  diseases  can  vary  significantly  between  the 
prionopathies. For example, the consequent insomnia observed in FFI is a result of bilateral 
degeneration  of  the  thalamus  (Belay,  1999).  In  contrast,  the  pathophysiology  of  kuru  is 
targeted to the cerebellum resulting in the involuntary movements and ataxia coupled with a 
fine tremor of the head, trunk and limbs (Brown, 1990; Liberski & Brown, 2004). Broadly 
however the prion diseases are characterised clinically by rapidly progressive and devastating 
dementia,  which  may  result  in  akinetic  mutism  within  weeks.  In  addition,  pyramidal  and 
extrapyramidal signs are observed, in addition to involuntary movements such as myoclonus, 
dystonia and chorea (Kubler et al., 2003; Poser, 2002).     33   
Prion pathogenesis can be separated into three distinct phases: infection and peripheral 
replication,  peripheral  migration  accompanied  by  neuroinvasion  and,  finally,  progressive 
neurodegeneration producing clinical symptoms. 
 
1.6.1. Infection and Peripheral Replication 
 
The oral route of infection is believed to be important in the natural pathogenesis of 
scrapie, variant CJD and other prion diseases (Jeffrey et al., 2006).  However, the transmission 
of the infectious agent from the gut to the CNS is not fully understood. It is believed that PrP
res 
transverses the gut wall by way of the M cells of the follicle associated epithelium (FAE) 
through transepithelial transport, and into the Peyer’s patches through the dome (Heppner et 
al., 2001; Neutra et al., 1996). Infectivity is then detected in the gut associated lymphoid 
tissue (GALT) in the very early stages of disease, as well as the tonsils, spleen and draining 
lymph nodes suggesting that initial replication of infectivity occurs in these tissues 
(Andreoletti et al., 2000; Sigurdson et al., 1999). Infectivity titres in the lymphorecticular 
system (LRS) increase towards a plateau during the early stages of incubation, a considerable 
amount of time prior to neuroinvasion. However, the time frame for this accumulation of 
infectivity and the overall prerequisite of the LRS for pathogenesis is highly dependent on the 
strain of the prion and/or polymorphisms of the PRNP gene (Jeffrey et al., 2006). Importantly, 
studies have demonstrated that mice are resistant to scrapie prion infection through extraneural 
routes following loss of functional germinal centres of lymphoid follicles (Klein et al., 1997; 
Mabbott et al., 2000a; Mabbott et al., 2000b). However, sheep homozygous for the VRQ 
allele demonstrate an earlier accumulation of PrP
res in lymphoid follicles of Peyer’s patches 
relative to ARQ homozygotes (Andreoletti et al., 2000; Jeffrey et al., 2001a; Jeffrey et al., 
2001b; van Keulen et al., 2002). In natural cases of BSE, infectivity is not detected at all in 
lymph nodes or the spleen following oral exposure or in the lymph nodes of Nor98 sheep 
(Benestad et al., 2003; Somerville et al., 1997; Terry et al., 2003; Wells et al., 2005). In the 
hyper (HY) strain of TME, both splenic and nodal prion replication is observed following both 
intra peritoneal (i.p.) and oral inoculation (Bartz et al., 2005). In contrast, PrP
res is not detected 
in the spleen or lymph nodes following i.p or oral challenge of the drowsy (DY) strain of 
TME. No clinical disease is observed at all with i.p inoculation. These data suggest highly 
variable, strain dependent modes of peripheral replication.   
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1.6.2. Peripheral Migration and Neuroinvasion 
 
Accumulation  of  infectivity  is  known  to  occur  within  the  follicular  dendritic  cells 
(FDC)  of  the  LRS  (Kitamoto  et  al.,  1991).  Prion  replication  within  the  spleen  has  been 
demonstrated  to  be  highly  dependent  on  PrP
c expressing  FDCs  (Brown  et  al.,  1999). 
Consequently, FDC deficient mouse models exhibit diminished prion replications relative to 
wild type mice following peripheral exposure (Prinz et al., 2002). Follicular dendritic cells 
support formation and preservation of lymphoid microarchitecture and, in addition, play  a 
pivotal  role  in  the  initiation  and  maintenance  of  the  secondary  antigen  response  through 
presentation of antigens to receptors of the complement system (Aguzzi, 2006). Transgenic 
mice lacking complement factors such as the C3 component display an increased resistance to 
peripheral scrapie inoculation (Klein et al., 2001; Mabbott et al., 2001).  
Initial deposition of PrP
res in the CNS can be observed in the dorsal motor nucleus of 
the vagus nerve and in the intermedio lateral column of the spinal cord indicating that neither 
the blood nor lymph fluid is responsible for the transportation of infection to the CNS (Jeffrey 
et al., 2006). Data has suggested that the autonomic nervous system is responsible for 
transport of prion infectivity from lymphoid organs to the CNS (McBride & Beekes, 1999). 
Importantly, the innervation pattern of lymphoid organs is primarily sympathetic and 
sympathectomy has been demonstrated to delay the onset of clinical scrapie following i.p 
inoculation (Felten et al., 1988; Glatzel et al., 2001). Conversely, sympathetic 
hyperinnervation enhances splenic prion replication and consequent neuroinvasion. There is 
strong evidence to suggest that accumulation of prions within the FDCs is followed by 
movement of the infectious agent to neighbouring nerve endings followed by progression 
through a neuroretrograde mechanism to the CNS. However, there is no direct physical 
synapse between FDCs and sympathetic nerve endings (Heinen et al., 1995). The distance 
between FDCs and splenic nerves has been demonstrated to reduce the velocity of 
neuroinvasion (Prinz et al., 2003). The mechanism of the movement between FDCs and nerve 
endings is unclear, whether by passive diffusion or the active process of transport by mobile 
cells such as B cells. Importantly, blood borne infectivity implies that mobile cells are likely 
to be important in the peripheral spread of prions (Llewelyn et al., 2004; Peden et al., 2004). 
The nature of the cells is likely to be haematopoietic as wild type bone marrow has been 
demonstrated to restore prion replication in PRNP
0/0 spleens (Blattler et al., 1997). Moreover, 
data suggests that in the presymptomatic stages of disease, PrP
res may be largely associated 
with white blood cells, whilst at later disease stages it is largely present, unattached to cells,     35   
within the plasma due to brain leakage (Saa et al., 2006a).  As FDCs are immobile and thought 
to derive from non haematopoietic stem cells, they are not directly responsible for prion 
transportation. However, interaction with B cells of the immune system has been shown to be 
highly important for peripheral migration of prions, with expression of PrP
c not a prerequisite 
for neuroinvasion (Klein et al., 1997; Klein et al., 1998). As a result, B cells are unlikely to 
represent a major replicative compartment. However, B cells are mainly localised to areas of 
lymphoid follicles such as the spleen, lymph nodes, tonsils and Peyer’s patches and express 
lymphotoxin α/lymphotoxin β trimers on their surface. Interaction with this structure is 
required by FDCs for maturation (Aguzzi, 2006). Blockage of lymphotoxin β signalling has 
been shown to impair neuroinvasion, accumulation of peripheral PrP
res and infectivity 
(Montrasio et al., 2000). Whilst physiologically localised to areas of lymphoreticular organs, 
following chronic inflammation B cells migrate to and colonise the site of inflammation. 
Interestingly, superimposing chronic inflammation of the liver, pancreas or kidney with prion 
infection has been demonstrated to result in progressive accumulation of PrP
res at the site of 
inflammation to a degree that can be expected in tissues of the LRS (Heikenwalder et al., 
2005). 
 
1.6.3. Neurodegeneration 
 
Premature  cell  death  due  to  apoptosis,  as  identified  by  caspase  activation,  is  a 
characteristic feature of prion disease (Ferrer, 2002). However, this is preceded by several 
early  changes  in  normal  cellular  function.  These  include  primary  neuronal  dysfunction 
associated with early behavioural impairments and a loss of synapses (Cunningham et al., 
2003; Mallucci et al., 2003; Mallucci et al., 2007). In ME7 scrapie infected mice, a significant 
reduction in synaptophysin was observed in CA1 pyramidal cells, 13 weeks after hippocampal 
inoculation suggesting a loss of pre synaptic terminals (Cunningham et al., 2003). This also 
manifests physically as a reduction in burrowing, nesting and glucose consumption; several 
highly conserved behavioural changes observed in mice during the early stages of scrapie 
disease. Dendritic atrophy is also a prominent feature of prion disease (Jamieson et al., 2001). 
Levels of Notch 1, which is involved in dendrite growth and maturation, and the intracellular 
fragment  of  Notch 1,  increase  in  parallel  with  PrP
res  expression  in  the  neocortex  of  mice 
(Ishikura et al., 2005).  
  The mechanisms of neurodegeneration leading to neuronal death and the consequent 
clinical symptoms remain unclear. The most widely discussed hypothesis behind the     36   
conversion of the prion protein to a pathological conformer is attributed to a toxic gain of 
function whereby PrP
res possesses deleterious effects that are not related to the normal 
physiological function of PrP
c. Current data however suggests that the normal physiological 
function of PrP
c is crucial for the induction of prion induced neuropathology. Expression of 
the cellular protein is required to render neurons in the brain susceptible to toxic affects of 
PrP
res in grafted brain tissue and neighbouring astrocytes (Brandner et al., 1996; Mallucci et 
al., 2003). Consequently, a potential loss of function could possibly be used to explain the 
onset of prion neuropathology whereby the normal physiological activity of PrP
c is lost or 
reduced leading to neurodegeneration upon contact with PrP
res. This, however, remains 
unlikely for several reasons. Firstly, a loss of function model for the acquisition of prion 
disease is contrary to the dominant mode of inheritance of familial prion diseases such as 
fCJD. Secondly, pre natal and post natal knockouts of PrP expression do not lead to 
pathological features associated with prion disease, although normal functioning of PrP
c may 
be adopted by another protein in its absence (Bueler et al., 1992; Mallucci et al., 2002). 
Interestingly, a loss of function has been implicated in other amyloidoses. Huntington (Htt) 
promotes neuronal survival under normal physiological conditions and, as such, loss of 
function may lead to disease pathogenesis (Cattaneo et al., 2001). Mice lacking Htt 
demonstrate extensive cell death and lethality in the embryonic ectoderm and over expression 
of this protein has been shown to lead to a decrease in cellular toxicity in Htt mutants 
(Rubinsztein, 2002; Zeitlin et al., 1995). In Parkinson’s disease, α synuclein which can be 
found throughout the Lewy bodies in pathological brain tissue may possess anti apoptotic 
activity. Expression of wild type α synuclein in primary neurons has been shown to protect 
against cell death in several induced stresses (da Costa et al., 2000).  
The theory of a subversion of function would account for the problems associated with 
the loss and gain of function mechanisms but is yet to be conclusively proven. This suggests 
that interaction with PrP
res leads to the cell receiving neurotoxic signals from PrP
c thereby 
subverting the normal neuroprotective role. This may be a result of aggregation of PrP
res at the 
cell surface or blocking of critical residues of PrP
c important for normal physiological activity. 
This mechanism has been supported by crucial data suggesting that the in vivo cross linking of 
PrP
c with primary antibodies induces neuronal apoptosis in the hippocampus and cerebellum 
(Solforosi et al., 2004).  
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1.7. FACTORS INFLUENCING PRION DISEASE TRANSMISSION 
 
1.7.1. Prion Strains 
 
  One  of  the  greatest  challenges  to  the  validity  of  the  prion  hypothesis  has  been 
describing the existence of multiple strains of the infectious agent, in the absence of a prion 
associated nucleic acid  or virus. Besides natural prion strains, there are a wide variety  of 
experimental strains, isolated from diverse sources, that are available as laboratory models of 
prion disease (Table 3).  
 
Table 3 Experimental prion strains and their origin. Adapted from Beringue et al., 
2008b. 
Name  Origin  Host 
ME7
  Sheep scrapie
a  Mouse 
87A
  Sheep scrapie
a  Mouse 
221C  Sheep scrapie
a  Mouse 
87V  Sheep scrapie
a, SSBP/1
c  Mouse 
79A  SSBP/1
bc  Mouse 
79V  SSBP/1
bc  Mouse 
139A or RML  SSBP/1
bc  Mouse 
22C  SSBP/1
b  Mouse 
22H  Uncloned 22C  Mouse 
22L  SSBP/1
b  Mouse 
22A  SSBP/1
b  Mouse 
22F  Cloned 22A  Mouse 
301C  BSE  Mouse 
301V  BSE  Mouse 
6PB1  BSE  Mouse 
139H  Cloned 139A  Syrian Hamster 
263K  SSBP/1
bc  Syrian Hamster 
SC237  Subclone of 263K  Syrian Hamster 
ME7 H  Cloned ME7  Syrian Hamster 
HY
d  TME  Syrian Hamster 
DY  TME  Syrian Hamster 
aField  isolate, 
bSSBP/1:  sheep  scrapie  brain  pool  1, 
cPassage  of  SSBP/1 
through  goats, 
dTME:  Transmissible  spongiform  encephalopathy  – 
Stetsonville isolate. 
 
Divergent  strains  are  defined  by  their  altered  incubation  times,  in  addition  to  the 
biochemical  properties  and/or  immunological  properties  of  PrP
res,  including  glycosylation 
pattern and degree of PK resistance which is reflected by altered access to the N terminal of     38   
the prion protein (Beringue et al., 2008b; Scott et al., 1997). In addition, different strains also 
demonstrate clearly distinct patterns of PrP
res deposition and patterns of vacuolation, which 
can be expressed as pathological lesion profiles (Figure 6) (Peretz et al., 2002; Safar et al., 
1998). These properties are stable following serial passaging in the same host. 
For example, the incubation times of the two experimental prion scrapie strains ME7 
and  263K  are  168  and  90  days,  respectively  (Fichet  et  al.,  2004;  Guenther  et  al.,  2001). 
Sporadic  CJD  and  variant  CJD  can  also  be  separated  from  one  another  based  on  their 
incubation times; 4 months and 13 months, respectively (Murray et al., 2008). The newly 
classified form of CJD, PsPr, has also shown an increased sensitivity to PK resistance and, 
therefore, biochemical stability, compared to other CJD isolates (Gambetti et al., 2008). In 
terms of the glycosylation pattern, BASE and BSE H can be separated from each other based 
on their electrophoretic profile (Biacabe et al., 2004; Casalone et al., 2004). Moreover, in 
terms of the lesion profile and deposition of PrP
res, variant CJD is markedly different from 
kuru,  demonstrating  significantly  increased  concentrations  of  PrP
res  across  all  areas  of  the 
CNS (McLean, 2008).  
  Different organ tropisms are also recognisable between strains. Some strains directly 
target the CNS and demonstrate a low abundance or complete absence in secondary lymphoid 
tissues. In contrast, other strains also exhibit deposition of PrP
res and infectivity in the CNS in 
addition  to  widespread  distribution  throughout  lymphoid  organs.  For  example,  the 
pathogenesis of vCJD differs substantially from other forms of CJD due to the extensive and 
uniform  colonisation  of  PrP
res  throughout  the  lymphoreticular  system  (Head  et  al.,  2004; 
Wadsworth et al., 2001). As a result, clinical diagnosis of vCJD can often be made by tonsil 
biopsy with comparative levels of PrP
res reaching 10 % of those in the CNS (Hill et al., 1999; 
Wadsworth et al., 2001). Conversely, infectivity in kuru is present in the CNS but very rarely 
in muscle, which would explain the distribution of disease mainly in the women and children 
of the Forè tribe described in section 1.2 (Brandner et al., 2008). 
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Figure 6 Strain specified propagation of prions. A) Generation of new infectious seeds under 
the  nucleated  polymerisation  model  of  prion  replication.    B)  Experimental  inoculation  of 
infectious seeds from two different prions strains into rodent model results in death. Strain 1 
and strain 2 demonstrated clearly distinct 1) attack rate and incubation periods preceding onset 
of symptoms and death; 2) Electrophoretic profiles of PrP
res upon detection using Western blot 
with  three  separate  banding  patterns  corresponding  to  the  size  and  relative  ration  of 
biglycosylated (BiGc), monoglycosylated (MonoGc) and unglycosylated (UnGc)  glycoforms; 
3)  Distribution  of  PrP
res  deposition  throughout  the  CNS  as  demonstrated  by  histoblots  of 
coronal sections; 4) Distribution and intensity of vacuolation in standardised brain areas as 
shown in a “lesion profile”. Taken from Beringue et al., 2008b. 
   
1.7.2. The Species Barrier 
 
  It is suggested that the properties of strains are encoded within their conformation and 
not by the host protein, with glycosylation patterns and specific polymorphisms capable of 
enhancing diversity (Caughey et al., 1998; Manuelidis et al., 2009; Peretz et al., 2002; Safar et 
al., 1998). In addition, the role of varied aggregate fragmentation rates between strains has 
also been suggested (Tanaka et al., 2006). However, the so called “species barrier” is also an     40   
important  modulator  of  cross species  transmission  which  can  be  highly  variable  either 
resulting  in  a  failure  to  generate  disease,  increased  incubation  times  or  a  normal  clinical 
course. The species barrier is thought to be controlled by the interplay of several host factors 
important for strain diversity which can impact on the structural homology of the cellular and 
pathogenic prion protein isoforms between donor and host (Johnson et al., 2006; Moore et al., 
2005). The resistance of mice to hamster scrapie can be subverted by expression of hamster 
PrP
c  in  transgenic  mice  suggesting  a  primary  role  for  structural  differences/similarities 
between  recipient  PrP
c  and  donor  PrP
res  in  regulation  of  the  species  barrier,  potentially 
influenced by protein X (Scott et al., 1989). Interestingly, resistance can be abrogated upon 
repeated subpassages of a strain within a resistant host reflecting a host donor adaptation. The 
route of infection can also greatly modify the magnitude of the species barrier. Classically, 
peripheral  or  oral  routes  are  less  effective  that  i.c.  inoculation,  with  infectivity  of  mouse 
scrapie 5 log lower upon intragastric compared with i.c. inoculation (Kimberlin & Walker, 
1988). Importantly, the aspects of strain diversity and the species barrier have been brought 
together in several studies to assess the transmission properties of BASE and BSE H forms of 
BSE. Mice are completely resistant to the BSE H subtype (Beringue et al., 2008a). However, 
the BASE variant has been shown to propagate in transgenic mice expressing human PrP with 
no  significant  transmission  barrier.  This  is  supported  by  a  complete  attack  rate,  lack  of  a 
reduction  in  incubation  time  and  conservation  of  PrP
res  electrophoretic  profile.  However, 
transmission of BSE to some mice demonstrates a substantial species barrier suggesting BASE 
may represent a higher zoonotic risk than classical BSE (Kong et al., 2008). This has also 
been  confirmed  in  transmission  studies  using  primates  whereby  the  phenotypic  and 
biochemical  properties  of  BASE  demonstrated  similarities  to  a  subtype  of  sCJD  patients 
raising the possibility that this form of sCJD may be acquired as a result of the consumption of 
BASE infected meat products (Brown et al., 2006; Casalone et al., 2004; Comoy et al., 2008).  
 
1.7.3. Genetic Susceptibility 
 
  The influence of the PRNP gene in cross species transmission can be observed by the 
difference in genetic susceptibility in several species. Sheep exhibit variable susceptibility to 
both experimental and natural scrapie which is highly influenced by polymorphisms at codons 
136,  154  and  171  (Goldmann  et  al.,  1990;  Goldmann,  2008).  Amino  acids 
alanine/valine/threonine  (A/V/T),  arginine/histidine/leucine  (R/H/L)  and  arginine/histidine/ 
glutamine/lysine  (R/H/Q/K)  can  be  encoded  as  these  positions,  respectively.  Sheep     41   
homozygous for the VRQ alleles at these three positions are highly susceptible to classical 
scrapie, whereas ARR homozygote genotypes display a marked resistance to infection (Belt et 
al., 1995; Elsen et al., 1999). Interestingly, atypical scrapie cases occur, not only in classical 
scrapie susceptible genotypes such as VRQ or ARQ, but also in highly resistant genotypes of 
classical  scrapie  such  as  ARR  and  AHQ  (Buschmann  et  al.,  2004;  Everest  et  al.,  2006). 
Moreover, sheep homozygous for the ARQ allele are also more susceptible to BSE infection 
than ARQ heterozygotes (Houston et al., 2003). 
In humans, several polymorphisms are thought to play a role in susceptibility. A lysine 
rather  than  a  glutamine  at  codon  219  of  PRNP  may  be  protective  against  sporadic  CJD 
(Aguzzi, 2006). Recently, Mead et al., (2009) identified an association between vCJD and 
kuru susceptibility and incubation times in a region upstream of STMN2, a gene encoding the 
neural growth associated protein SCG10. However, the description of CJD in two siblings 
unexplained  by  PRNP  mutation  suggests  other  susceptibility  factors  unassociated  with  the 
prion protein gene (Webb et al., 2008).  
That prion transmission proceeds more efficiently when host PrP
c and donor PrP
res are 
identical in structure is supported by the fact that the majority of sporadic and acquired cases 
of CJD occur in individuals homozygous at codon 129. The single nucleotide polymorphism at 
codon 129 is the greatest identified modulator of genetic susceptibility in humans, with either 
a methionine (M) or valine (V) encoded (Mead et al., 2009). Polymorphisms at this locus have 
been suggested to influence the exposure of the helix 1 region of PrP, potentially influencing 
the kinetics of amyloid formation (Lewis et al., 2006b; Pham et al., 2008).  
It is estimated that around 39 % of the Caucasian population of the UK are 
homozygous for the more common allele methionine at codon 129. Approximately 50 % are 
known to be heterozygotes and the remainder (around 11 %) homozygous for valine (Gacia et 
al., 2006; Will, 2003). Importantly around 85 % of all cases of sCJD occur in patients 
homozygous at codon 129, where around 70 75 % are MM rather than VV (Collinge et al., 
2006; Ena, 2005). Additionally, 50 % of patients with iatrogenic CJD and all known cases of 
the new prionopathy PSPr have been VV homozygotes (Ena, 2005; Gambetti et al., 2008). It 
is therefore apparent that subjects who are heterozygotes (MV) appear to have an increased 
resistance to disease.  
  This is of critical importance in light of the BSE outbreak and subsequent risk of 
variant CJD in humans. All vCJD patients to date have been methionine homozygous at codon 
129 (Aguzzi, 2006; Asante et al., 2006). However, both valine homozygotes and 
heterozygotes are known to be susceptible to disease. Successful transmission of variant CJD     42   
to “humanised” transgenic mice has been achieved for each codon 129 genotype and suggests 
that MV and VV individuals are likely to remain in an infectious, asymptomatic state for a 
significantly longer period of time before disease onset, with incubation periods occasionally 
exceeding the average life span (Bishop et al., 2006). Moreover, in humans, transmission of 
vCJD through blood transfusion to an MV heterozygote has previously been described and an 
anonymous screening study of archived appendix tissues identified two valine homozygotes 
that were positive for vCJD associated PrP
res (Ironside et al., 2006; Peden et al., 2004). 
Therefore, if the influence of this locus is ultimately on incubation time rather than 
susceptibility, a second wave of vCJD cases with an increased latent period may be 
forthcoming.  
 
1.7.3.1. Asymptomatic carriers 
 
Importantly, long incubation periods exceeding 50 years have been observed in cases 
of kuru, relative to the standard 3 6 months usually observed (Collinge et al., 2006). Eleven 
kuru patients with the MV genotype at codon 129 demonstrated an incubation period of 
between 39 – 56 years until disease onset, suggesting that this genotype is indeed associated 
with an increase in incubation time. A consequence of long incubation periods is the potential 
for asymptomatic carriers of disease. A so called “carrier state” can be established following 
prion inoculation into a second species (Race et al., 2001). Wild type mice inoculated with 
Sc237 hamster prions have been shown to propagate mouse adapted PrP
res but progress 
through a normal life span in the absence of disease symptoms (Hill et al., 2000). Prions were 
shown to replicate slowly in these mice but ultimately reach titres normally associated with 
end stage clinical disease. In addition, PrP
res is detectable in the blood of asymptomatic sheep 
and cattle, in the absence of either in vitro or in vivo amplification (Terry et al., 2009). 
Moreover, the saliva and blood of pre symptomatic CWD deer have also been shown to 
contain detectable PrP
res and infectivity capable of transmitting to naïve deer (Mathiason et al., 
2009).  
In humans, an elderly patient was shown to have contracted vCJD through a blood 
transfusion of non leucodepleted red cells from a patient who later developed the disease 18 
months after donation (Peden et al., 2004). The same report also identified seventeen other 
individuals who received labile blood components from donors who were later diagnosed with 
vCJD. A model of the future course of the vCJD epidemic, accounting for subclinical infection 
and a wider genetic susceptibility, optimistically estimated the number of cases between 2004     43   
and 2080 as fifty four (Clarke & Ghani, 2005). However, a pessimistic approach suggests that 
363 cases of vCJD may arise in the same time period. Screening of archived surgical 
specimens has suggested that 237 per million of the population may be incubating the disease 
(Hilton et al., 2004).  
 
 
1.8. IATROGENIC CREUTZFELDT JAKOB DISEASE  
   
  The first case of iatrogenic CJD (iCJD) was reported in 1974 following a corneal 
transplant (Duffy et al., 1974; Martinez Lage et al., 2005). Since that time cases of iCJD have 
been documented following dural grafts, cadaveric derived human growth hormone (hGH) and 
gonadotropin transfer, in addition to blood transfusions (Centers for Disease Control, 1985; 
Centers for Disease Control, 1987; Cochius et al., 1990; Cochius et al., 1992; Hammersmith et 
al., 2004; Martinez Lage et al., 2005; Peden et al., 2004; Preusser et al., 2006; Sato, 2003; 
Thadani et al., 1988; Wallis et al., 2004). Approximately 400 cases of iCJD have been 
confirmed worldwide; with half of all cases as a result of dura mater grafts (Hamaguchi et al., 
2009; Yamada et al., 2009). All iCJD cases have involved transmission of infection by 
material in, or adjacent to, the CNS with inoculation by the parenteral route through surgery or 
intramuscular injection (Will, 2003).  
Consequently, there is significant concern that iatrogenic transmission of prions may 
occur through neurosurgery and contaminated neurosurgical instruments such as EEG depth 
electrodes. The infectious agent has been shown to associate avidly with surgical grade 
stainless steel, with particular affinity for nickel and molybdenum (Flechsig et al., 2001; Luhr 
et al., 2009; Zobeley et al., 1999). Moreover, the physiochemical nature of PrP
res creates a 
significant challenge for decontamination practices. Standard methods for the disinfection of 
bacteria and viruses, such as germicidal light, glutaraldehyde, formaldehyde and alcohol 
possess a negligible effect on the inactivation of TSE agents (McDonnell & Burke, 2003; 
Moore et al., 2005). Furthermore, prion extracts from crude brain tissue of scrapie infected 
hamsters have been shown to withstand temperatures of up to 600 ºC and remain infective 
(Brown et al., 2000). Whilst some antimicrobial agents, such as steam sterilisation, have 
shown limited ability to reduce the risks associated with surface contamination, in most cases 
TSE agents are clearly more resistant than traditionally used bacterial spores to validate such 
processes (Fichet et al., 2004).      44   
The iatrogenic spread of prions by surgical instruments has been proven as an effective 
route of disease transmission. Bernoulli et al., (1997) demonstrated cases of two patients who 
contracted and rapidly developed CJD through a neurosurgical electrode which had previously 
been inserted into the cerebral cortex of a patient with prion disease. Subsequent 
decontamination involved treatment with benzene, 70 % ethanol and formaldehyde vapour. 
Infectivity upon implantation of the same electrode tip into the brain of a chimpanzee was 
demonstrated several years later (Gibbs, Jr. et al., 1994).  
Currently, patients are routinely assessed prior to undergoing “high risk” surgical or 
neuro endoscopy procedures to determine whether they have an increased risk of CJD. High 
risk surgery is classed as those involving either the brain, spinal cord, dura mater, cranial 
nerve (specifically the optic nerve and intracranial components of other cranial nerves), cranial 
nerve ganglia, posterior eye and the pituitary gland (guidance from the Health Protection 
Agency). In addition, those patients identified as receiving blood transfusions from eighty or 
more donors since 1980 are determined to have an increased risk of vCJD and special 
infection control procedures are implemented. An average of fifty such cases are identified per 
year (Department of Health, 2003). However, whilst the highest infectivity titres are 
associated with the CNS, studies into the pathophysiology of prion diseases have identified 
extraneural deposition of PrP
res in a wide range of tissues in both the variant, iatrogenic and 
sporadic forms of CJD. Among these, PrP
res is readily detected in lymphoid tissues including 
the spleen, tonsil, rectal tissue, skeletal muscle and blood suggesting a significant risk of 
transmission through extraneural surgery, in addition to neurosurgical procedures (Bruce et 
al., 2001; Glatzel et al., 2003; Peden et al., 2006; Wadsworth et al., 2007). Interestingly, an 
asymptomatic carrier state has been shown to be induced by low dose inocula, such as may be 
encountered in extra neural tissues (Thackray et al., 2002). This indicates that transmission by 
surgical practice may be able to establish a chronic subclinical state in patients resulting in 
further transmission assuming ineffective instrument decontamination. Indeed, studies have 
implicated surgery, other than neurological procedures and corneal transplantation, as a risk 
factor for sporadic CJD, although with inconsistent results (Davanipour et al., 1985; Harries 
Jones et al., 1988; Kondo & Kuroiwa, 1982; Ward et al., 2002; Ward & Knight, 2008; 
Wientjens et al., 1996; Zerr et al., 2000). Endodontic and ocular surgery have been 
highlighted as particular risk factors (Armitage et al., 2009; Bourvis et al., 2007). A history of 
major surgery conducted over 20 years before the onset of sCJD symptoms has also been 
shown to be a significant risk factor (Mahillo Fernandez et al., 2008). Specifically, surgery of 
the digestive system, spleen, female genitalia, peripheral nerves and lymphatic system was     45   
associated with an increased risk of sCJD. Hamster oral tissue preparations have also 
demonstrated transmissible scrapie with significant levels of infectivity in the trigeminal 
ganglia, gingival and pulpal tissues of 263K scrapie inoculated mice (Adams & Edgar, 1978; 
Carp, 1982; Ingrosso et al., 1999). Importantly, small clusters of CJD cases with a link to 
previous dental procedures have been reported (Arakawa et al., 1991).  
 
 
1.9. DECONTAMINATION OF SURGICAL INSTRUMENTS 
 
A risk assessment carried out by the Department of Health (DOH) and endorsed by the 
Spongiform  Encephalopathy  Advisory  Committee  (SEAC)  indicated  that  improving 
decontamination procedures would offer the largest reduction in the risk of transmission of 
CJD through surgical instruments. However, a survey of decontamination services within the 
NHS highlighted examples where the current standards of decontamination where not being 
met (NHS Estates, 2001; Report of a Scottish Executive Health Department Working Group, 
2001).  Despite  a  £200  million  investment  in  SSD  services  and  facilities  in  2001,  several 
studies  have  questioned  the  efficiency  of  current  standards  for  the  decontamination  of  re 
useable surgical instruments in the health services. 
Murdoch et al., (2006) assessed levels of total protein contamination on a wide range 
of  surgical  instruments  as  an  indication  of  the  effectiveness  of  current  decontamination 
procedures. A number of instruments at the point of use demonstrated levels of protein that 
could pose a direct cross contamination risk. A McIvor gag, Draffin rod and Yankaur sucker 
showed 1.028 mg, 1.286 mg and 2.228 mg of extractable protein respectively (Murdoch et al., 
2006).  Lipscomb  et  al.,  (2006)  also  demonstrated  large  concentrations  of  residual 
contamination (0.42 – 4.2  g/mm
2) in addition to general bioburden at the ends of diathermy 
forceps and pencils, instruments routinely used to cauterize vessels or dissect tissues, as well 
as  general  surgical  instruments  (Lipscomb  et  al.,  2006b;  Lipscomb  et  al.,  2006d).  An 
assessment of 220 endodontic files collected from 22 dental practices demonstrated visible 
debris on 98  % of devices at the point of use  (Smith et al., 2005). Residual protein was 
detected on all files within a range of 0.5 – 63.2  g suggesting highly variable efficiency in the 
methods used to decontaminate endodontic files.  
A significant issue is the current standard of instrument cleanliness validation methods 
utilised by sterile service departments (SSDs). These are described in the Health Technical 
Memorandum  2030  and  based  on  colorimetric  chemical  changes  such  as  the  Ninhydrin     46   
reaction which utilises a reaction between amino acids, peptides and proteins and 1, 2, 3 
indantrione monohydrate. However, serious concerns have been raised over the sensitivity of 
such tests and this insensitivity could lead to significantly contaminated instruments returned 
to use after inadequate decontamination treatment within an SSD (Lipscomb et al., 2006a). 
Moreover, an assessment of test soils which are routinely used to help validate cleaning cycles 
indicated a large degree of variability in their quality, with a number easily removed by rinsing 
with cold water (de Bruijn & van Drongelen, 2005). 
To reduce the risk surrounding transmission of the infectious agent in prion disease, 
the World Health Organisation recommends extended steam sterilization and/or chemical 
treatment involving 1 M sodium hydroxide or 20,000 ppm sodium hypochlorite for the 
treatment of high risk re useable instruments (Sehulster, 2004; Taylor, 2004). However, due to 
their harsh chemical nature, these treatments are incompatible with the majority of surgical 
instruments, especially devices containing gum, plastic, joints or electronic components 
(Brown et al., 2005). Moreover, whilst they have been demonstrated to be highly effective, 
complete inactivation of the infectious agent is not always achieved by these methods (Fichet 
et al., 2004; Taylor, 2000). Efforts to implement single use instruments in non emergency 
tonsillectomies and adenoidectomies to manage the risk of iCJD in the UK have previously 
been considered. Critically, their implementation resulted in an increase in postoperative 
haemorrhaging to 7.8 – 12 % of patients compared with 1 % observed with reusable 
instruments and the recommendation was withdrawn (Maheshwar et al., 2003; Nix, 2003). 
Consequently, improved methods of decontamination have been investigated that are 
compatible for use on re useable surgical instruments. Several studies have presented 
significant data for various enzymatic and chemical compounds which are able to remove 
and/or inactivate infectivity from stainless steel surfaces (Fichet et al., 2004; Fichet et al., 
2007b; Jackson et al., 2005; Peretz et al., 2006). However, in the case of enzymatic 
compounds, it has been suggested that high concentrations, pH values >9 and high 
temperatures must be utilised, therefore limiting their clinical applicability (Pilon et al., 2009). 
Recently, a combined exposure of copper and hydrogen peroxide (H2O2) has been 
demonstrated to be fully effective at removal of infectious disease from surgical stainlesss 
steel (Lehmann et al., 2009). However, unlike previously published scientific studies, the 
decontamination of surgical instruments within a hospital SSD is typically an amalgamation of 
several treatments or chemistries. The potential influence of an individual chemistry on the 
removal of infectivity by a subsequent autoclave procedure was demonstrated whereby disease     47   
transmission in the animal bioassay was increased using a combined enzymatic treatment 
followed by autoclaving compared with a single autoclave treatment alone (Yan et al., 2004).  
 
 
1.10. PROJECT AIMS AND RATIONALE 
 
  This body of work will detail studies which have been undertaken to address the highly 
relevant issue of iatrogenic transmission of CJD from surgical instruments in light of the risk 
of asymptomatic carriers of the disease and the prospect of further variant CJD cases in other 
genetically susceptible patient cohorts. The project had three general aims: 
 
•  Evaluate current methods of decontamination both within SSDs and in a laboratory 
setting, 
•  Assess prion identification techniques and, 
•  Improve detection techniques. 
 
Of  critical  importance  was  that  the  work  should  address  current  issues  and 
decontamination  techniques  for  surgical  instruments,  rather  than  focus  on  the  design  or 
assessment of novel methods for prion inactivation so as to be relevant and applicable to 
SSDs. In addition, previous studies have assessed decontamination efficiency based on the 
presence  or  absence  of  contamination  but  have  not  included  relevant  guidance  on  how 
decontamination processes may be improved to yield a safer final product. This project aims 
to target more specific areas of the decontamination cycle, rather than the cleanliness of the 
end product, in order to permit more stringent working guidelines to be implicated which will 
improve the final outcome. 
Consequently, an initial aim of the project is to assess current SSD working practices 
with a view to identifying areas of the cycle which could be improved to produce a cleaner 
end product. This work is detailed in Chapter 3. 
Concurrently, another important aim of the project is to develop a laboratory method 
for analysing decontamination cycles, rather than single chemistries as previous studies have 
performed, described in Chapter 4. The objective behind using the stainless steel wires as 
carrier surfaces for decontamination studies is to correlate in vitro analysis with infectivity in 
the animal model, which utilises the same surface. For analysis of wire contamination, the 
project aims to continue the development of an in situ, novel, fluorescent dual stain procedure     48   
by  our  group.  This  method  utilises  SYPRO  Ruby  to  detect  general  protein  and,  more 
specifically, prion associated amyloid as a biological marker of disease detected by Thioflavin 
T (Hervé et al., 2009). Whilst the development of this fluorescent staining procedure is an 
aspect of this project, the methodology optimisation will not be detailed herein. However, a 
significant objective of this body of work aims to employ this methodology for the in situ 
detection of prions under various conditions which may effect prion decontamination (Chapter 
4 and 5).  
During the course of this project, a significant amount of work has been performed by 
other groups into the relationship between prion associated amyloid, PrP
res and infectivity. 
Consequently, I felt it was also critical to address this issue with regards to the techniques used 
to  assess  decontamination.  Therefore  prion associated  amyloid  and  PrP
res,  as  detected  by 
Thioflavin T and Western blot, respectively, will be correlated with infecitivity. 
As  previously  mentioned,  an  important  aim  of  the  project  was  to  improve  prion 
detection  techniques.  Due  to  the  publication  of  a  Thioflavin  T  analogue  known  as  2 (4’ 
Methylaminophenyl) Benzothiazole (BTA 1) for use in in vivo positron emission tomography 
(PET) imaging, the aim will be to develop an in vitro fluorescent detection method to enhance 
amyloid detection in prion disease (Klunk et al., 2003; Mathis et al., 2002). Consequently, 
through collaboration with the Department of Chemistry, University of Southampton, I aim to 
obtain further thiazole analogues for this project. The aim will be to assess their ability to 
identify, in vitro, prion associated amyloid, relative to their precursors, in addition to other 
amyloidoses  such  as  Alzheimer’s  disease.  Moreover,  fluorescent  compounds  capable  of 
amyloid detection have demonstrated the ability to attenuate progression to end stage disease 
in several laboratory models of TSE. It is hoped that this work will be able to assess these 
novel compounds for therapeutic effects in the animal model of infectivity.  
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CHAPTER 2 
 
 
 
MATERIALS AND METHODS 
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2.1. ANIMALS 
 
C57BL/6J mice (Harlan Olac Ltd) were housed in a Containment Level 2 facility 
within the School of Biological Sciences, University of Southampton and handled in 
accordance with United Kingdom Home Office Guidelines.  
Syrian golden hamsters and C57BL/6J mice (Charles River, France) were held at the 
Institute of Emerging Disease and Innovative Therapies within the Commissariat á l’Énergie 
Atomique (CEA), Fontenay aux Roses, France. All work with the animals was carried out in a 
Containment Level 3 facility officially registered for prion experimental studies on rodents 
(agreement number A 92 032 02 for animal care facilities, agreement number 92 189 for 
animal experimentation).  
 
 
2.2. STRAINS AND PREPARATION OF BRAIN TISSUE 
 
2.2.1. ME7 Scrapie Infected Brain Homogenate 
 
ME7 scrapie infected brains and C57BL/6J healthy brains were provided as a gift by 
Dr C. Cunningham and Professor V. H. Perry (School of Biological Sciences, University of 
Southampton). The ME7 scrapie strain was selected due to high PrP
res accumulation and wide 
spread amyloidosis in the CNS of infected C57BL/6J mice and increased resistance to 
proteolytic degradation relative to other rodent strains (Cunningham et al., 2005; Kuczius & 
Groschup, 1999). Briefly, C57BL/6J mice were anesthetized through an intraperitoneal 
injection of 2, 2, 2 tribromoethanol (Avertin) and positioned in a sterotaxic frame. They were 
then injected with 1  l of 10 % (w/v) ME7 infected C57BL/6J brain homogenate made in a 
solution of phosphate buffered saline (PBS) into the right dorsal hippocampal region of the 
brain using a 10  l Hamilton syringe. Control animals were injected
 with 10% (w/v) non 
infected brain homogenate (NBH), derived from a naïve C57BL/6J mouse (Cunningham et al., 
2005). All procedures were performed
 in accordance with a United Kingdom Home Office 
license. 
Calculated by the Reed and Muench method, ME7 in this mouse strain demonstrates a 
median lethal dose or LD50 of 10
8 per gram of brain and a disease incubation period of
 
approximately 168 days (Guenther et al., 2001; Mahal et al., 2007; Reed & Muench, 1938). 
Animals show initial clinical symptoms such as hyperactivity and motor impairments at     51   
approximately 133 days progressing through to a further reduction in mobility, hunched 
posture and poor coat condition. As a result, the animals were sacrificed between 133 and 147 
days post inoculation following anesthetization
 with sodium pentobarbitone. The brains were 
removed and frozen on liquid nitrogen and stored at –80 ºC until use.  
A 10 % (w/v) homogenate was then prepared in PBS.  Protein concentrations of serial 
dilutions of the brain homogenate were determined and homogenous preparations ensured 
using a total protein assay (Bio rad, Hercules, CA, USA).  
 
2.2.2. 263K Scrapie Infected Brain Homogenate 
 
Hamster 263K scrapie infected brains were provided as a gift by Dr E. Comoy at the 
CEA, Fontenay aux Roses, France. This strain was selected for the studies due to its high 
stability to extended PK exposure and high resistance to degradation relative to other strains 
(Brown et al., 2000; Fichet et al., 2007b; Kuczious & Groschup, 1999). The hamster adapted 
scrapie  strain  263K  was  stabilized  and  propagated  in  female  Syrian  Golden  hamsters 
(Kimberlin & Walker, 1977). The incubation period for this strain is approximately 90 ± 2 
days  (Fichet  et  al.,  2004)  with  early  clinical  signs  including  destruction  of  nest  and 
hyperactivity to noise and sudden movement (Kimberlin & Walker, 1977). As with the ME7 
scrapie  model,  these  symptoms  progress  through  to  uncoordinated  movement  and  motor 
impairment,  including  head  bobbing,  ataxia  of  gait  and  generalised  tremor  (Seidel  et  al., 
2007). Brains of hamsters at the terminal stage of disease, typically displaying between 10
10 
and 10
11 LD50 per gram were removed and frozen at –80 ºC before transport on dry ice by 
courier to The University of Southampton. Upon receipt, the brains were thawed and a 10 % 
(w/v) homogenate made in PBS with total protein assays carried out to determine protein 
content. Non infected brain homogenate (NBH) was also prepared from naïve hamster brains. 
 
2.2.3. Preparation of Brain Sections 
 
  Whole brain tissue was removed from storage at  80 ºC. The brains were embedded in 
the inert mounting medium Tissue Tek (OCT Embedding Compound, Sakura, Bayer, UK). 
Following embedding, the tissue was transferred to a Leica CM3050 Cryostat and 10  m 
sections were cut from the hippocampus and placed onto aminopropylsilane (APS) coated 
glass slides. The sections were covered and allowed to dry overnight to prevent the formation 
of ice crystals within the tissue section upon freezing at  80 ºC.      52   
2.3. CONTAMINATION OF TEST SURFACES 
 
2.3.1. Standard Stainless Steel Wires 
 
Surgical grade 316L stainless steel wires (Ormiston Wire Ltd; length: 5.0 mm x 
diameter: 0.16 mm) were cleaned using ultrasonication in a 2 % (v/v) Triton X 100 solution in 
deionised water for 15 min. This was followed by three separate 3 min sonications in 
deionised water to rinse. The wires were then dried for 1 h at room temperature before 
contamination.  
For surfaces undergoing microscopic evaluation only, an additional step in the process 
was added. Subsequent to sonication, the wires were immersed in deionised water filtered 
through a 0.2  m filter, autoclaved for 20 min at 121 ºC and then dried for 1 h at room 
temperature. This ensured a pristine surface suitable for fluorescence microscopy.  
  Contamination was performed through immersion of the wires in 200  l of 10 % (w/v) 
prion infected brain homogenate or NBH for 1 h at room temperature. The wires were then 
dried for 16 h at room temperature.  
 
2.3.2. Artificially Degraded Stainless Steel Wires 
 
  Artificial degradation of the wires was performed by collaborators at the CEA, 
Fontenay aux Roses, France as part of a blind study. Surgical grade 316L stainless steel wires 
were cut to 5 mm in length and autoclaved for 18 min at 134 ºC in 1M sodium hydroxide 
(NaOH) to degrade the wire surface. Following autoclaving, the wires were subjected to 
rinsing in deionised water and were prepared as described in section 2.3.1 prior to inoculation 
with 10 % (w/v) 263K scrapie infected brain homogenate or hamster NBH. 
 
2.3.2.1. Conformation of wire surface topography 
 
  Surface tomography was assessed by microscopy comparing normal and degraded 
surfaces following their staining and evaluation. However, in order to quantify the degree of 
surface degradation and maintain the blind nature of the study, wires (n = 7) were sent to Dr I. 
Lipscomb, School of Engineering, University of Southampton.  The degree of surface 
roughness was determined using a laser confocal scanning system (Xyris 4000 CL; Taicaan). 
The system utilises a 670 nm visible red laser with a spot size of 2  m. Applying a sampling     53   
rate of 1.4 kHz with a resolution of 0.1  m, the system scanned the length of the wires. The 
scans were then analysed (BODDIES software, Taicaan) and mean surface roughness (Ra) 
calculated across 10 wires. 
 
2.3.3. Stainless Steel Tokens 
 
  For surface Western blot studies, surgical grade 316L stainless steel tokens (length:   
76 mm x width: 26 mm width x diameter 1 mm) were prepared as detailed in section 2.3.1. A 
volume of 20  l of 10 % (w/v) brain homogenate was aliquoted onto each token followed by 
drying at room temperature for 16 h. 
 
2.3.3.1. Contamination of stainless steel tokens by handling 
   
  The degree of proteinaceous contamination applied by a single thumb print was 
investigated on stainless steel tokens (n = 6) previously prepared as described in section 2.3.1. 
Contamination by a single thumb print from a hand wearing standard nitrile laboratory gloves 
was also assessed (n = 6). To compare the deposition of protein by a thumb print with that of 
normal handling and manipulation by bare and gloved hands, each token (n = 6 for each 
handling condition) was contaminated with ten thumb prints. Twelve tokens were used as 
untouched controls. Following staining, twenty random fields of view were imaged from each 
token and analysed for fluorescently labelled total protein. 
 
 
2.4. SURFACE DECONTAMINATION TECHNIQUES 
 
2.4.1. Decontamination of Wires Using a High Temperature and Pressure Autoclave 
Treatment  
 
  Stainless steel wires were inoculated in 10 % (w/v) hamster NBH. Immediately 
following inoculation, wires (n = 7) were rinsed in deionised water for 5 min and dried 
overnight at room temperature. Inoculated wires (n = 7) were also subjected to autoclaving at 
121 ºC for 15 min after inoculation followed by a 5 min rinse in deionised water and overnight 
drying. 
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2.4.2. Decontamination Using Simulated Washer Disinfector Cycles 
 
  Stainless steel wires were inoculated in either 10 % (w/v) ME7 scrapie infected brain 
homogenate, 10 % (w/v) NBH or nanopure water (18.2 M , pH 6.5) as experimental controls 
and either dried at room temperature overnight or processed immediately. 
All wires were subject to simulated decontamination steps under laboratory conditions 
as  described  in  Table  4.  Each  cleaner  was  heated  to  operating  temperature  prior  to  wire 
exposure  and  treatment  was  performed  as  per  the  manufacturer’s  guidelines.  Each  cycle 
commenced  with  a  pre treatment  stage.  This  involved  the  use  of  an  enzymatic  cleaner 
(Klenzyme
® Enzymatic Presoak and Cleaner; STERIS Ltd, 0.8 % (v/v) in water for 5 min at 
room  temperature)  or  a  pre soak  wetting  agent  designed  to  prevent  the  soil  drying  (PRE 
Klenz
TM;  STERIS  Ltd,  neat,  5  min  at  room  temperature).  As  a  comparison,  a  cycle  was 
incorporated which did not involve a pre treatment. Following immediate transfer into a rinse 
in deionised water at room temperature for 1 min, wires (n = 7) were removed and left to dry 
at room temperature over night.  
The remaining wires were immediately immersed in the main wash alkaline chemistry 
(HAMO
TM 100; STERIS Ltd, 0.4 or 0.8 % (v/v), 15 or 7 min at 45 ºC). Wires were then rinsed 
in deionised water at between 45 – 50 ºC (n = 7), removed and left to dry overnight, with the 
remaining wires subjected to disinfection at 90 ºC in deionised water for 1 min. Each cycle 
was performed in autoclaved  glass tooled neck  vials (Fisher Sciences,  USA) in a Reactor 
Station Heat Block (Fisher, UK) with magnetic stirrers to allow for gentle mixing.  
 
Table 4 Laboratory simulated decontamination cycles describing the varying pre 
treatments, concentrations and exposure times for each phase tested; 20 ºC was the 
approximate room temperature at the time of exposure. 
Cycle phases  Exposures  Time (min)  Temp (ºC)  Concentration 
Pre treatment 
Enzymatic 
cleaner/Pre soak/ 
No pre treatment 
5  20  0.8 % / neat /   
Rinse  Deionised water  1  20    
WIRES REMOVED 
Wash 1  Alkaline cleaner  15 / 7  45  0.4 % + 0.8 % 
Rinse  Deionised water  1  45   50    
WIRES REMOVED 
Disinfection  Deionised water  1  90    
WIRES REMOVED 
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2.4.3. Decontamination of Artificially Degraded Wires 
 
  Standard stainless steel wires and artificially degraded stainless steel wires were 
inoculated with 10 % (w/v) 263K scrapie infected homogenate. Uninoculated wires were used 
as negative controls to confirm cleanliness of the wires following degradation process. 
Exposures, as detailed in Table 5, were carried out at the CEA, Paris as part of a blind study. 
For confidentiality reasons, the product names have been omitted at the request of the 
provider. Working solutions were prepared in deionised water. 
In addition, wires were also treated with exposure to vaporised hydrogen peroxide 
(VHP) coupled to a VHP1000 Biodecontamination System (STERIS Ltd). Contaminated 
stainless steel wires were placed on plastic plates and exposed to the vacuum process at 30 ºC 
for 3 h maintaining a dry (non condensing) hydrogen peroxide gas at a concentration of 1.0 to 
1.5 mg/L. Following treatment, the wires were rinsed in deionised water, frozen at –80 ºC and 
posted on dry ice by courier to The University of Southampton.  
 
Table 5 Chemical, enzymatic and physical treatments including corresponding exposure 
parameters for the treatment of surgical grade stainless steel wires inoculated with 263K 
scrapie or hamster NBH. Contact times of 10 + 5 min denote double treatments of the 
same chemistry separated by 1 h drying at room temperature; 20 ºC was the approximate 
room temperature at the time of exposure. NaOH: “sodium hydroxide”, NaOCl: “sodium 
hypochlorite”, ppm: “parts per million”, M: “molar”, mg/L: “milligram/litre”.  
  Treatment  Contact time 
(min) 
Temperature 
(ºC) 
Concentration 
(% or as stated) 
T1  Enzymatic A  15  50  0.5 
T2  Enzymatic A  10 + 5  20  0.5 
T3  Enzymatic B  10 + 5  20  0.4 
T4  Enzymatic C  10 + 5  20  0.5 
T5  Alkaline 1  15  43  1.6 
T6  Alkaline 1  10 + 5  20  1.6 
T7  Dry Autoclave  18  134    
T8  Immersion 
(H2O) autoclave  18  134    
T9  NaOH  60  20  1M 
T10  NaOCl  60  20  20,000 ppm 
T11  Bleach 1  60  20  20,000 ppm 
T12  Bleach 2  60  20  20,000 ppm 
T13  VHP  180  30  1   1.5 mg/L 
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2.4.4. Decontamination of Wires: Methodology correlation study 
 
  Stainless steel wires were inoculated with 10 % (w/v) 263K scrapie infected 
homogenate or corresponding hamster NBH. The wires (n = 7) were then placed in autoclaved 
glass tooled neck vials and subjected to various chemical and enzymatic exposures from 
individual cleaners under the parameters described in Table 6. Treatments included five 
enzymatic cleaners: Enzymatic 1 (Yan et al., 2004), Enzymatic 2 (a newly developed 
enzymatic cleaner; STERIS Ltd), Enzymatic 3 (Klenzyme
®; STERIS Ltd), Enzymatic 4 
(Enzycare
® II; STERIS Ltd) and Enzymatic 5 (Adi Zyme
®; STERIS Ltd), in addition to an 
alkaline detergent; Alkaline 1 (HAMO 100
TM, STERIS Ltd). Working concentrations of all 
cleaners were constructed in deionised water (pH: ~ 7.2) as per manufacturers guidelines.  
Exposures were carried out in a Reactor Station Heat Block with magnetic stirrers for 
gentle mixing. Following treatment, the wires were immersed in deionised water and rinsed 
for 3 min followed by 16 h drying overnight at room temperature. 
 
Table 6 Chemical, enzymatic and physical treatments including corresponding exposure 
parameters for the treatment of surgical grade stainless steel wires inoculated with 263K 
scrapie infected brain homogenate or hamster NBH; 20 ºC was the approximate room 
temperature at the time of exposure. 
Treatments  Contact time (min)  Temperature (ºC)  Concentration (%) 
Enzymatic 1  10  20  2 
Enzymatic 2  15  50  0.8 
Enzymatic 3  5  20  0.8 
Enzymatic 4  5  60  0.5 
Enzymatic 5  5  43  1 
Alkaline 1  7  43  0.8 
 
 
2.5. STAINING TECHNIQUES 
 
  To prevent fluorescent signal loss, all staining using fluorescent compounds was 
performed in the dark. 
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2.5.1. General Protein Stain 
 
  General protein staining was performed using SYPRO Ruby (Invitrogen). Static 
surfaces were immersed in 100 % (v/v) SYPRO Ruby for 15 min. To remove excess and non 
specifically bound stain, the surface was subjected to two 3 min PBS rinses followed by one   
1 min deionised water rinse to prevent the formation PBS crystals and therefore remove the 
possibility of light scatter.   
  Seperately, a known concentration of protein, as analysed by a total protein assay, was 
stained with SYPRO Ruby, permitting quantification of proteinaceous contamination in 
ng/mm
2. 
 
2.5.2. Prion Amyloid Stain 
 
  Fluorescent labelling of prion associated amyloid was performed using Thioflavin T 
(Sigma Aldrich). For tissue section staining, pre cut slides were removed from storage at        
–80 ºC and incubated for 30 min at 37 ºC. The tissue was then statically immersed in a 
working solution of 1 mg/ml Thioflavin T (Sigma Aldrich) made in 0.1 % (v/v) hydrochloric 
acid (HCl) for 10 min followed by one 1 min rinse in PBS. To remove excess and non 
specifically bound Thioflavin T, the sections were rinsed in 0.1 % (v/v) acetic acid for 10 min 
followed by a further PBS rinse for 3 min and a final rinse for 1 min in deionised water. Brain 
sections stained with Thioflavin T were cover slipped using SHUR mount (Electron 
Microscopy Sciences), a toluene based acrylic resin mounting medium. 
 
2.5.3. Thioflavin T/SYPRO Ruby Dual Staining Technique 
 
  To differentiate between general tissue protein and prion associated amyloid, a dual 
staining protocol has been developed. This procedure allows for the fluorescent detection of 
prion associated amyloid using Thioflavin T. This is counterstained with SYPRO Ruby to 
indiscriminately identify total protein. 
  A working solution of 1 mg/ml Thioflavin T was made in 0.1 % (v/v) hydrochloric 
acid (HCl) and applied onto static samples for 10 min followed by a 1 min rinse in PBS. This 
was followed by a 10 min rinse in 0.1 % (v/v) acetic acid and a further 1 min rinse in PBS. 
The samples were counter stained with a 100 % (v/v) solution of SYPRO Ruby for 15 min 
followed by two 3 min rinses in PBS and a final deionised water rinse.  Using a known     58   
concentration of brain homogenate fluorescently labelled with SYPRO Ruby, quantification of 
proteinaceous contamination in ng/mm
2 was achieved. As previously described, amyloid 
concentration was estimated as a function of the total protein (Hervè et al., 2009). Following 
this, Thioflavin T positive signal on ME7 scrapie wires was normalised against non specific 
fluorescence on corresponding NBH wires.  
 
2.5.4. 2 (4’ Methylaminophenyl) Benzothiazole (BTA 1) Stain for Prion Amyloid 
 
  To further enhance the sensitivity of amyloid detection, optimisation of a fluorescent 
staining method of the Thioflavin T derivative BTA 1 (Sigma Aldrich) was performed. 
Through personal correspondence with Professor W. Klunk, University of Pittsburgh, an 
initial 500  M stock solution was prepared in dimethyl sulfoxide (DMSO). To optimise the 
working concentration, various nanomolar (nM) dilutions of the stock solution in PBS were 
constructed. Prion infected 263K scrapie and naïve brain sections were removed from storage 
at –80 ºC and incubated for 30 min at 37 ºC. The working solutions were applied to sections 
for 15, 30, 45 min or 1 h time frames. Following incubation in BTA 1, the slides were 
immersed in PBS for 10 seconds to rinse and the sections cover slipped using Fluorescent 
Mounting Medium (DAKO). A final working concentration of 50 nM and a 45 min contact 
time was concluded.  
    
 
2.6. ANALYSIS OF THIAZOLE ANALOGUES 
 
  Synthesis of fourteen Thioflavin T analogues and twenty one BTA 1 analogues was 
carried out by Mr. Christopher Ryan and Dr. H. Franks under the supervision of Dr. A. 
Ganesan within the Department of Chemistry, University of Southampton. A brief overview of 
the routes of analogues synthesis, including the chemical structures of the thirty five 
compounds is contained in the Appendix A.  
Methods detailing the subsequent initial testing of the analogues and isolation of a 
compound of interest for further evaluation are described herein. Due to low product yields, 
the extent to which further evaluation could be conducted was limited. 
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2.6.1. Assessment of Analogue Staining Efficiency 
 
Initial evaluation of the analogues was carried out based on their ability to identify 
amyloid plaques in ME7 scrapie infected brain sections relative to naïve brain sections from 
healthy mice. 
Prion infected ME7 scrapie infected and naïve brain sections were removed from 
storage at –80 ºC and incubated for 30 min at 30 ºC. Due to the constraints imposed by the 
total volume of each analogue synthesised a simple staining procedure was carried out. The 
analogues were separated based on the structural similarity to their precursor, either Thioflavin 
T or BTA 1, and fluorescent staining was carried out using the precursor’s respective 
previously optimised protocols (sections 2.5.2 and 2.5.4). In the case of BTA 1 analogues, 
working concentrations of 100 nM and 50 nM were evaluated. Each analogue was applied to 
ME7 and naïve sections in triplicate, in parallel with its precursor for comparison. Blank 
section controls, where no staining was performed, were also evaluated for potential sample 
autofluorescence. Photomicrographs were imaged and assessed by four volunteers using an 
arbitrary scale of X → ￿￿￿￿￿. Assessment was carried out based on the presence of 
positive/potential positive signal in comparison to precursor staining, where X indicated no 
positive signal. This increased to ￿￿￿￿￿ where analogue and precursor staining were 
indistinguishable from one another in respect of their ability to identify prion amyloid 
deposits. Average scores were attributed to each analogue based on a majority opinion where 
X = 0 and ￿￿￿￿￿ = 5. The scores of each volunteer were recorded blind. 
 
2.6.2. Analysis of 2 (4’ Dimethylaminophenyl) 6 Methyloxybenzothiazole (28d) Binding 
Specificity 
 
  Initial evaluation identified the compound 2 (4’ Dimethylaminophenyl) 6 
Methyloxybenzothiazole (28d), a BTA 1 analogue, for further appraisal. 
263K scrapie infected and naïve sections were removed from storage at –80 ºC and 
incubated for 30 min at 37 ºC. Sections were fluorescently labelled using 28d and BTA 1 at a 
working concentration of 50 nM as described in section 2.5.4. At a constant exposure, amyloid 
plaques (n = 10) of similar dimensions were imaged using each compound and analysed for 
amyloid bound pixel intensity versus background pixel intensity in naïve brain tissue. 
Using the Image Pro Plus software package, a mean pixel intensity value for every 10 
pixels was obtained, followed by the mean pixel value for the entire amyloid plaque. This was     60   
compared against the average surrounding pixel intensity produced through binding of the 
respective thiazole to naïve tissue. This allowed a measure of binding specificity to be 
calculated as a function of the ratio between amyloid specific and non specific labelling by 
both 28d and BTA 1. 
 
2.6.3. Analysis of the Rate of Photobleaching of 2 (4’ Dimethylaminophenyl) 6 
Methyloxybenzothiazole (28d) Relative to BTA 1. 
 
  Strain 263K scrapie infected and naïve sections, as negative controls, were removed 
from storage at –80 ºC and incubated for 30 min at 37 ºC.  The sections were fluorescently 
labelled with either 28d or BTA 1 using the optimised protocol detailed in section 2.5.4. 
Amyloid plaques of similar dimensions (n = 3 per compound) were visualised over a 10 min 
time course at a constant exposure. Photomicrographs were imaged every 10 seconds.  
  Using the Image Pro Plus software package, pixel intensity was measured for each 10 
second photomicrograph taken across ten separate points within the centre of the amyloid 
plaque. Mean signal intensity was calculated and plotted against time to assess fluorescent 
signal loss for each compound. 
 
2.6.4. Correlation of 2 (4’ Dimethylaminophenyl) 6 Methyloxybenzothiazole (28d) and 
BTA 1 Fluorescence with the Monoclonal Anti PrP Antibody 6H4. 
 
  Brain sections of 263K scrapie infected and naïve hamsters were removed from storage 
at –80 ºC and incubated for 30 min at 37 ºC. The sections were then fluorescently labelled 
with BTA 1 as described in section 2.5.4 and visualised using EDIC/EF. Prion associated 
amyloid deposits labelled with BTA 1 were imaged. Following an overnight rinse in 50 % 
ethanol, the removal of BTA 1 fluorescence was confirmed and the protocol described in 
section 2.5.4 was repeated utilising 28d. Visualisation and imaging of the same prion amyloid 
deposits was once again carried out using EDIC/EF. Following this, further fixation was 
carried out using 100 % ethanol for 10 min at 4 ºC. Following a 1 min rinse in PBS, the 
sections were immersed in deionised water and autoclaved for 15 min at 121 ºC. The slides 
were left in situ for 5 min and then removed and left to cool. To further denature PrP
c, the 
slides were immersed in 95 % (v/v) formic acid for 5 min, followed by 1 % (v/v) H2O2 in PBS 
for 10 min to remove endogenous peroxidases.     61   
  Using a Vectastain ABC Kit (Mouse IgG; Vector Laboratories), slides were incubated 
with mouse on mouse (MOM) Ig blocking reagent for 1 h. An overnight incubation was then 
performed at 4 ºC using the primary antibody 6H4 (Prionics; 1/4000 dilution). This primary 
antibody recognises the highly conserved sequence DYEDRYYRE of the prion protein, 
corresponding to amino acids 144 – 152 in humans (Zanusso et al., 2004).  In both murine and 
hamster species, the tyrosine at position 145 is substituted by a tryptophan although this does 
not affect binding. 
  Subsequently, the slides were incubated with a horseradish peroxidase conjugated 
secondary antibody for 10 min followed by application of the ABC reagent for 30 min. The 
reaction was developed with a 3, 3’ diaminobenzidine tetrahydrochloride solution and 
counterstained with haematoxylin. The sections were dehydrated through ethanol to xylene 
and mounted with DPX neutral mounting medium (Lamb). 
 
 
2.7. EPISCOPIC DIFFERENTIAL INTERFERANCE CONTRAST MICROSCOPY 
COUPLED WITH EPI FLUORESCENCE (EDIC/EF) 
 
  Standard Differential Interference Contrast (DIC) microscopy implements the 
destructive/constructive nature of light waves. In standard DIC, light passes through a 
polarizer beneath the substage condenser which produces the necessary plane polarised light 
for interference imaging (Figure 7). The polarised light then passes through a Nomarski 
modified Wollaston prism located below the condenser. This prism, also known as a 
condenser prism, is composed of two precisely ground and highly polished quartz wedges 
which are cemented together at the hypotenuse. The original polarised light beam is split into 
two separate rays, vibrating perpendicular to one another. These rays intersect at the front 
focal plane of the condenser and pass through, travelling parallel to one another until contact 
with the specimen. The wave paths of both beams are altered based on the properties 
(thickness, slope and refractive index) of the sample. Subsequent to traversing the specimen, 
the optical path difference of the parallel beams is altered for varying areas of the sample.  
Upon passing through the objective, the beams are focused. The distance between the 
rays, known as the shear, and the original path difference between the beams is then removed 
by a second Nomarski prism or objective prism. A second polariser, known as the analyser, is 
positioned above the objective prism in order to generate interference. This is accomplished by 
bringing the beams, which up until this point have had a different path length, into the same     62   
plane and axis. The light then passes on through the eye piece where it is viewed as 
differences in intensity and colour, leading to a pseudo three dimensional appearance.  
 
 
 
Figure 7 An illustration of the passage of light in Differential Interference Contrast (DIC) 
microscopy from the light source through to the eye pieces where a pseudo three dimensional 
image is viewed. Image taken from the Olympus Microscopy Resource Center. 
 
 
A disadvantage of the standard DIC set up is the requirement of cover slips and oil 
immersion lenses which is inadequate for visualisation of opaque or curved surfaces such as 
surgical instruments. An improvement of the DIC set up, Episcopic Differential Interference 
Contrast microscopy, coupled with epi fluorescence (EDIC/EF) rearranges the polarizer and 
Nomarski prisms into the headpiece above the stage, rather than below (Keevil, 2003). An 
adjustable analyser is fitted to the main body between the DIC block and eye piece which can 
be withdrawn for epi fluorescence with a filter block, incorporating the excitation filter, 
dichroic mirror and barrier filter, moved into the light path. This gives the microscope the 
ability to switch between EDIC and epi fluorescence without the need for lens changing and 
the stage/lighting to be altered. Incorporation of a slider housing for the DIC and fluorescent     63   
filter blocks into the microscope allows dual staining and image superimposition to be 
performed, with realisation of a particulates position in or on a detailed surface using DIC. 
  The EDIC/EF system is coupled with the implementation of non contact, long distance 
working objective lenses. Substrata are illuminated with a metal halide lamp (120 W). The 
lamp posses a spectrum range of 300 750 nm and a life span of 1500 hours. In addition, an 
adjustable disphragm allows control of the light intensity output from 100, 50, 25, 12 and 0 %. 
Moreover, a fully automated stage is utilised to allow x, y and z specimen scanning. Image 
capture is performed using a CCD camera (Roper Industries, UK). Data quantification is 
performed using the image analysis software Image Pro Plus software, purchased separate to 
the microscope from MediaCybernetics (Bethesda, MD, USA). This software allows 2D and 
3D image processing and analysis and incorporates extensive measurement and customisation 
features. Importantly for this work it permits image tiling and alignment to allow large areas of 
a surface, such as a surgical instrument, to be scanned along the x and y plane and the 
production of a composite image. Features such as background correction and subtraction, in 
addition to co localisation of fluorescence through two different channels enhance image 
quality. Through the construction of an automated set of macros, specific for the emitted light 
following SYPRO Ruby, Thioflavin T and BTA 1 staining, image analysis is both sensitive 
and rapid. 
 
2.7.1. Epi fluorescence Filter Blocks 
 
  Routinely used throughout the work in the following chapters were the fluorophores 
SYPRO Ruby, Thioflavin T and BTA 1. Filter blocks were custom designed for each of these 
fluorescent compounds and the spectral data for each of these is shown in Table 7. The 
dichroic mirror or transition wavelength value separates the excitation and emission light 
paths. The mirror is incorporated into the filter block to reflect the light below the transition 
wavelength value and transmit wavelengths above this value.  
 
Table 7 Filter block spectral data for three fluorophores: SYPRO Ruby, Thioflavin T and   
BTA 1 showing excitation filter, dichroic mirror and barrier filter ranges. 
Fluorophore  Excitation filter (nm)  Dichroic mirror  Emision filter (nm) 
SYPRO Ruby  465 – 495  505  605 – 655 
Thioflavin T  405 – 445  460  475 
BTA 1  340 – 380  400  420 
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2.7.2. Statistical Analysis 
 
  The aim of statistical analysis in this body of work was to determine significance 
between data means. Consequently, analysis was carried out using T tests, in the majority of 
cases, and Analysis of Variance (ANOVA) methods where stated in the text, with the null 
hypothesis that there was no significance between data sets. At a 95 % confidence interval, a P 
value of less than 0.05 resulted in rejection of the null hypothesis in favour of the alternative 
(ie. a statistically significant difference between the data sets). Conversely, a P value greater 
than 0.05 at the 95 % confidence interval resulted in an acception of the null hypothesis. 
  
 
2.8. WESTERN BLOT  
 
2.8.1. Preparation of Samples – Suspension Studies 
 
  Working solutions of each chemistry were prepared and pre warmed. Twenty 
microliters of either 10 % (w/v) ME7 scrapie infected or 263K scrapie infected homogenate 
were aliquoted into sterile eppendorfs in a ratio of 1:4 (v/v) with 80  l of cleaner. Exposure 
was carried out in the presence of regular, gentle agitation to mix. The samples were then 
centrifuged for 5 min at 13,000 g to pellet. The eluate was removed without disturbing the 
pellet and replaced with 80  l of deionised water (pH: ~ 7.2). Following re suspension of the 
pellet, the sample was kept on ice prior to use.  
 
2.8.1.1. Exposure parameters intended for the preparation of homogenate samples for 
antibody mapping of PrP
res 
 
   Exposure of 10 % (w/v) 263K infected brain homogenate was performed as described 
in section 2.8.1. Parameters for the treatment of prion infected brain homogenate samples are 
described in Table 8. These treatments included three enzymatic cleaners: Enzymatic 1 (Yan 
et al., 2004), Enzymatic 2 (a newly developed enzymatic cleaner; STERIS Ltd) and Enzymatic 
3 (Klenzyme
®; STERIS Ltd), in addition to an alkaline detergent: Alkaline 1 (HAMO 100
TM; 
STERIS Ltd) and two phenolic chemistries: Phenolic 1 (LpH; STERIS Ltd) and Phenolic 2 
(LpHse; STERIS Ltd). Exposure to a 1M solution of sodium hydroxide (NaOH) was also 
performed.      65   
Table 8 Chemical and enzymatic treatments including corresponding contact parameters 
for the exposure of 263K scrapie infected brain homogenate for subsequent analysis of 
PrP
res structure by Western blot; 20 ºC was the approximate room temperature at the time 
of exposure. M: “molar”.  
Treatments  Contact time (min)  Temperature (ºC)  Concentration 
(% or as stated) 
Enzymatic 1  10  20  2 
Enzymatic 2  15  50  0.8 
Enzymatic 3  5  20  0.8 
Alkaline 1  7  43  0.8 
Phenolic 1  5  20  5 
Phenolic 2  5  20  5 
NaOH  0.5  90  1 M 
 
2.8.2. Preparation of Samples – Surface Studies 
 
  Immunoblots, incorporating elution of samples from stainless steel tokens, were 
carried out as part of a blind study and performed by Dr G. Fichet at the CEA, Fontenay aux 
Roses, France. 
 Stainless steel tokens were prepared and inoculated as detailed in section 2.3.3 and 
exposure was carried out under the parameters described in Table 6, in autoclaved glass vials 
with gentle mixing. Following treatment, the dried inoculum was manually removed along 
with the upper layer of the token and the sample was re suspended in 120  l deionised water 
and kept on ice until use. 
 
2.8.3. Western Blot Protocol 
 
  The samples were first treated with increasing concentrations of proteinase K (PK; 
Sigma Aldrich) for 1 h at 37 ºC to degrade PrP
c. Following transfer onto ice to slow enzymatic 
digestion, Pefabloc (Sigma Aldrich), added at half the concentration of PK, was used to 
completely inactivate PK. Samples were then boiled for 5 min in Laemmli’s buffer containing 
2 % (w/v) sodium dodecyl sulphate (SDS), 10 % (v/v) glycerol, 2 % (v/v) β mercaptoethanol 
and 0.001 % (v/v) of the dye bromophenol blue in 50 mM Tris/HCL, pH 6.8. The SDS content 
of the buffer surrounds the protein with a negative charge, the β mercaptoethanol prevents 
reformation of disulphide bonds and the glycerol increases the sample density against the 
running buffer aiding sample loading. Following boiling, the samples were cooled on ice and 
then loaded onto a 12 % (w/v) polyacrylaminde gel (Bio rad; brain homogenate equivalent to     66   
50  g per well) and separated using electrophoresis at 70 V/h. Transference to a 
polyvinylidene fluoride (PVDF) membrane (Biorad) was performed overnight at 30 V/h. 
  Subsequent blocking of the membrane was accomplished using a 5 % (w/v) non fat 
dry milk solution in PBS containing 0.1 % (v/v) Tween 20 (PBS T; Sigma Aldrich) for 1 h at 
room temperature. Following two 3 min rinses in PBS T, PrP was detected using one of six 
mouse monoclonal antibodies shown in Figure 8. These antibodies were a gift from Dr E. 
Comoy at the CEA, Fontenay aux Roses, France. The primary antibody was added at the 
concentration detailed in Figure 8 in PBS T for 1 h. This was followed by three 3 min rinses in 
PBS T and application of a horseradish peroxidase conjugated anti mouse IgG secondary 
antibody (1/5000 in PBS T; GE Healthcare) for 1 h. Following a further four 3 min rinses in 
PBS T, immunoreactive bands were visualised using enhanced chemiluminescence utilizing 
the ECL Plus Western blotting detection reagent (ECL, Amersham Biosciences; 5 ml reagent 
A, 125  l reagent B) added for 3 min. Development was carried out in an automatic xograph 
film processor using ECL Hyperfilm (ECL, Amersham Biosciences).  
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2.9. ANIMAL BIOASSAY STUDIES 
 
  Animal bioassays were carried out by our collaborators at the CEA, Fontenay aux 
Roses, France under the supervision of Dr E. Comoy using previously published methodology 
(Fichet et al., 2004; Fichet et al., 2007c).  
Normal and artificially degraded surgical grade 316L stainless steel wires were 
prepared and contaminated as detailed in section 2.3.1 and 2.3.2 respectively and inoculated 
with 10 % (w/v) 263K scrapie infected brain homogenate. Decontamination of the wires was 
carried out as described in section 2.4.2.  
  Following exposure, the wires were individually implanted into the prefrontal 
subcortical region of anesthetized 6 week old Syrian golden hamsters. The animals were 
regularly monitored for clinical signs of TSE and sacrificed at the terminal stage of disease. 
Diagnosis of prion disease was confirmed by the immunohistochemical detection of PrP
res in 
the brains according to a previously described protocol (Barret et al., 2003). 
 
 
2.10. HOSPITAL STERILE SERVICE DEPARTMENT (SSD) STUDIES 
 
  This work was carried out with the assistance of The Basingstoke and North 
Hampshire Hospital Sterile Service Department.  
 
2.10.1. An Assessment of the Effectiveness of a Validated Washer Disinfector Cleaning 
Cycle 
 
  A set of new instruments was allowed to progress through an initial cleaning cycle 
upon removal from the manufacturers packaging. The instruments were then sent to the 
operating theatre and, upon return to the SSD, were cleaned according to an automated 
washer disinfector cycle similar to those detailed in section 2.4.1. This cycle of cleaning 
incorporated a PRE Klenz
TM pre soak and wetting agent (STERIS Ltd) immediately after use 
in the operating theatre. The instruments were kept immersed in this wetting agent until 
loading into the washer disinfector. They were then decontaminated using an automated 
HAMO T 21 washer disinfector cycle incorporating HAMO
TM 100 (STERIS Ltd; 0.4 % (v/v), 
4 min). In addition, a set of instruments was removed from circulation following failure of     69   
visual inspection. The instruments were packaged for transport and taken for microscopic 
analysis following fluorescent labelling for general protein using SYPRO Ruby. 
 
2.10.2. An Assessment of the Acquisition of Proteinaceous Contamination Through 
Handling by SSD Staff in the Clean Room 
 
  Two new sets of surgical instruments were recovered after ten surgical procedures and 
confirmed to possess similarly low levels of proteinaceous contamination. Each set included 
plain dissecting forceps, scissors angled on flat, Hagar dilator, straight mosquito forceps, 
curved mosquito forceps, and curved Dunhill artery forceps. Following a subsequent cleaning 
cycle in the SSD washer disinfector unit, staff in the clean room were instructed to handle one 
instrument set with bare hands as per normal SSD operating procedures carrying out a visual 
inspection of each instrument. The other instrument set was handled in an identical way by 
staff wearing standard latex gloves. Each instrument set was then sterilised through a high 
temperature and pressure autoclave treatment and taken for staining using SYPRO Ruby.  
Analysis was performed using a previously published contamination index (Lipscomb 
et al., 2006b; Lipscomb et al., 2007c). This index utilises an increasing scale from 0 – 4 taking 
into account surface coverage as well as particulate height and width to rapidly assess 
proteinaceous contamination of a surface. For example, Index 0 refers to no visible 
contamination. This increases to Index 4 where surface coverage is <50 % and contaminant 
height and width exceed 20 – 100  m and 50  m respectively. Representative 
photomicrographs of contamination index scores are shown in Figure 9. 
 
 
 
a)  b) 
Index 0     70   
 
 
 
 
Figure 9 Representative photomicrographs showing increasing contamination of surgical 
instrument relative to the increasing contamination index; (a),(c),(e),(g),(i) display white light 
images taken of the instrument surface, (b), (d), (f), (h), (j) show the corresponding SYPRO 
Ruby images of the identical instrument region. Taken from Lipscomb et al., 2006c. 
  
Twenty areas displaying representative instrument contamination were photographed 
from four separate areas of the instrument surface; the handle, arm, joint and tip/blade. In a 
blind study, using comparative photomicrographs of the contamination index, five volunteers 
c)  d) 
e)  f) 
g)  h) 
j)  i)  i 
Index 4 
Index 3 
Index 2 
Index 1     71   
allocated scores accordingly for each of the images. Each of the four areas of each instrument 
was then given a mean contamination index value.  
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CHAPTER 3 
 
 
 
ASPECTS OF THE DECONTAMINATION OF SURGICAL 
INSTRUMENTS IN HOSPITAL STERILE SERVICE 
DEPARTMENTS 
 
 
 
 
 
 
 
 
 
     73   
3.1. INTRODUCTION 
 
The effective implementation of decontamination procedures within SSDs is crucial in 
order to render re useable surgical instruments safe for both patients and hospital staff. The 
build up of organic material such as tissue and bodily fluids through inefficient instrument 
reprocessing can decrease the effectiveness of subsequent disinfection and sterilisation 
procedures (Ransjo et al., 2001). Other solutions such as iodine and saline can also discolour 
and corrode stainless steel if allowed to dry for any length of time (Khammo & McDonnell, 
2006).  
The inherent risks to a patient’s health during surgical procedures increase when 
preceded by poor ineffective decontamination processes. Blood borne pathogens such as the 
Hepatitis B virus (HBV) represent a particular concern for both medical and dental practices 
(Lowe et al., 2002). The risk of iatrogenic transmission of vCJD through neurosurgical 
procedures creates further problems for SSDs due to the resistance of the causative prion 
protein to standard sterilisation methods (Gibbs, Jr. et al., 1994).  
Using EDIC/EF microscopy it is possible to visualise both proteinaceous and non 
proteinaceous contaminants in situ without the need for elution of soiling from the instrument 
surface which can decrease the sensitivity of detection (Keevil, 2003; Lipscomb et al., 2006b). 
Rather, the sensitivity of EDIC/EF microscopy is in fact influenced by the choice of 
fluorescent stain. SYPRO Ruby is a luminescent metal chelate stain incorporating ruthenium 
into an organic complex with the capacity to fluorescently label proteins. A previous study has 
demonstrated a detection sensitivity of 0.25 1 ng protein/mm
2 on PVDF membranes (Berggren 
et al., 1999). However, coupled with EDIC/EF microscopy, SYPRO Ruby has been shown to 
be able to fluorescently label protein concentration of <400 pg/mm
2 on surgical grade stainless 
steel (Lipscomb et al., 2006b). This technique has lead to the proposal and subsequent 
application of a contamination index able to sensitively and rapidly assess instrument 
contamination levels as a function of particulate size and area coverage (Lipscomb et al., 
2006b; Lipscomb et al., 2007c).  
In this chapter EDIC/EF microscopy, coupled with SYPRO Ruby, has been utilised to 
evaluate the effectiveness of SSD decontamination procedures. An initial assessment was 
performed to evaluate the efficacy of a decontamination cycle within a sterile service 
department. A set of new instruments was recovered after a single surgical procedure and 
subsequent decontamination. In situ levels of protein contamination were compared against a 
significantly older set of instruments where one device had failed a visual inspection.      74   
In addition, concerns regarding the potential for reapplication of contamination onto 
instruments following cleaning were addressed, specifically the risk of unnecessary 
transference of proteinaceous contamination following cleaning through instrument handling 
by department staff. The transference of protein by a single fingerprint onto a PVDF 
membrane as detected by SYPRO Ruby has been shown previously although this has not 
subsequently been demonstrated on stainless steel (Berggren et al., 1999). Importantly, 
handling of the instruments following a washer disinfector cycle is performed in a clean room 
prior to sterilisation, typically in high temperature and pressure autoclaves. As a result, 
contamination applied within the clean room is likely to be encrusted onto the instrument due 
to the sterilisation process, therefore decreasing the effectiveness of further decontamination 
procedures.  
 
 
3.2. MATERIALS AND METHODS 
 
  The methodology for this section of work is described in Chapter 2. An initial 
assessment of a washer disinfector cycle in use at The Basingstoke and North Hampshire 
Hospital sterile service department was undertaken as described in section 2.10.1. In addition, 
the risk of transmission of proteinaceous contamination onto surgical instruments following 
cleaning by means of handling by the SSD staff in the clean room was addressed. Laboratory 
studies to determine the potential for protein transference by hand onto stainless steel tokens 
are described in section 2.3.3.1. In addition, stainless steel wires were prepared as described in 
section 2.3.1 and inoculated with hamster NBH. To evaluate the effect of high temperature 
and pressure sterilisation on the tenacity of proteinaceous wire contamination to subsequent 
removal the wires were treated as detailed in section 2.4.1. Subsequent to this, the impact of 
protein deposition by handling, and its alleviation by implementation of gloves, on the total 
protein levels on surgical instruments was determined (section 2.10.2). Fluorescent labelling 
of proteinaceous contamination on all stainless steel instruments and tokens was performed 
using the luminescent compound SYPRO Ruby, as detailed in section 2.5.1, and analysis was 
completed using EDIC/EF (section 2.7 and 2.7.1). 
 
 
 
     75   
3.3. RESULTS  
 
3.3.1. Evaluation of a Washer Disinfector Cycle 
 
  The effectiveness of a single washer disinfector cycle was evaluated on a set of new 
instruments which had undergone a single surgical procedure and fully decontaminated 
according to the department’s SSD protocols for instrument reprocessing. Visual inspection of 
the instruments identified low levels of proteinaceous contamination across several locations 
of the device; including the tip/blade, outer surface and the hinges or box joints (Figure 10). 
However, protein deposition was visualised at relatively low concentrations, often associating 
with areas of scarring or abrasion (Figure 10e) and insignia branding sites (Figure 10f). 
  A significantly larger concentration of proteinaceous contamination was observed on 
devices within a set which had previously failed a visual inspection (Figure 11) relative to the 
new instruments. As noted upon inspection of the new set of instruments, protein deposition 
was often situated around and within damaged or heavily scarred regions of the devices 
(Figure 11a and 11d). The damage observed on the instruments was increasingly more severe 
than that observed on the new instruments. However, there was also a marked increase in in 
situ protein observed within box joints (Figure 11c and 11d), teeth (Figure 11e and 11f) and on 
the outer surface (Figure 11a and 11b).  
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Figure 10 Representative photomicrographs taken using EDIC/EF after staining of 
proteinaceous contamination on surgical instruments using SYPRO Ruby and following a 
single surgical procedure and decontamination cycle. a) & b): instrument blade tip, c) & d): 
outer surface of instrument, e): box joint, f): manufacturer insignia branded onto instrument 
surface. Arrows indicate areas of protein deposition. Scale bars: 100  m 
 
a)  b) 
c)  d) 
e)  f)     77   
 
 
Figure 11 Representative photomicrographs taken using EDIC/EF after staining of 
proteinaceous contamination using SYPRO Ruby on surgical instruments removed from 
circulation due to a failure of a device during visual inspection. a) & b): outer surface of 
instruments, c) & d): box joints, e) & f) blade/tip. Arrows indicate areas of protein deposition. 
Scale bars: 100  m 
 
a)  b) 
c)  d) 
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3.3.2. Protein Contamination of Stainless Steel by Hand 
 
Using a known concentration of brain homogenate extract stained with SYPRO Ruby 
as a standard reference, the quantity of protein transferred onto stainless steel through handling 
was calculated (Figure 12 and 13). One thumb print was able to transfer 0.51 ng/mm
2 of 
protein. Handling, as mimicked by ten thumb prints to the surface of the token, corresponded 
to a mean level of proteinaceous contamination of 0.67 ng/mm
2. Statistical analysis showed 
that there was no significant difference between the mean concentration of protein observed 
following a single thumb print and handling of the tokens with bare hands (P = 0.24). 
Importantly, <0.06 pg/mm
2 was detected on the surface of the token following a thumb print 
by a gloved hand. This concentration was not statistically different from the quantity of 
protein observed on clean, untouched control tokens (P = 0.195). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12 Mean levels of proteinaceous contamination observed on stainless steel tokens 
(n=6/treatment condition) following either a thumb print or handling using bare and gloved 
hands. * denotes two sets of data with no statistically significant difference as calculated by a 
T test to compare data means.  
 
Contamination condition
Control
Thumb print
Handling
P
r
o
t
e
i
n
 
(
n
g
/
m
m
2
)
0.0
0.2
0.4
0.6
0.8
1.0
Bare hand
Glove
  * 
 *     79   
        
 
                                                  
  
 
 
 
 
 
Figure 13 Representative photomicrographs of the surface of stainless steel tokens (n=6/ 
treatment condition) following contamination with bare hands from a) a single thumb print 
and b) handling. Arrows indicate several proteinaceous deposits. Scale bars: 100  m. 
 
3.3.3. Protein Contamination of Surgical Instruments by Hand 
 
Assessment of proteinaceous contamination using the contamination index is displayed 
for each individual instrument as well as instrument sample regions in Figure 14. Each 
instrument handled by staff wearing gloves displayed a statistically significant decrease in the 
mean contamination index score (P = 0.0 for five of the six instruments, P = 0.012 for straight 
mosquito forceps). For five of the instruments analysed, this difference corresponded to an 
approximate one index score less than corresponding instruments handled with bare hands. 
Representative photomicrographs of protein deposits taken in situ on the surface demonstrated 
the increased level of contamination of instruments handled by bare hands (Figure 15). 
Instruments handled with gloved hands demonstrated much lower concentrations of protein 
contamination, despite the surfaces appearing heavily scarred and pitted due to repeated 
cleaning cycles. Interestingly, many of the protein deposits visualised on the instruments 
showed similarities in size and estimated protein concentration with those observed on the 
stainless steel tokens (~15  m diameter, 9.71 pg ± 0.8). 
Isolation of the contamination index scores by sample region also demonstrated a 
statistically significant difference between the two handling conditions (inside hinge and arm: 
P = 0.0, blade/tip and outside hinge: P = <4 x 10
 7). An increase in index score by a factor of 
one was observed on the outside hinge joint and arm sampling regions of instrument handled 
by bare hands. The difference in score was less pronounced from inside the hinge joint and the 
a)  b)     80   
blade/tip sampling regions, although significant proteinaceous contamination was observed in 
these sampling regions relative to instruments handled with gloves.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14 Mean contamination index scores obtained attributed to surgical instruments 
(n=6/set) under two separate handling conditions within the clean room prior to sterilisation. a) 
contamination index expressed as variations between instruments within a single set; b) 
regional variation of mean contamination index scores for all six instruments. 
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Figure 15 Representative photomicrographs taken using EDIC/EF microscopy of surgical 
instruments (n=6/set) following handling with bare hands; a) & b) and gloved hands; c & d) 
within the clean room prior to sterilisation. Arrows indicate several proteinaceous deposits. 
Scale bars: 100  m. 
 
3.3.4. Effect of Autoclave Treatment on Protein Attachment to Stainless Steel 
 
  Hamster NBH control wires demonstrated a protein surface coverage of 7.1 ng/mm
2, as 
identified by SYPRO Ruby (Figure 16). Following a 5 min rinse of control wires with 
deionised water subsequent to inoculation, total protein levels were markedly decreased, with 
a residual coverage of 0.17 ng protein/mm
2. In contrast, 11.7 ng/mm
2 of protein was detected 
on inoculated wires subjected to an autoclave treatment followed by a 5 min rinse in deionised 
water. There was no statistically significant difference in protein concentrations between 
control wires and autoclaved wires (Figure; P = 0.084). 
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Figure 16 The effect of a high temperature and pressure autoclave treatment on the tenacity of 
bound protein to stainless steel wires (n=7/treatment group).* denotes two sets of data with no 
statistically significant difference as calculated by a T test to compare data means. 
 
 
3.4. DISCUSSION 
 
Decontamination is an amalgamation of practices used to render a re useable item safe 
for further use for both patients and staff (NHS Estates, 2003). The life cycle of a surgical 
instrument begins upon purchase, through both cleaning and disinfection to sterilisation and 
use. For efficient decontamination, high standards must be set and implemented at all stages of 
the life cycle in order to minimise the risk of transmitting infection to a patient during surgical 
procedures. These high standards must involve the application of effective pre cleaning 
procedures, such as the prevention of drying of soil onto instruments which has been shown to 
decrease the effectiveness of subsequent cleaning as well as damage and discolour stainless 
steel devices (Khammo & McDonnell, 2006; Lipscomb et al., 2007b). Upon reaching the 
cleaning stage, it is crucial that an effective washer disinfector cycle is employed. Failure of a 
validated washer disinfector cycle to efficiently remove soiling from the device is likely to be 
amplified as an instrument ages. Damage and scarring through everyday use creates a surface     83   
with a greater resistance to decontamination and the subsequent build up of soiling over time 
is likely to lead to ineffectual sterilisation with a consequent increase in risk to the patient.  
In this chapter, visualisation of proteinaceous contamination on both new and 
significantly older surgical instrument sets was performed. Each set had been decontaminated 
and sterilised using identical procedures for the duration of their use. This protocol included 
the use of a wetting agent to prevent the drying of surgical soil onto the instrument, followed 
by treatment with an alkaline cleaner within a validated washer disinfector cycle. The 
instruments are then visually inspected and sterilised in high temperature and pressure 
autoclaves. The new set of instruments displayed low levels of in situ protein following 
fluorescent labelling with SYPRO Ruby suggesting an extremely efficient decontamination 
protocol for instrument reprocessing within this particular SSD. Detectable residual protein 
was located within areas of scarring and damage, as a likely result of the manufacturing 
process or preceding surgical procedure, or within the heavily blemished area of the 
producer’s insignia. In contrast, the older instruments demonstrated markedly increased 
degrees of scarring and damage to the surface. As a consequence, the effectiveness of the 
decontamination process has been reduced with the accumulation of large concentrations of 
residual protein associating with these areas of damage. However, large concentrations of 
proteinaceous contamination were also visualised on areas of the instruments such as the box 
joints, teeth and outer surface. Given the absence of protein in these areas on the new 
instruments and the efficiency of the instrument reprocessing protocol this suggests that 
residual protein in these areas is a likely result of inaccessibility of the areas to the actions of 
the decontamination process. This may be a result of the complexity of the instruments (in the 
case of the teeth or box joints) or due to poor loading practice of the instruments into the 
washer disinfector. The latter may also explain the presence of large concentrations of 
proteinaceous deposition on the outer surface of the instrument in the absence of any 
association with areas of damage or scarring. However, protein deposition onto the instrument 
surface is also feasible following cleaning within the washer disinfector.  
The majority of focus into the effectiveness of SSD practices centres on two main 
stages of an instrument life cycle: instrument treatment immediately after use in surgical 
theatre and the effectiveness of various cleaning chemistries at the removal of general 
bioburden and pathogens. However the process of handling and cleanliness evaluation within 
the clean room has the potential to reinstate contamination onto instruments following 
cleaning if not properly controlled.  
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This chapter has addressed the influence of current clean room practices in the 
handling of devices and the possibility for the transference of protein from hands to stainless 
steel instruments. Laboratory studies using stainless steel tokens were able to determine that a 
single finger print could apply an estimated 0.51 ng/mm
2 of protein. This figure did not 
increase significantly following mimicked handling of the token, whereby 0.67 ng/mm
2 was 
observed, demonstrating that one finger print can introduce a substantial quantity of protein 
onto stainless steel. Importantly, the use of standard laboratory nitrile gloves resulted in a 
significant reduction in the concentration of protein applied to the token following a thumb 
print and none following mimicked handling. The former displayed an observed protein 
concentration of <0.06 pg/mm
2 which was not statistically significant when compared to 
untouched controls. This level of protein detection on stainless steel is in agreement with 
previous studies demonstrating an increased sensitivity of fluorescent protein detection using 
the SYPRO Ruby protein stain when compared with the sensitivity of currently recommended 
Ninhydrin and Biuret tests for instrument cleanliness (9.25  g and 6.7  g protein, 
respectively) (Lipscomb et al., 2006a). 
   Using a previously proposed contamination index, studies were conducted into 
whether handling in the clean room may contribute to observed levels of protein on surgical 
instruments within current SSD working procedures. Using the contamination index, an 
increase in index by a factor of one was observed on the majority of instruments relative to 
those handled by staff wearing gloves. This corresponds to an increase in field of view 
coverage from 1 – 2 % to 5 – 10 % following handling with bare hands, representing a five to 
ten fold increase in proteinaceous contamination.  
Data obtained from laboratory studies into the tenacity of stainless steel bound protein 
indicates that removal is more difficult when preceded by a high temperature and pressure 
autoclave treatment. There was no statistically significant difference between in situ protein 
detected on untreated control wires and those exposed to autoclaving at 121 ºC for 15 min 
followed by a rinse. The increase in mean protein on autoclave exposure wires relative to 
controls (11.7 ng/mm
2 and 7.1 ng/mm
2, respectively) is a likely result of structural alterations 
in protein as a consequence of high temperatures resulting in an increase in SYPRO Ruby 
fluorescence.  
Assuming that subsequent sterilisation of instruments following handling in the clean 
room results in the fixation of 100 % or 75 % of the total protein estimated to be transferred by 
a single finger print, following 50 decontamination cycles, 25.5 – 19 ng/mm
2 of protein, 
respectively, will be present on an instrument as a result of current clean room handling     85   
guidelines. Moreover, poor decontamination protocols will be amplified over any given time 
period as residual bioburden following each cycle of instrument reprocessing is heat fixed to 
the surface of the device. While unlikely to pose a direct risk to patient health, protein 
acquired by handling will add to the bioburden of an instrument and decrease the effectiveness 
of successive cleaning and sterilisation cycles. This will subsequently increase the risk to 
patient health over an instrument life cycle as levels of fixed contamination rise. This study 
suggests that the implementation of gloves for use by SSD staff working within the clean 
room will ensure that the acquisition of soiling following cleaning is significantly reduced.  
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CHAPTER 4 
 
 
 
DECONTAMINATION OF TISSUE PROTEIN AND PRION 
AMYLOID FROM SURGICAL STAINLESS STEEL DURING 
SIMULATED WASHER DISINFECTOR CYCLES  
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4.1. INTRODUCTION 
 
The prospect of asymptomatic carriers and long incubation periods in prion disease 
means that efforts to guarantee the prevention of iatrogenic transmission of prions must be 
actively sought (Collinge et al., 2006; Peden et al., 2004; Race et al., 2001). This is coupled 
with the pathophysiology of the infectious agent in both variant and sporadic CJD which is 
known to result in colonisation of extra neural tissues suggesting a significant risk to patients 
undergoing a range of different surgical procedures (Bruce et al., 2001; Glatzel et al., 2003). 
Consequently, a variety of new decontamination measures have been proposed (Fichet et al., 
2004; Fichet et al., 2007b; Jackson et al., 2005). However, even without the implementation of 
these new procedures, the incidence of proven iCJD through surgery remains low. There have 
been only 7 cases of iCJD through contaminated neurosurgical instruments or intracerebral 
electrodes to date (NHS, 2006).  
The negative influence of a single product on the efficiency of prion decontamination 
has  previously  been  demonstrated  (Yan  et  al.,  2004).  As  such,  for  the  assessment  of 
chemistries  to  be  relevant  to  decontamination  practices,  they  must  be  analysed  within  the 
context of the various pre cleaning and validated cleaning steps to assure the safety of such 
practices. In this study, current decontamination processes in sterile service departments have 
been evaluated using simulated washer disinfector cycles for the first time. Surgical grade 
stainless steel suture wires inoculated with scrapie brain homogenate were passed through an 
entire  cycle  incorporating  no  pre treatment  or  a  pre treatment  (with  a  transport  gel,  or  an 
active enzymatic formulation). This was followed by an alkaline detergent based main wash 
and disinfection, with removal of wires after each stage. The effect of the concentration and 
contact time of the main wash alkali detergent and the initial drying time of inoculum onto the 
wires were determined. In situ visualisation of the wires was carried out using EDIC/EF and a 
previously  described  dual  staining  technique  (Hervé  et  al.,  2009).  This  method  utilises  a 
sensitive amyloid fluorophore, Thioflavin T, for in situ detection of prion associated amyloid 
(Hervé  et  al.,  2009;  Lipscomb  et  al.,  2007a).  The  surface  was  then  counter stained  with 
SYPRO Ruby to fluorescently label total protein. As such, tracking of both general protein 
soiling and prion associated amyloid, as a marker of disease, was performed throughout each 
stage of the decontamination process. 
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4.2. MATERIALS AND METHODS 
 
  The methodology for this section of work is described in Chapter 2. Standard stainless 
steel wires were prepared and inoculated with ME7 scrapie homogenate as described in 
section 2.3.1. Decontamination using laboratory simulated SSD decontamination practices was 
carried out as detailed in section 2.4.2. Following treatment, the wires were fluorescently 
labelled for both total protein and prion associated amyloid (section 2.5.3) and analysed using 
EDIC/EF (section 2.7 and 2.7.1). Western blot analysis of the effectiveness of the enzymatic 
and alkaline treatments used in this study was carried out in suspension as described in section 
2.8.1 and 2.8.3 using the mouse monoclonal antibody SAF 60 raised against hamster PrP 
codon 142–160. For Western blotting, exposure of the enzymatic (Klenzyme
® Enzymatic Pre 
soak and Cleaner; STERIS Ltd) was carried out at a concentration of 0.8 % (v/v) at room 
temperature for 5 min, identical to the wires. The alkaline detergent (HAMO
TM 100; STERIS 
Ltd) was added at 0.4 % (v/v) and 0.8 % (v/v) at 45 ºC for 15 min. 
 
 
4.3. RESULTS  
 
The effect of the enzymatic pre treatment and alkali detergent on PrP
c, PrP
res and its 
associated protease resistance was determined by Western blot using the primary antibody 
SAF 60 targeted to the central core of the prion protein (Figure 17). The enzymatic pre 
treatment (which contains proteases) reduced the total detectable protein at room temperature; 
however PrP
res (indicated by resistance to 200  g/ml of proteinase K) had only a slight 
reduction in the overall signal relative to controls. Treatment with the alkaline detergent 
(ingredients including potassium hydroxide) resulted in degradation of PrP
res and sensitisation 
to proteinase K, which was evident under exposure at the lowest test concentration (0.4 % 
v/v).  
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Figure 17 Western blot analysis demonstrating the effectiveness of PrP
 and PrP
res degradation 
in NBH (  brain homogenate) or ME7 (+ brain homogenate) upon treatment with an enzymatic 
pre treatment or alkaline detergent. All lanes correspond to the analysis of 50  g of brain 
equivalent.  
 
A dual staining procedure to distinguish general protein contamination and prion 
associated amyloid on surfaces was applied to wires subjected to various decontamination 
steps. Using a known protein concentration of brain homogenate as a standard, quantification 
of wire bound protein was determined. From this, amyloid content was estimated as a function 
of the total protein. Thioflavin T positive signal observed on ME7 scrapie inoculated wires 
was normalised against non specific fluorescent signal present on corresponding wires 
contaminated with NBH. Dual stain analysis of uninoculated wires confirmed the cleanliness 
of the wire surface prior to inoculation (data not shown). However, analysis of experimental 
control wires inoculated with nanopure water throughout each cycle phase allowed an overall 
cut off value or limit of detection of 0.001 ng/mm
2 to be established. Consequently, wire 
bound contamination below this cut off was not considered significant and the wires were 
assessed as clean. 
Tracking of total protein and prion amyloid removal was initially performed on a 
decontamination cycle integrating the pre soak, an alkaline wash at 0.8 % (v/v) for 15 mins 
and disinfection (Figure 18a). It is important to note the brain inoculum had been allowed to 
dry for 16 h prior to testing. As a result, wires inoculated with normal or scapie brain 
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homogenates displayed less than a 1 log reduction in total protein following the pre soak 
treatment and subsequent water rinse relative to controls. Similarly, levels of bound amyloid 
were not statistically different from those observed on control wires (T test to compare data 
means; P = 0.519). Wires subjected to subsequent alkaline cleaning demonstrated a significant 
decrease in both total protein and amyloid.  
Wires allowed to continue into the disinfection stage of the cycle demonstrated an 
increase in non specific background signal in several cycles (Figure 19a and 19b). 
Consequently, whilst disinfection was included in subsequent cycles, analysis of residual 
amyloid levels was performed following alkaline washing. Importantly, an estimated 0.09 
ng/mm
2 of prion associated amyloid was found to remain on the wires following alkaline 
treatment in this cycle. Furthermore, at both pre soak and alkaline treatment stages, 
decontamination of total protein as identified by SYPRO Ruby from wires initially inoculated 
with NBH was more efficient than the corresponding scrapie infected brain inoculated wires 
(P = 0.00414 at the pre treatment stage; P = 0.0179 following alkali treatment). However, 
subsequent cycle analysis showed that this apparent resistance of ME7 scrapie homogenate to 
decontamination over NBH was mainly prevalent during the pre treatment stages (Figure 19) 
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Figure 18 (a) Application of a dual stain method for the identification of total protein and 
prion associated amyloid on surgical grade stainless steel wires (n=7/treatment group) 
subjected to a simulated washer disinfector cycle. (b) Total protein and prion associated 
amyloid on wires inoculated with ME7 scrapie homogenate and subjected to variations in 
alkaline cleaning contact time and concentration. *denotes two sets of data demonstrating no 
statistically significant difference as calculated by a T test to compare data means. 
 
Further analysis of decontamination cycles incorporated variations in pre treatment 
and inoculum drying time. This analysis also involved the application of a reduced 
concentration of alkaline detergent from 0.8 % to 0.4 % and, in addition, a reduction in contact 
time from 15 min to 7 min. Results demonstrated that a reduction in concentration had no 
significant effect on either protein or amyloid removal within the 15 min and 7 min time 
cohorts, as denoted by pairs of corresponding asterixes in Figure 18b. Conversely, a reduced 
mean protein and prion associated amyloid concentration was observed on wires under 
identical cycle conditions where the only parameter altered was a shorter contact time of the 
alkaline detergent. However, in all but one group (total protein between 0.4 %, 15 min and   
0.4 %, 7 min; P = 0.037) this difference was not statistically significant (0.4 %, 15 min and 7 
min amyloid: P = 0.109; 0.8 %, 15 min and 7 min protein: P = 0.19; 0.8 %, 15 min and 7 min 
amyloid: P = 0.053).  
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Comparison of variations in pre treatment and inoculum drying time were assessed 
under alkali exposure conditions of 7 min at 0.8 % (v/v) concentration (Figure 19). The 
enzymatic pre treatment was the most effective in terms of both total protein (Figure 19 a & b) 
and amyloid (Figure 19c) removal with a reduction of approximately 2 log in comparison to 
the pre soak (which does not include any physical removal) under conditions where inoculum 
had been allowed to dry (Figure 19a). Following immediate processing after inoculation, the 
enzymatic pre treatment was a further 1 log more efficient at removal of amyloid. In cycles 
where the pre soak was utilised, immediate processing of the wires following inoculation 
resulted in a 2 log and 1 log reduction in total protein and amyloid respectively compared to 
dried soil wires.  
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Figure 19 Tracking of total protein and prion associated amyloid removal from stainless steel 
wires (n=7/treatment group) during typical decontamination cycles with variations in pre 
treatment involving either an enzymatic cleaner, a pre soak or in the absence of any pre 
treatment. Exposure of the alkaline detergent was carried out for 7 min at 0.8 % in all cycles. 
a) Removal of total protein from wires where the inoculum was allowed to dry for 16 h before 
decontamination. b) Removal of total protein from wires where decontamination was initiated 
immediately following inoculation. Solid lines represent ME7 scrapie inoculated wires; 
dashed lines represent NBH inoculated wires. c) Mean residual amyloid on wires following 
different stages of a washer disinfector cycle where decontamination was carried out 
following drying of inoculum for 16 h (d) or immediately post inoculation (w); line represents 
experimental cut off value at 0.001 ng/mm
2. 
 
  Following alkaline treatment in a cycle beginning with the active enzymatic pre 
treatment, total protein and prion associated amyloid concentrations were reduced below the 
experimental cut off value of 0.001 ng/mm
2. This occurred irrespective of whether the 
inoculm had been allowed to dry or not. Conversely, under either drying condition, residual 
total protein, as identified by SYPRO Ruby, was detected following alkaline treatment in 
cycles initiated with either the pre soak or no pre treatment with the exception of one cycle 
(Figure 19b; NBH inoculated, no pre treatment wire cohort). However, there was no 
statistically significant difference in either ME7 or NBH total protein levels following alkaline 
cleaning between wires processed immediately or those dried for 16 h prior to 
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decontamination (pre soak: ME7 P = 0.427, NBH P = 0.268; no pre treatment:ME7 P = 0.179, 
NBH P = 0.061 using a T test to compare data means).  
  With respect of prion associated amyloid, alkaline cleaning subsequent to a pre soak 
pre treatment was able to completely remove detectable amyloid from the wires which were 
immediately processed (Figure 19c). Residual prion associated amyloid following alkaline 
treatment on wires initially dried for 16 h was not significantly different from the experimental 
cut off (P = 0.97). Critically, cycles which did not incorporate a pre treatment step displayed 
an estimated 0.03 ng/mm
2 of residual prion amyloid on wires following drying of soil and 
treatment with the alkaline detergent. Similar to the two other pre treatment conditions, 
immediate processing of the wires following contamination resulted in complete removal of 
detectable prion associated amyloid through treatment with the alkaline detergent alone. 
  Importantly, correlation of EDIC/EF detection of prion associated amyloid (Figure 
19c) with the Western blot method (Figure 17) suggests a relative increase in sensitivity of the 
staining procedure. Both the Western blot and EDIC/EF detection method were capable of 
identifying residual PrP
res following treatment with the enzymatic pre treatment. However, 
PrP
res signal by Western blot is almost completely removed following alkaline treatment, in 
contrast to EDIC/EF detection of prion associated amyloid (Figure 19c; no pre treatment). 
 
 
4.4. DISCUSSION 
 
The emerging pathophysiology of the infectious agent in prion disease suggests that 
iatrogenic transmission of CJD from surgical instruments should pose a greater risk to patient 
health than has currently been documented. Nevertheless, concerns remain over the lack of 
world wide accepted methods for prion inactivation and reports persist over possible 
iatrogenic cases of CJD after neurosurgical procedures (Keeler et al., 2006). In the UK for 
example, there have been 317 documented incidents of potential iatrogenic exposure to CJD 
from surgery between 1 January 2000 and 30 June 2007 where instruments potentially 
contaminated with the infectious agent have been subsequently re used on further patients 
(Health Protection Agency, 2007). However, of these, only 17 incidents were considered to be 
in serious danger of exposure to CJD, with a further 72 considered “at risk” of CJD.  
New decontamination procedures have been proposed to ensure the safety of surgical 
and medical devices as a result of the incompatibility of current WHO guidelines. To date, 
assessment techniques involve immunoblotting and animal bioassays. The lack of sensitivity     95   
of the immunoblot technique has been well documented (Lipscomb et al., 2007a; Solassol et 
al., 2004). However, in vivo animal models have been developed which utilise an assay based 
on the insertion of stainless steel suture wires into the rodent CNS to simulate the contact of 
surgical instruments in living organisms (Zobeley et al., 1999). The technique has been shown 
to detect infectivity down to a 1 x 10
 6 dilution of positive scrapie brain into negative brain 
homogenate and is currently considered the best standardised in vivo model for evaluating 
prion inactivation ability (Fichet et al., 2004; Fichet et al., 2007c; Peretz et al., 2006). 
However, experimental time course, in addition to cost and ethical issues, limit the application 
of this method. Alternative cell culture methods are currently being developed but require 
further optimization although a recent assay for the detection of prions on stainless steel has 
been described which may provide an effective method to assess methods of decontamination 
(Edgeworth et al. 2009).  
In this study, a fluorescent staining method has been applied to evaluate established 
decontamination procedures within the context of conditions for the reprocessing of surgical 
instruments  currently  used  in  the  hospital  environment.  Thioflavin  T,  routinely  used  for 
amyloid  detection  and  fibril  formation  studies,  has  demonstrated  in  situ  levels  of  prion 
detection on stainless steel 2 log higher than that of standard Western blot and a maximal 
detection level in the picogram range (Colby et al., 2007; Hervé et al., 2009; Leffers et al., 
2005; Lipscomb et al., 2007a; Roostaee et al., 2009; Stohr et al., 2008). Several other studies 
have demonstrated Thioflavin T detection of oligomeric sub species of murine tandem PrP 
and Aβ oligomers by analogues of Thioflavin T in fluorescence intensity studies (Maezawa et 
al., 2008; Simoneau et al., 2007). This suggests a sensitivity of Thioflavin T greater than the 
detection  of  aggregated  amyloid  deposits  and  is  likely  to  include  PrP
res  molecules  under 
certain experimental conditions. As such, this method represents a rapid and highly sensitive 
means for in situ detection of prion amyloid and analysis of prion decontamination techniques. 
Utilisation of existing cleaning chemistries used for manual or automated cleaning 
cycles has confirmed previous reports on the reduced sensitivity of the Western blot technique 
relative to other detection assays (including EDIC/EF combined with Thioflavin T), to assess 
the effectiveness of PrP
res degradation. The removal or disruption of antibody binding 
epitopes, in addition to altered solubility of PrP
res following treatment, is likely to account 
significantly for this loss of sensitivity which procedures such as the EDIC/EF dual stain 
technique are not affected by. This study respresents the first application and critical 
assessment of the EDIC/EF dual stain method for the evaluation of decontamination 
procedures for which this assay was designed. Importantly, under conditions used to assess     96   
decontamination, this study established an experimental cut off of 0.001 ng/mm
2, 1 log lower 
than the picogram maximal level of detection previously described (Hervé et al., 2009; 
Lipscomb et al., 2007a). Moreover, following heat treatment, an increase in background 
fluorescence of negative control/NBH wires was observed suggesting limitations of the dual 
stain under high temperature conditions where protein structural modification can occur.  
Both EDIC/EF and Western blot methods were able to confirm residual PrP
res 
following enzymatic exposure. Immunoblotting suggests that the enzymatic treatment had no 
obvious effect on the structure of PrP
res, with the reduction in amyloid observed using 
Thioflavin T a result of removal from the wires rather than degradation. Previously published 
in vivo data, under identical wire preparation and disinfection conditions on the 263K scrapie 
strain, demonstrated transmission of disease in all rodent test subjects following treatment 
with the same enzymatic chemistry (Fichet et al., 2004). Both the dual stain and Western blot 
procedures confirmed the presence of PrP
res in solution and bound to stainless steel following 
treatment with the main wash alkali; although at varying sensitivities. However, the 
immunoblot assay suggests a sensitisation of residual PrP
res to protease degradation following 
treatment. No transmissible disease in the 283K animal model under 7 min exposure at 0.8 % 
(v/v) was observed in another study (Fichet et al., 2007c). 
Analysis of the effect of a reduction in the concentration of the alkali detergent on total 
protein and amyloid removed from stainless steel there was no statistically significant effect. 
A reduction in contact time of the alkali detergent led to a drop in mean residual protein and 
amyloid, although this was not significant in all but one case. It is unclear why reducing the 
contact time provided more efficient removal. The close correlation of data between the 
groups of wires where concentration was the only altered parameter would argue against 
variability within the test method suggesting it may be an effect driven by the formulation of 
the alkaline detergent. 
Analysis of simulated decontamination cycles using the EDIC/EF dual stain method 
suggested that, predictably, the enzymatic chemistry used in this study was the most effective 
pre treatment. Importantly, the data indicate that it is during the pre treatment stage where the 
effects of soil drying time are most prevalent. The enzymatic pre treatment was 1 log more 
effective at removal of prion associated amyloid following immediate processing relative to 
dried inoculum. Moreover, following drying of the inoculum, addition of the pre soak 
transport gel had little effect on protein removal and no significant effect on in situ amyloid. 
This is not surprising as the recommended use of this product is following immediate 
contamination in order to prevent soil drying. As such, immediate immersion in the pre soak     97   
gel following inoculation of the wires resulted in a 1 log reduction in amyloid and a 2 log 
reduction in total protein through a water rinse alone. 
However, when taken in context of the end product of the entire cycle, soil drying time 
had no effect on the efficacy of cycles which incorporated pre treatments. Concentrations of 
total protein demonstrated no statistically significant difference between drying conditions. 
Moreover, prion associated amyloid levels were removed to levels below, or not significantly 
different from the experimental cut off. Even in cycles without a pre treatment, total protein 
levels were not significantly different between drying conditions. This implies that the 
subsequent alkaline wash used in this cycle was sufficiently effective to account for an 
unsuccessful, or lack of a pre treatment in terms of protein removal in all cycles and, with 
respect to prion associated amyloid in those cycles with pre treatments. This data clearly 
highlights the need to assess decontamination in the context of an entire cycle rather than 
individual treatments. 
  Critically, it is important to note that cycles with no pre treatment following drying of 
the inoculum were the least effective in terms of amyloid removal. A concentration of        
0.03 ng/mm
2 of prion associated amyloid was detected in situ on the wires. However, even in 
the absence of a pre treatment, immediate processing of the wires following inoculation 
resulted in complete removal of detectable prion associated amyloid. 
  This study has, for the first time in the field, assessed prion decontamination 
techniques within the context of typical reprocessing conditions in an SSD. It has 
demonstrated that not only the chemistry type but also the various decontaminations steps 
involved can have a profound effect on the overall outcome of instrument decontamination. 
Moreover, the data also demonstrate that whilst immediate processing was clearly beneficial 
in all cycles, even with soil drying, particular cycles were capable of significant, and in some 
cases complete reduction of detectable total protein and prion associated amyloid. As a result, 
current decontamination processes, with validated chemical formulations, combined with the 
prevention of contaminant drying and/or immediate processing, are likely to provide a highly 
effective safe guard against iatrogenic transmission of prions. This is in agreement with 
previous reports (Fichet et al., 2007a). Assuming these practises are carried out, it may also 
account for the low incidence of iCJD from surgical instruments.  
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CHAPTER 5 
 
 
 
THE EFFECT OF SURFACE DEGRADATION ON THE 
EFFICIENCY OF PRION DECONTAMINATION 
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5.1. INTRODUCTION 
 
  Chapter 3 demonstrated that even with an effective decontamination cycle, a 
significant accumulation of surface proteinaceous material still occurs during the life cycle of 
a surgical instrument. Instrument bioburden is likely to increase in parallel with scarring and 
damage, thereby creating a surface which is less amenable to decontamination techniques.  
  The impact a heavily scarred surface may have on the efficiency of prion 
decontamination has not previously been assessed. The removal of PrP
res and infectivity is 
often assessed on prion infected brain homogenate in suspension or using the stainless steel 
wire implant model, which do not represent a worst case scenario in terms of a typical 
instrument surface which is likely to be encountered within an SSD. 
  Consequently, this chapter aims to assess the effect of surface degradation on prion 
removal. Stainless steel wires were artificially degraded using an immersion autoclave 
treatment in 1M sodium hydroxide. Following inoculation with 263K scrapie infected 
homogenate, the effect of surface degradation on transmission and incubation period was 
assessed in untreated controls. In situ detection of total protein and prion associated amyloid 
following various physical, chemical and enzymatic decontamination techniques was achieved 
using the fluorescent labelling technique described in Chapter 4. Correlation of this method 
with infectivity was also performed for the first time.  
 
 
5.2. MATERIALS AND METHODS 
 
  The methodology for this section of work is described in Chapter 2. Standard stainless 
steel wires were prepared and inoculated with 263K scrapie infected homogenate as described 
in section 2.3.1. To compare the effects of surface degradation on the efficiency of prion 
decontamination, wires were artificially degraded and inoculated as detailed in section 2.3.2. 
An assessment of the extent of wire surface degradation was performed (section 2.3.2.1) and 
decontamination was carried out under the conditions described in section 2.4.3. The treated 
wires were then fluorescently labelled using a dual staining technique to identify total protein 
and prion associated amyloid (section 2.5.3) and analysed using EDIC/EF (section 2.7 and 
2.7.1). Removal of infectious disease from the wires was determined using the animal 
bioassay as described in section 2.9. 
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5.3. RESULTS  
 
5.3.1. Degradation of Stainless Steel Wire Surface 
 
  Evaluation of artificially degraded stainless steel wire topography was performed by 
visual analysis with EDIC (Figure 20) and using a laser confocal scanning system to determine 
average surface roughness (Figure 21). 
 
Figure 20 Representative photomicrographs taken using EDIC/EF of the surface of artificially 
degraded (a, b & c) and normal (d, e & f) stainless steel wires (n=7/treatment group).  
Scale bar: 10 m.  
a) 
c)  d) 
e)  f) 
b)     101   
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Figure 21 Analysis of the mean surface roughness (Ra) of degraded and normal stainless steel 
wires (n=7/treatment group) using a laser confocal scanning system to quantify surface 
degradation. Rq indicates the varying quadratic mean. 
 
Assessment of the surface degradation method by visual analysis using EDIC indicates 
an overall increase in surface roughness relative to unaltered wires. While small degrees of 
scarring were present on unaltered stainless steel wires this was rarely observed and a likely 
product of the drawing process used in their manufacture (Figure 20). Stainless steel wires 
subjected to the degradation process demonstrated pitting and an increase in the size and 
degree of scarring of the surface. To exclude the possibility of viewer bias, these findings were 
confirmed in a blind study to observe the average surface roughness using a laser confocal 
scanning system. This permitted quantification of the degree of surface degradation and 
assessment to be performed by a t test to compare data means. A statistically significant 
difference was observed in both the average surface roughness (P = 0.0079) and the root mean 
squared, otherwise described as the quadratic mean to assess the statistical measure of a 
varying quantity (P = 0.0093). 
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5.3.2. Removal of Total Protein and Prion Associated Amyloid from Normal and 
Degraded Stainless Steel Wires  
 
  Fluorescence analysis of bound total protein and prion associated amyloid from 
untreated normal and degraded control wires is shown in Figure 22, with representative 
photomicrographs displayed in Figure 23. Quantification of in situ prion associated amyloid 
suggests statistically similar concentrations attached to each wire (P = 0.222), although the 
mean of the degraded wire cohort was increased relative to normal wires (11.5 ng/mm
2 
compared to 7.5 ng/mm
2). However, a statistically significant (P = 0.049) increase was 
observed in concentrations of in situ total protein on degraded wires in comparison to normal 
wires. Visual analysis with EDIC confirmed that, rather than an increase in surface coverage, 
this statistically significant increase of in situ total protein was a likely consequence of larger 
aggregates of protein able to attach and remain bound to the degraded surface. 
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Figure 22 Variation in binding of total protein and prion associated amyloid, as identified by 
SYPRO Ruby and Thioflavin T, respectively, to normal and degraded stainless steel wires 
(n=5/treatment group) inoculated with 263K scrapie infected homogenate.   
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Incorporating the previously established cut off of 0.01 ng/mm
2 under decontamination 
conditions, Figure 24 illustrates the residual in situ total protein and prion associated amyloid 
concentrations on wires following various decontamination techniques. None of the 
enzymatics (both T1 and its double treatment T2, in addition to T3 and T4) were capable of 
removing protein to levels below 1 ng/mm
2 on either the normal or degraded wires. With the 
exception of T4 (P = 0.04), there was no statistically significant difference between protein 
removal from normal or degraded wires treated with either T1, T2 or T3. In the case of T4, 
removal of protein was significantly more difficult from degraded wires (mean residual 
protein: 1.83 ng/mm
2 on normal wires; 4.89 ng/mm
2 on degraded wires). However, less than 
0.1 ng/mm
2 of prion associated amyloid was visualised in situ following treatment on all 
wires, with the exception of T2 treated degraded wires (D T2, mean: 0.11 ng/mm
2). Complete 
removal of detectable amyloid was observed on both normal and degraded T4 treated wires 
and there was no statistically significant difference observed between the experimental cut off 
of 0.01 ng/mm
2 and residual prion associated amyloid observed on degraded wires treated 
with T1 (P = 0.182). Importantly, no significant difference was observed between amyloid 
removal from either normal or degraded wires in all enzymatic treatment cases. Statistical 
analysis using the analysis of variance (ANOVA) method also suggests that there was no 
statistically significant difference between T1 and T2 treatment on normal and degraded wires 
(P value of F test: protein: 0.062, amyloid P = 0.11). 
  Complete removal of detectable amyloid was also noted following treatment with T5 
on normal and degraded wires. Interestingly, treatment with T6 (a double treatment of the 
same alkali chemistry as T5) was less effective at removing prion associated amyloid from 
both normal and degraded wires and statistical analysis suggests residual amyloid on N T6 
and D T6 wires was significantly different from the experimental cut off. In addition, there 
was no statistically significant difference between protein removal following T5 and T6 
treatment between normal and degraded wires. 
  Critically, analysis of T7 treatment wires, involving an autoclave treatment at 134 ºC 
for 18 min, suggests an increase in non specific fluorescence which can also be observed in 
Figure 25. Whilst a statistically significant difference was detected between in situ protein on 
untreated control wires and T7 treated normal (P = 0.001) and degraded wires (P = 0.0004), 
indicating a decrease in total protein, no removal of amyloid was observed. Mean 
concentrations of in situ prion associated amyloid were determined to be 8.29 ng/mm
2 
following T7 treatment, relative to 7.51 ng/mm
2 of amyloid detected on untreated normal 
control wires. Whilst this difference was not statistically significant in the case of the normal     105   
wires (P = 0.79), analysis of degraded wires demonstrated a significant increase (P = 0.02) in 
amyloid, with mean concentrations of 30.93 ng/mm
2 detected relative to 11.54 ng/mm
2 on 
untreated degraded control wires.  
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Figure 24 Analysis of total protein and prion associated amyloid, as identified by SYPRO 
Ruby and Thioflavin T, respectively, bound to normal (N) and degraded (D) stainless steel 
wires (n=5/treatment group) inoculated with 263K scrapie infected homogenate following 
decontamination with a variety of enzymatic, chemical and physical processes. Control wires 
represent untreated wire cohorts.     106   
 
Figure 25 Representative photomicrographs taken using EDIC/EF of wires (n=5) inoculated 
with 263K scrapie infected homogenate and decontaminated using a high temperature and 
pressure autoclave treatment (T7). a) Protein as detected by SYPRO Ruby; b) Amyloid as 
detected by Thioflavin T. Scale bars: 100  m 
 
  An increase in protein removal was observed following immersion autoclaving (T8) 
relative to T7. Non specific amyloid fluorescence also appeared to be reduced upon analysis 
of T8 treated wires. However, prion associated amyloid removal was significantly improved 
on T8 treated degraded wires, relative to normal wires (P = 0.014). Conversely, protein 
removal was more efficient upon treatment of normal wires compared with degraded wires 
following exposure to 1M NaOH (T9). Treatment with T9 also removed all detectable prion 
associated amyloid from both wire groups. Complete removal of detectable prion associated 
amyloid, in addition to total protein, was also observed on normal wires following treatment 
with T10 (sodium hypochlorite) and T11 (Bleach 1). Whilst the residual mean total protein 
and prion associated amyloid were increased on degraded wires relative to normal wires, the 
concentrations were not significantly different from the experimental cut off. Interestingly, 
T12 (Bleach 2), was less effective than NaOCl and Bleach 1 at both total protein and prion 
amyloid removal, with only an approximate 1 log in total protein. Concentrations of residual 
total protein and prion associated amyloid were comparable, as can be seen in Figure 24. 
However, more efficient removal of both total protein and amyloid was observed on normal 
wires compared to degraded wires (total protein: P = 0.043, prion associated amyloid: P = 
0.0007). Residual protein and prion associated amyloid was visualised on the wires following 
b) 
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T13 treatment on both normal and degraded wires, with no statistically significant difference 
between the two wire cohorts (total protein: P = 0.13, prion associated amyloid: P = 0.7). 
High resolution EDIC/EF imaging of the wire surface is shown in Figure 26 and 27. 
Residual protein and prion associated amyloid was seen to associate largely, although not 
entirely, with areas of scarring and damage on both normal and degraded wires. Those areas of 
scarring and roughing were considerably more extensive on degraded wires, confirming initial 
assessments (Figure 20 and 21). 
 
Figure 26 Representative photomicrographs taken using EDIC/EF of residual proteinaceous 
deposits staining with SYPRO Ruby following decontamination with a) TN1; b) TD1; c) TN2; 
d) TD2; e) TN3 & f) TD3. Arrows indicate protein deposits. Scale bars: 10  m. 
a)  b) 
c)  d) 
e)  f)  
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5.3.3. Removal of Infectivity from the Surface of Normal and Degraded Stainless Steel 
Wires 
 
  Infectivity was assessed using the rodent bioassay model by the implantation of 
stainless steel wires into the CNS of hamsters. The effect of the carrier surface on wires 
inoculated with serial dilutions of a 10 % (w/v) 263K infected brain homogenate into NBH are 
shown in Table 9. All dilutions of the wire inoculum induced disease in the rodent model on 
both normal and degraded carrier surfaces. Interestingly, degradation of the wire surface 
indicated a prolonged incubation period relative to the same dilution series inoculated onto 
normal wires. However, whilst the mean incubation period was increased with degradation of 
the wire surface in all dilutions, it was only significantly different at the 10
 1 dilution.  
 
Table 9 Surface infectivity of normal and degraded stainless steel wires  
(n=11/wire group) inoculated with serial dilutions of 10 % (w/v) 263K  
scrapie infected homogenate into NBH indicating percentage transmission  
to hamsters and the incubation period of scrapie disease. 
Normal Wires  Degraded Wires 
Dilution  Transmission 
(%) 
Incubation 
(days) 
Transmission 
(%) 
Incubation 
(days) 
10
 1   100  90 ± 2  100  100 ± 5 
10
 2   100  98 ± 5  100  111 ± 8 
10
 3   100  117 ± 6  100  133 ± 13 
10
 4   100  124 ± 11  100  138 ± 16 
 
  Infectivity of the wires following decontamination treatments is shown in Table 10. 
None of the enzymatic chemistries (T1, T2, T3 and T4) used in this study were capable of 
completely removing infectious disease. Neither T3 nor T4 induced any effect on transmission 
rate or incubation period, with no log reduction of infectious load. A single treatment with T1 
resulted in a 3 log reduction in infectivity but no effect on overall transmission. A double 
treatment with the same enzymatic (T2) produced a 37 % reduction in transmission of disease 
and a further 1 log reduction in infectious load relative to T1.  
  Treatment with the alkali T5, 1 M NaOH (T9), NaOCl (T10) and immersion 
autoclaving in water (T8) completely eliminated infectivity. A dry autoclave procedure (T7) 
produced a 40 % reduction in transmission of disease and a 4.4 log reduction in infectivity.     110   
Interestingly, a 0.1 log increase in reduction of infectious load was observed following 
treatment with T13, relative to T7. Incubation periods between the two treatments were 
comparable, however transmission of infectious disease was only noted in 33 % of the rodents 
following treatment with T13 relative to 60 % of the T7 animal group. 
 
Table 10 Surface infectivity of normal and degraded stainless steel wires inoculated with 10 
% (w/v) 263K scrapie infected brain homogenate indicating percentage transmission to 
hamsters, incubation period of scrapie disease and log reduction of infectivity following 
various decontamination methods.     indicates exposure not tested. 
Normal Wires  Degraded Wires 
Treatment  Transmission
a 
(%) 
Incubation 
(days) 
Log.Red.
b 
Transmission
a 
(%) 
Incubation 
(days) 
Log.Red.
b 
T1                 100  179 ± 22  3 
T2                 63  316 ± 36  4 
T3                 100  102 ± 6  0 
T4                 100  99 ± 4  0 
T5  0  > 365  5.5                
T6                               
T7  60  197 ± 86  4.4                
T8  0  > 365  5.5                
T9  0  > 365  5.5  0  > 365  5.5 
T10  0  > 365  5.5                
T11                               
T12                               
T13  33  170 ± 33   4.5                
aExperiment stopped at 365 days. 
bLog reduction of infectivity was estimated from the initial infectivity of 10 % brain 
homogenates used to inoculate test surfaces. 
 
 
5.4. DISCUSSION 
 
  The influence of surface degradation and roughing on decontamination and, more 
specifically prion removal from surgical stainless steel, has not been investigated previously. It 
is clear that surgical instruments which have been in circulation longer within SSDs are more     111   
difficult to clean than those recently introduced. A significant cause of this is the increase in 
surface scarring, roughing and damage. This can be acquired through interaction with other 
devices or through the gradual loss of the passivation layer creating a surface upon which 
decontamination processes involving reverse osmosis (RO) water and high pH chemistries can 
impact upon (personal communication with J.Harrison).  
  Immersion autoclave treatment with 1 M sodium hydroxide is known to both damage 
and degrade stainless steel instruments (Brown et al., 2005; McDonnell & Burke, 2003). This 
process was employed in order to provide a worst case scenario, damaged, stainless steel wire 
surface which was less amenable to decontamination. Assessment of the degraded wires by 
visual analysis using EDIC, and in a blind study using a laser confocal scanning system, 
confirmed that autoclaving in 1 M NaOH significantly altered wire surface integrity relative to 
normal, untreated wires. Significant surface roughing was present following treatment which 
was not visualised on normal wires. Moreover, residual protein and prion associated amyloid 
deposits were observed to largely associate with areas of induced and existing surface 
degradation on degraded and normal wires, respectively. 
  Consequently, the wires were inoculated with 263K scrapie infected homogenate. 
Importantly, concerns have been raised recently over the use of experimental animal prion 
strains (Giles et al., 2008). The applicability of conclusions due to the divergent physical and 
biochemical properties of these strains, relative to those such as vCJD and BSE for which the 
work is intended, has been brought into question. However, the use of vCJD and BSE strains 
is severely limited by the availability of adequate facilities to handle such material, in addition 
to attainable material. Moreover, experimental prion strains such as 263K scrapie have been 
demonstrated to be highly resistant to decontamination methods. Studies have indicated that 
263K scrapie in particular is one of the most biochemically stable and resistant strains of TSE 
(Fernie et al., 2007). This strain has been shown to be more resistant than mouse adapted BSE 
and comparable to human CJD and bovine BSE strains in terms of resistance to 
decontamination methods (Brown et al., 2000; Fichet et al., 2007b; Fichet et al., 2007c). As 
such, 263K scrapie represents an extremely pertinent prion strain to evaluate the efficiency of 
decontamination processes. The 263K animal bioassay model is used extensively as an 
assessment of residual infectivity on stainless steel wires and has been shown to be highly 
reproducible  (Fichet et al., 2007c; Lemmer et al., 2008; Lemmer et al., 2004; Yao et al., 
2005). In this study, the use of this method permitted an assessment of the effect of surface 
degradation on disease transmission and also correlation of infectivity with EDIC/EF and 
Thioflavin T detection of prion associated amyloid.     112   
  Analysis of both normal and control wires using the fluorescent dual staining method 
suggested that, whilst both wire cohorts possessed similar concentrations of prion associated 
amyloid, there was a significantly greater concentration of total protein bound to degraded 
wires relative to normal wire controls. Visual inspection of the wires and representative 
images displayed in Figure 23 suggests that the degradation of the surface permitted 
attachment of larger aggregates of protein. Implantation of both normal and degraded wires 
into the hamster prefrontal subcortical region induced disease in 100 % of animals at all serial 
dilutions of the wire inoculum. The reproducibility of the 263K animal model has previously 
been demonstrated and data has closely correlated despite separate homogenate inoculum 
preparations (Fichet et al., 2007c). However, a prolonged incubation period was observed in 
this study at all inoculum dilutions on degraded wires (mean increase in incubation period:  
10
 1 dilution: 10 days, 10
 2: 13 days, 10
 3: 16 days and 10
 4: 14 days). Whilst this observed 
increase was only statistically significant at one out of the four inoculum dilutions, these data 
suggest that surface degradation can potentially influence the time course to clinical disease, 
potentially resulting in a longer subclinical incubation period. Previous data up to a 10
 4 
inoculum dilution argues against the possibility that the variation in incubation period 
observed in this study was a result of the intrinsic variability of the testing method, although 
due to statistical data, this can not be discounted (Fichet et al., 2007c). Importantly, it is clear 
that the wire implant model presented in this chapter can not reproduce the degree of surface 
degradation and damage that is observed on surgical instruments. Indeed, only following T4, 
T9 and T12 exposure was a statistically significant increase in residual total protein observed 
on degraded wires in relation to normal wires. This is likely to explain the lack of statistical 
significance in incubation periods between wire cohorts at three of the four inoculum 
dilutions. However, a potential implication of the wire data is that disease incubation period 
may increase in parallel with the extent of surface damage.  
  Various enzymatic, chemical and physical decontamination techniques were evaluated 
using EDIC/EF and the fluorescent dual stain technique to detect both total protein and prion 
associated amyloid on normal and degraded wires. All of the enzymatic treatments, designated 
T1, T2, T3 and T4, demonstrated concentrations of residual total protein greater than               
1 ng/mm
2 following exposure on either normal or degraded wires. With the exception of T2 
treatment of degraded wires, prion associated amyloid was removed to concentrations below         
0.1 ng/mm
2 on all wires exposed to the enzymatic chemistries. Interestingly, T2 represents a 
double treatment of the same enzymatic as T1. However, on both normal and degraded wires, 
no statistically significant difference was observed between either protein removal or prion     113   
amyloid removal suggesting an increased treatment with the same chemistry had no effect on 
protein and amyloid removal. Conversely, complete removal of detectable prion associated 
amyloid was following a single treatment of an alkali based chemistry (T5) but a double 
treatment with the same chemistry proved less effective with concentrations of amyloid 
significantly elevated above the experimental cut off. These data correlate with Figure 18 in 
Chapter 4 using the same alkali confirming that prolonged exposure to this particular 
chemistry can decrease the effectiveness of decontamination relative to a shorter contact time. 
This chapter also confirms that high heat and pressure autoclave treatment increases the 
background signal associated with Thioflavin T, thereby decreasing the sensitivity of the dual 
stain procedure. Whilst a decrease in total protein on both normal and degraded wires was 
observed, no significant difference was observed between prion associated amyloid 
concentrations on normal wires relative to controls. On degraded wires, a statistically 
significant increase was observed with mean prion associated amyloid detected by Thioflavin 
T increasing from 11.54 ng/mm
2 to 30.93 ng/mm
2 following treatment. This can be observed 
in Figure 25 as an increase in the concentration of protein which is identified as amyloid by 
the Thioflavin T fluorophore. 
   Complete removal of both detectable total protein, including prion associated 
amyloid, was observed following treatment with 1 M NaOH (T9), 20,000 ppm NaOCl (T10) 
and bleach 1 (T11) from normal wires. Prion associated amyloid was also removed from 
degraded wires although residual protein was observed in situ at concentrations above the 
experimental cut off following treatment with T9. Residual protein on degraded wires 
following treatment with T10 and T11 was not significantly different from the experimental 
cut off. Interestingly, a second bleach product (T12) demonstrated only a 1 log and >1 log 
reduction in total protein and prion associated amyloid respectively.  
Whilst infectivity data were not available for T12 or T11, the animal bioassay 
demonstrated removal of infectivity from the wires following treatment with T9 and T10, 
confirming the effectiveness of WHO approved recommendations for the treatment of 
reusable surgical instruments at risk of CJD contamination (Sehulster, 2004; Taylor, 2004). 
The absence of transmissible disease correlates with a removal of prion associated amyloid 
from the wires and was also noted following T5 exposure. In addition, a correlation between 
in situ prion associated amyloid and infectivity was also detected following treatments T2, T3 
and T13. However, critically for the identification of prion associated amyloid as a marker of 
disease, infectivity was observed in the absence of prion associated amyloid following     114   
treatments T1 and T4. Conversely, the presence of prion associated amyloid was also 
observed in the absence of infectious disease following T8 exposure. 
These data confirm that prion associated amyloid and infectious disease can be 
disassociated from each other under certain exposure conditions. As a result, the use of prion 
associated amyloid as a marker for disease is highly dependent on the decontamination 
techniques employed and their direct impact on prion associated amyloid. Enzymatic 
chemistries such as T1 and T4, exposure to which results in removal of infectivity in the 
animal bioassay, appear to break down larger amyloid deposits to levels below the detection 
limit of Thioflavin T. Therefore, improvement of fluorescent amyloid detection techniques 
may elicit a better correlation with infectivity than is demonstrated by Thioflavin T in cases 
where infectious disease is evident in the absence of detectable amyloid.  
Degradation of the wire surface in order to provide a worst case scenario surface for 
the wire implant model proved effective under certain treatment conditions in terms of 
removal of proteinaceous contamination as identified by SYPRO Ruby. Importantly, initial 
observations suggest a prolonged incubation period may be induced by a prion contaminated, 
degraded stainless steel surface. This may be a direct consequence of the altered surface 
integrity of degraded wires relative to normal, unaltered wires or due to the increase of 
surrounding total protein resulting in a dissemination of the infectious agent to surrounding 
tissues. Critically, however, these initial findings require further assessment in order to be 
confirmed.  
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CHAPTER 6 
 
 
 
CORRELATION OF IN VITRO AND IN VIVO  
METHODS OF PRION DETECTION 
 
 
 
 
 
 
 
 
 
 
     116   
6.1. INTRODUCTION 
 
In prion diseases, little is known about the relationship between infectivity and particle 
size. Many of the studies appear in agreement with a smaller oligomeric PrP molecule as the 
infectious agent. Whilst oligomeric PrP has been demonstrated to be highly infectious in vitro 
and in vivo (Redecke et al., 2007; Silveira et al., 2005), other studies have disagreed with their 
infectivity levels relative to higher order amyloid. One such study showed mature amyloid 
fibrils produced from full length recombinant PrP to be highly toxic to cultured cells, primary 
hippocampus and cerebella neurons in a time and dose dependent manner. However, the lethal 
effects were comparable to those exhibited by small, soluble β oligomers, suggesting that, in 
vitro at least, both amyloid and oligomeric intermediates are neurotoxic (Novitskaya et al., 
2007). Importantly, an oligomeric subspecies of PrP is yet to be classified, in addition to the 
role of PrP
res and amyloid in prion disease. 
Methods to assess the effectiveness of decontamination techniques currently include 
conventional immunoblotting and infectivity bioassays using the rodent wire implant model 
(Fichet et al., 2004; Fichet et al., 2007b; Fichet et al., 2007c; Yan et al., 2004). The latter 
method is expensive and time consuming to undertake, in addition to the ethical implications 
of such work, but provides an assessment of the presence or absence of infectivity irrespective 
of the size or nature of the infectious unit. Immunoblotting utilises antibodies targeted to 
specific amino acid sequences of the prion protein and, combined with a protease such as 
proteinase K to degrade normal cellular PrP, identifies PrP
res as a marker of disease. The loss 
of antibody binding epitopes through enzymatic or chemical decontamination treatments has 
the capacity to drastically decrease the sensitivity of this method. This is combined with the 
uncertainty over the relationship of PrP
res with transmissible disease. Furthermore, 
immunoblotting can be carried out in suspension or surface studies whereby only the extent of 
degradation or denaturation of PrP
res is considered in suspension. Surface studies observing 
the physical removal of the prion protein from a test surface incorporate manual removal of a 
treated sample which may further reduce the sensitivity of this procedure thus overestimating 
the effectiveness of decontamination techniques.  
The present study has aimed to correlate infectivity in the rodent wire implant model 
with fluorescent detection of amyloid using Thioflavin T on wires treated with enzymatic and 
alkali chemistries. In addition, suspension and surface immunoblotting was undertaken in 
parallel to observe the effect of the treatments on denaturation and physical removal of PrP
res. 
Antibody mapping of PrP
res using Western blot following treatment with enzymatic, alkali and     117   
phenolic chemistries was also performed to assess the correlation between removal or 
degradation of epitopes and infectious disease.  
 
 
6.2. MATERIALS AND METHODS 
 
  The methodology for this section of work is described in Chapter 2. Stainless steel 
wires were prepared and inoculated with 263K scrapie brain homogenate as described in 
section 2.3.1. Decontamination was performed (section 2.4.4) and the treated wires were then 
fluorescently labelled using a dual staining method to identify total protein and prion 
associated amyloid (2.5.3). Examination of the wires was carried out using EDIC/EF (section 
2.7 and 2.7.1).  Standard Western blot analysis was performed in suspension and surface 
studies as described in section 2.8 using the mouse monoclonal antibody SAF 60 raised 
against hamster PrP codon 142–160. Sample exposure conditions were identical to those 
described for the wire treatment in section 2.4.3. Protocols for antibody mapping Western blot 
analysis as described in section 2.8.1.1. Western blots were performed in suspension utilising 
six different monoclonal antibodies (Figure 8). These identification methods were correlated 
with infectious disease determined using the animal bioassay as described in section 2.9. 
 
 
6.3. RESULTS  
 
6.3.1. Correlation of the EDIC/EF Dual Stain with Immunoblotting and the Animal 
Bioassay 
 
In vitro analysis of the wires was performed using the fluorescent dual staining method 
previously described (Figure 28). Control wires demonstrated a mean concentration of bound 
total protein of 11.1 ng/mm
2 and bound prion associated amyloid of 6.7 ng/mm
2. Statistical 
analysis suggested there was no significant difference between the two values (P = 0.74).  
Analysis of total protein levels following treatment indicated that, in the case of 
Enzymatic 3 and 4 and Alkaline 1 cleaners, 263K inoculated wires were more difficult to 
decontaminate than corresponding negative control wires (P = 0.019, 0.021 and 0.034,  
respectively). No statistically significant difference was noted in total protein between 263K 
and NBH inoculated wires following exposure with Enzymatic 1, 2 and 5 cleaners.     118   
Fluorescently labelled prion associated amyloid was detected in situ following treatment with 
enzymatic 1, 3, 4 and 5 and Alkaline 1 cleaners (estimated residual amyloid; Enzymatic 1: 15 
pg/mm
2, Enzymatic 3: 7.9 pg/mm
2, Enzymatic 4: 3.7 pg/mm
2 and Alkaline 1: 5.1 pg/mm
2). A 
3 – 3.5 log reduction in amyloid relative to controls was observed with each of these 
treatments although no statistically significant difference in residual amyloid was observed 
between the treatment groups. Interestingly, complete removal of detectable prion associated 
amyloid was observed on wires treated with Enzymatic 2 in the presence of a relatively poor 
removal capacity of total protein, as identified by SYPRO Ruby. In the case of the NBH 
inoculated control and Enzymatic 2 treated NBH wires, wire bound total protein levels were 
not statistically different (P = 0.42). The least effective treatment at removal of amyloid was 
Enzymatic 5 with a mean level of residual amyloid of 0.2 ng/mm
2. 
Analysis of the degradation and removal of PrP
res by each treatment was performed by 
immunoblotting carried out in suspension and surface studies (Figure 29 & 30). In contrast to 
the data obtained through fluorescent amyloid detection in the Enzymatic 1, 3, 4 and 5 and 
Alkaline 1 treatment cohorts, all of the enzymatic treatments displayed complete removal of 
detectable PrP
res signal from the stainless steel tokens. Only treatment of test surfaces with 
Enzymatic 2 demonstrated a positive correlation between Thioflavin T amyloid detection and 
Western blot data with complete removal of detectable prion associated amyloid and PrP
res. 
However, transmissible disease in the animal bioassay model was observed following 
treatment with Enzymatic 2, as well as Enzymatic 3 and 4 in this study (Table 11).   
Enzymatic 1 previously demonstrated a 100 % transmission rate, but also an increase in prion 
resistance, under the experimental conditions tested in this study on the 263K scrapie model 
(Yan et al., 2004). Enzymatic 5 was unavailable for evaluation at the time of the study.  
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Homogenate & Treatment
NBH Control
263K Control
Enzymatic 1 NBH
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Total Protein
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Figure 28 Analysis of bound total protein and prion associated amyloid, fluorescently labelled 
with SYPRO Ruby and Thioflavin T, respectively, for wires (n=7/treatment) inoculated with 
either 10 % (w/v) 263K scrapie infected brain homogenate or NBH and decontaminated with 
various enzymatic and alkali chemistries.     120   
Table 11 Surface infectivity of stainless steel wires (n=11/treatment) inoculated 
with 10 % (w/v) 263K scrapie infected brain homogenate indicating percentage 
transmission to hamsters, incubation period of scrapie disease and log reduction 
in infectivity following various decontamination methods.  
Treatment  Transmission (%)
a  Log. Red
b 
Enzymatic 2  10/10  1 
Enzymatic 3  10/10  3.5 
Enzymatic 4  7/8  ~ 3 
Alkali 1  0/0  5.5 
aExperiment stopped at 365 days. 
bLog reduction in infectivity was estimated from the initial infectivity of 10 %  
brain homogenates used to inoculate test surfaces. 
 
Figure 29 Western blot analysis of the effectiveness of PrP
res degradation and removal upon 
treatment with different enzymatic chemistries in suspension studies or on samples eluted 
from stainless steel tokens. All lanes correspond to the analysis of 50  g of brain equivalent.     121   
Importantly, none of the enzymatic treatments displayed any detectable capacity to 
degrade PrP
res or render it PK sensitive as observed by Western blot. Variations in 
concentration of enzyme chemistry, (an example of which is shown in Figure 30) demonstrate 
that even upon a two fold increase, PrP
res remains stable in suspension. Alkaline 1 
demonstrated residual PrP
res signal both in suspension and surface studies at a concentration of 
0.1 %. Both physical removal from the token and degradation in suspension were achieved at 
a concentration of 0.4 %. Infectivity data obtained from the animal bioassay model indicate 
removal/inactivation of the infectious agent in the Alkaline 1 treatment cohort alone (total 
death/total #: 0/10) suggesting that any residual amyloid detected by Thioflavin T was unable 
to transmit disease. 
 
 
Figure 30 Western blot analysis of the effectiveness of PrP
res degradation and removal upon 
treatment with an enzymatic and alkali chemistry in suspension studies or on samples eluted 
from stainless steel tokens. All lanes correspond to the analysis of 50  g of brain equivalent. 
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6.3.2. Correlation of Structural Alterations in PrP
res and Infectivity 
 
  Immunoblotting was performed using six different antibodies targeted to different 
regions of the prion. Homogenates of scrapie strain 263K were treated with Enzymatics 1, 2 
and 3, Alkali 1 and two phenolic compounds designated Phenolic 1 and 2 (Figure 31). In 
addition, homogenates were also treated with a 1 M solution of NaOH (Figure 32). Exposure 
time for the NaOH treatment was limited to 30 sec in order to detect early structural alterations 
to PrP
res. Exposure for a time greater than 90 sec demonstrated total degradation of PrP
res 
beyond the detection levels of the conventional immunoblot. 
Treatment with Enzymatic 1 and 3 resulted in almost complete removal of the Bar 210 
binding epitope. Whilst SAF 37, SAF 70, SHA 31, SAF 60 and Pri 917 signal was reduced 
relative to untreated controls, the remaining PrP
res was resistant to increasing concentrations of 
PK.  
Enzymatic 2 treatment indicated an almost complete removal of Bar 210, SAF 37 and 
Pri 917 binding epitopes. However, the central core of SHA 31, SAF 60 and SAF 70 labelled 
epitopes remained stable to increasing PK concentrations.  In contrast, PrP
res treated with 
Alkaline 1 demonstrated removal of Pri 917 and Bar 210 binding epitopes with sensitisation of 
the central core to PK, as has been demonstrated in preceding chapters.  
Phenolic 1 treatment of PrP
res resulted in an almost complete degradation of the Bar 
210 and SAF 37 binding epitopes. However, the remaining epitopes were stable and resistant 
to degradation under increasing concentrations of PK, as were SHA 31 and SAF 70 epitopes. 
In contrast, the SAF 60 epitope was sensitive to PK degradation.  
Treatment of PrP
res with Phenolic 2 almost completely degradeed Bar 210, SAF 37, 
SAF 70 and SAF 60 binding sites. However, these epitopes, in addition to Pri 917 and SHA 31 
epitopes were resistant to PK.  
At a 30 sec exposure time of 1 M NaOH, Pri 917 and Bar 210 epitopes were 
completely removed. The central core binding epitopes labelled by SAF 60, SAF 70, SHA 31 
and SAF 37 were reduced in concentration and remain sensitive to PK (Figure 32). An 
extension of exposure time from 30 sec to 90 sec to 1 M NaOH completely degraded all 
binding epitopes.  
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Figure 32 Western blot analysis of PrP
res degradation following treatment with 1M NaOH 
at 100 ºC for 30 sec and 1 min 30 sec. Detection was performed using six different primary 
antibodies. All lanes correspond to the analysis of 50  g of brain equivalent. 
 
 
6.4. DISCUSSION 
 
Ambiguity over the infectious agent in prion disease has clinical implications, 
including the uncertainty over detection techniques for the validation of methods used to 
remove or inactivate infectivity from surfaces, such as surgical instruments. The current 
gold standard approach is the rodent bioassay. Aside from ethical and financial concerns, 
the time course for disease development is slow with studies routinely lasting a year before 
a complete set of results can be obtained (Fichet et al., 2007c; Yan et al., 2004).     125   
Techniques such as immunoblotting and fluorescent amyloid detection are limited in their 
range of sensitivity and may not encompass, at least entirely, the infectious agent.  
 
6.4.1. Correlation of the EDIC/EF Dual Stain with Immunoblotting and the Animal 
Bioassay 
 
In this study, stainless steel suture wires were inoculated with 263K scrapie 
homogenate. Treatment was carried out using a selection of commercially available 
decontamination chemistries that were enzymatic, phenolic and alkaline in nature. The 
effect of these treatments on transmissible disease was determined using the animal 
bioassay which  was correlated with two routinely used methods. Firstly, standard Western 
blots were used to assess the activity of these chemistries on PrP
res in suspension and its 
removal from surfaces using previously published methodology (Fichet et al., 2004). 
Secondly, stainless steel wires, identical to those used in the in vivo rodent wire implant 
model, were fluorescently labelled with the EDIC/EF dual staining procedure to identify 
total protein and prion associated amyloid. 
Analysis of control wires demonstrated a significant concentration of amyloid 
present on the wires as a result of the amyloid rich nature of the cerebral cortex in the 
263K scrapie strain. A calculated mean concentration of 6.7 ng/mm
2 of prion associated 
amyloid was identified on the wires’ surface relative to 11.1 ng/mm
2 of total protein. As 
such, removal of 263K infected homogenate was significantly more difficult than NBH 
following treatment with Enzymatic 2, 4 and Alkaline 1. However, the increased resistance 
of 263K homogenate to removal relative to NBH was dependent on the treatment with 
Enzymatic 1, 2 and 5 showing no difference in removal capacity.  
  In situ residual amyloid was detected on wires following treatment with Enzymatic 
1, 3, 4 and 5, as well as Alkaline 1 despite a 3 – 3.5 log reduction for each treatment. This 
is in contrast with surface studies by Western blot which demonstrated a complete removal 
of PrP
res signal following treatment with all of the enzymatic chemistries. This is likely a 
result of the difficulties and sensitivity issues surrounding elution of the treated sample 
from the stainless steel tokens. In addition, this study also demonstrates residual amyloid 
on the wires following treatment with a 0.8 % working concentration of Alkaline 1 where 
PrP
res signal detected by suspension Western blotting was lost subsequent to treatment with 
a 0.4 % concentration. This study is in agreement with previously published data 
demonstrating an increased sensitivity of fluorescent amyloid detection by Thioflavin T 
relative to Western blot (Hervé et al., 2009; Lipscomb et al., 2007a). Importantly, in the 
study by Lipscomb et al., (2007a), Western blotting was performed in suspension without     126   
the need for elution of the sample from a surface. As such, the relative sensitivity of 
Thioflavin T detection is likely to be further increased relative to surface Western blotting 
and it must also be noted that the 20  l homogenate aliquoted onto the tokens will be 
significantly greater than the concentration absorbed onto the wires during inoculation. It is 
important to note that a previous study utilising surface Western blot demonstrated several 
cases where no correlation between immunoblot data and infectivity was observed, one of 
which was shown to induce a complete reduction in infectivity but no effect on PrP
res in the 
Western blot (Fichet et al., 2004). 
  Although Thioflavin T amyloid labelling clearly displayed a greater degree of 
sensitivity over surface Western blot studies, only Western blot data carried out in 
suspension correlated, in all treatment cases, with infectivity in the animal bioassay. 
Analysis of fluorescently labelled amyloid on the wires demonstrates correlation with 
infectivity in only two out of four cases (Enzymatic 3 and 4). Retrospective correlation of 
Enzymatic 1 analysis with previously published infectivity data for this treatment also 
demonstrated an association between in situ amyloid and infectivity (Yan et al., 2004). 
Whilst Enzymatic 5 was not available for evaluation using the animal bioassay, it is 
hypothesised that, given its relatively lower removal of prion associated amyloid in 
comparison with the other treatments and its lipase based enzymatic activity, a full rate of 
transmission of disease would be expected. In the case of Enzymatic 2, complete removal 
of detectable amyloid was demonstrated in the presence of infectivity and without 
degradation of PrP
res. Interestingly, this occurred with relatively little removal of general 
protein from the wires when compared with untreated controls suggesting that rather than 
an unlikely preferential removal of amyloid, treatment disrupted amyloid fibre stability 
with separation into monomers or concentrations below the detection limit of Thioflavin T. 
In contrast, Alkaline 1 treatment resulted in an absence of transmissible disease with an 
estimated 5.1 pg/mm
2 of residual prion associated amyloid on the wires. Previous studies 
using this alkaline detergent have also demonstrated a removal of infectivity from the 
wires in parallel with the presence of a proteinase K sensitive form of PrP
res (Fichet et al., 
2004). Given the correlation of suspension Western blots with infectivity, this suggests that 
the in situ methods of detection used within this study are either too insensitive (surface 
immunoblots) or do not label the infectious agent, in the case of Thioflavin T detection of 
amyloid. The latter finding is in agreement with studies indicating that mice expressing PrP 
lacking the GPI anchor demonstrated dense accumulations of amyloid plaques in the brain 
and extraneural tissues, including the heart, accompanied by minimal clinical 
manifestations (Chesebro et al., 2005). The blood and cardiac tissue of these GPI 
anchorless transgenic mice has been shown to induce scrapie disease in wild type mice     127   
(Trifilo et al., 2006). This is also replicated in a case of GSS whereby brain tissue 
demonstrated no spongiform degeneration and subsequent inoculation of the brain 
homogenate into transgenic mice resulted in striking amyloid deposition in the absence of 
disease (Piccardo et al., 2007).  
 
6.4.2. Correlation of Structural Alterations in PrP
res and Infectivity 
 
  Due to the correlation of suspension Western blots with infectivity, further studies 
attempted to detect a relationship between the presence or absence of prion epitopes and 
infectivity. This was performed using six different primary antibodies targeted to distinct 
regions of the prion protein following various decontamination treatments. The N  and C 
terminals were labelled using Bar 210 and Pri 917 respectively. The octapeptide repeat 
region was identified using the antibody SAF 37 and three antibodies were chosen to label 
the central core: SHA 31 (residues 145 152) encompassing the H1 region, SAF 60 
(residues 157 161) and SAF 70 (residues 156 162). Both SAF 60 and SAF 70 are targeted 
to similar amino acid residues of PrP
res. Interestingly, following treatment with Alkali 1, 
the SAF 60 binding region appears more sensitive to PK degradation relative to SAF 70 
with the opposite observed following treatment with    Phenolic 1. This suggests variable 
detection capabilities of the prion protein by Western blot analysis, dependent on the 
antibody and decontamination method. 
  Infectivity data from the animal bioassay, shown in Table 11, demonstrates a 
complete removal of infectivity following treatment with Alkali 1. Complete transmission 
of disease was observed in all animals following Enzymatic 2 and Enzymatic 3 treatment, 
with a corresponding 1 and 3.5 log reduction in infectivity, respectively. Enzymatic 1 has 
shown full transmission of disease and previously published infectivity data by 
collaborators indicates no transmissible disease following Phenolic 1 and NaOH treatment 
(Fichet et al., 2004; Yan et al., 2004). Conversely, Phenolic 2 has demonstrated full 
transmission of disease in the animal model and is four to five fold less effective than 
Phenolic 1 (Race & Raymond, 2004).   
Comparisons with infectivity and structural degradation of PrP
res suggest a distinct 
lack of correlation between the two. Western blotting following Alkali 1 treatment 
indicates a removal of the N terminus residues 26 34 and the C terminus residues 216 221, 
identified by Bar 210 and Pri 917 respectively.  The OR region and central core residues 
are detectable using Western blot but are rendered PK sensitive. This is also observed in 
the early stages of NaOH degradation of PrP
res. Importantly, treatment with Phenolic 1, the 
only other chemical evaluated which demonstrated complete removal of infectious disease     128   
in the animal bioassay, demonstrated an almost complete degradation of the N terminal 
and OR region. However, a confounding factor in the conclusion that the N terminus is 
involved in infectious disease is the removal of this epitope following treatment with both 
Phenolic 2 and Enzymatic 3, two chemistries which have no effect on overall transmission 
rate, although Enzymatic 3 demonstrates a 3.5 log reduction in infectivity. Moreover, 
whilst the C terminus is also removed during Alkaline 1 and early NaOH exposure, it is 
detected by Pri 917 following treatment with Phenolic 1.  
Interestingly, despite a 100 % transmission rate, Phenolic 2 appears extremely 
effective at the decontamination of PrP
res when analysed by Western blot. With the 
exception of the H1 domain and C terminus, Phenolic 2 is capable of a significant 
reduction in all other epitopes relative to the untreated controls and other chemistries. The 
N terminus, OR region and central core residues identified by SAF 60 and SAF 70 are 
almost completely degraded by this chemistry allowing for highly misleading conclusions 
to be drawn on the effectiveness of this cleaner if taken separately from the infectivity data.  
  Critically, EDIC/EF data displayed in Figure 28 suggests that both Enzyme 1 and 3 
are efficient at removal of protein from a surface. Residual protein concentrations are 
comparable with those following treatment with Alkaline 1 implying that residual 
infectivity is largely a result of the direct action of the chemical on PrP
res, rather than 
removal from the surface. It remains possible that infectivity resides within other epitopes 
of the prion protein than are identified by the primary antibodies utilised in this study. 
Importantly however, the structural changes associated with the rendering of PrP
res highly 
PK sensitive by Alkaline 1 and NaOH treatment appear able to remove the capability of 
the prion protein to transmit disease. 
 
Correlation of methodologies has highlighted the lack of sensitivity of Western 
blotting where elution of sample material from a surface is carried out and the relative 
improved sensitivity of Thioflavin T detection by EDIC/EF against conventional Western 
blotting, in suspension or surface studies. However, this study has observed infectivity in 
the absence of detectable amyloid and, conversely, wire bound prion associated amyloid in 
the presence of transmissible disease. Interestingly, the former of these observations 
demonstrated a breakdown of amyloid by the enzymatic treatment but no effect on overall 
PrP
res and infectivity. This is perhaps of note to therapeutic interventions in the 
amyloidoses which target amyloid aggregates. As such, whilst amyloid, as detected by 
Thioflavin T and EDIC/EF, may be a more sensitive biomarker relative to PrP
res detection 
with Western blot, it appears less likely to correlate with infectivity than PrP
res and 
therefore can not be considered as a marker for infectious disease. Improving the     129   
sensitivity of fluorescent amyloid detection by Thioflavin T analogues such as BTA 1 
which demonstrate a fifty fold higher affinity for amyloid may provide better correlation 
with infectivity (Klunk et al., 2001; Klunk et al., 2003). Whilst this does not suggest that 
amyloid is not infectious in an untreated state it is clear that under conditions designed to 
break down and denature amyloid and PrP
res, the infectious agent is smaller than the 
detection capacity of Thioflavin T. This study can not rule out PrP
res as the infectious 
agent, given the correlation with suspension Western blot and infectivity. However, 
antibody mapping of the prion protein to identify epitopes associated with infectivity was 
inconclusive. Epitopes such as the C  and N terminus removed by NaOH and Alkali 1 
treatment, in addition to the OR region almost entirely removed by Phenolic 1,  were also 
absent following treatment by chemistries which displayed no effect on transmissible 
disease, such as Phenolic 2 or Enzymatic 3. Given the uncertainty over the infectious unit 
in prion disease, infectivity assessment using the animal bioassay remains the only 
guaranteed method of prion disease detection.  
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CHAPTER 7 
 
 
 
ISOLATION AND EVALUATION OF A THIAZOLE 
ANALOGUE FOR THE FLUORESCENT DETECTION  
OF PRION ASSOCIATED AMYLOID  
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7.1. INTRODUCTION 
 
Thioflavin  T  (ThT)  was  first  introduced  by  Vassar  and  Culling  (1959)  who 
demonstrated  enhanced  fluorescence  and  highly  specific  binding  of  the  cationic 
benzothiazole dye to amyloid in the kidney. Thioflavin T binding is a universal feature of 
all  amyloid  fibrils  and  consequently  it  has  been  utilised  in  fibril  formation  studies,  in 
addition to in vitro, in vivo and in situ imaging of the Aβ peptide and PrP among other 
amyloidotic, disease associated proteins (Ban et al., 2003; Colby et al., 2007; Klunk et al., 
2001; Lipscomb et al., 2007a; Mathis et al., 2003). 
Investigations  into  the  association  of  amyloid  fibres  and  Thioflavin  T  have 
suggested  a  specific  and  regular  binding  model,  with  studies  using  laser  confocal 
microscopy  detecting  a  consistent  pattern  of  emission  (Krebs  et  al.,  2005).  Further 
confocal microscopy work has indicated that ThT binds to fibrils with the long axes of 
both  fibril  and  dye  parallel  to  each  other,  indicating  that  binding  occurs  in  ‘channels’ 
formed by β sheet side chains which stretch the length of the structure (Groenning et al., 
2007;  Krebs  et  al.,  2005).  The  proximity  of  the  β sheet  side  chain  structures  when 
associated with Thioflavin T leads to steric interactions producing intense fluorescence 
when in a bound state. Fluorescence is associated with a large Stoke’s shift, with excitation 
at around 353nm and emission at 482nm (Lockhart et al., 2005). However, although the 
interaction with amyloid fibrils is specific, it occurs with varying efficiency (Krebs et al., 
2005). Moreover, ThT also possesses low lipophilicity. Structurally, Thioflavin T contains 
a hydrophobic terminal, with a dimethylamino group attached to a phenyl, linked to a 
benzothiazole containing the polar nitrogen and sulphur (Khurana et al., 2005) (Figure 33). 
Consequently,  the  compound  is  charged  at  physiological  pH  and  therefore  does  not 
traverse the blood brain barrier limiting its use as an in vivo fluorescent probe. This fact 
has also been attributed to the identification of ThT as a substrate for P glycoprotein, a 
member of the ABC transporter family of membrane proteins (Darghal et al., 2006). For 
this reason, ThT is generally considered as a potential pharmacophore for the development 
of further amyloid imaging agents (Klunk et al., 2001; Voropai et al., 2003). 
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BTA 1
Thioflavin T
 
Figure  33  Chemical  structure  of  Thioflavin  T  and  its  derivative  BTA 1.  Red  circles 
indicate  modified  or  removed  chemical  groups  of  BTA 1  relative  to  the  precursor 
Thioflavin T and the loss of the positive charge on the quaternary heterocylic nitrogen.  
 
The compound 2 (4’ Methyaminophenyl) Benzothiazole (BTA 1) is a relatively 
new derivative of Thioflavin T (Figure 33).  It is more lipophillic than its precursor due to 
a loss of the positive charge of the quaternary heterocylic nitrogen of the benzothiazolium 
group (Klunk et al., 2003). Relative to ThT, BTA 1 also demonstrates a fifty fold higher 
affinity for Aβ fibrils and amyloid plaques in post mortem AD and prion positive brain 
tissue, where the Ki of BTA 1 is equal to 20.2 ± 3 nm, relative to Thioflavin with a Ki of 
890 nM (Klunk et al., 2001; Klunk et al., 2003; Mathis et al., 2002; Mathis et al., 2003). 
Consequently, in this chapter, BTA 1 was assessed for its ability to fluorescently 
label prion associated amyloid using EDIC/EF and a staining protocol was optimised. In 
collaboration with the Department of Chemistry, University of Southampton, fourteen 
Thioflavin T analogues and twenty one BTA 1 analogues were synthesised. Evaluation of 
each analogue was performed, permitting isolation of a compound of interest for which 
further testing was undertaken.  
 
 
7.2. MATERIALS AND METHODS 
 
  The methodology for this section of work is described in Chapter 2. ME7 and 263K 
scrapie and naïve brain tissue sections were prepared as detailed in section 2.2.3. 
Optimisation of a fluorescent staining protocol for the thiazole derivative BTA 1 was 
performed. Subsequent to this work, analysis of a series of thiazole analogues was 
performed as described in 2.6.1. Following isolation of a compound known as 2 (4’     133   
Dimethylaminophenyl) 6 Methyloxybenzothiazole or 28d, further evaluation was 
undertaken as detailed in sections 2.6.2, 2.6.3 and 2.6.4. Visualisation and analysis was 
carried out using EDIC/EF (section 2.7 and 2.7.1). 
 
 
7.3. RESULTS  
 
7.3.1. Optimisation of a BTA 1 Protocol for the Fluorescent Labelling of Prion 
Associated Amyloid 
 
  The previously optimised protocol for the fluorescent labelling of prion associated 
amyloid by Thioflavin T was utilised as a starting methodology. Through personal 
correspondence with Professor W. Klunk, University of Pittsburgh, an initial 500  M stock 
solution was prepared in dimethyl sulfoxide (DMSO). Various exposure times and working 
concentrations were subsequently evaluated and assessed on hippocampal sections of ME7 
scrapie infected brains (Figure 34). A final exposure time of 45 min and a working 
concentration of 50 nM were chosen based on the clear identification of prion associated 
amyloid against surrounding tissue and relative to staining of naïve brain tissue sections 
(Figure 35). As a consequence of the lipophilic nature of BTA 1 the acetic acid rinse step, 
used to reduce non specific background staining by Thioflavin T, was removed from the 
protocol and a brief rinse in PBS was incorporated to remove excess BTA 1 solution.  
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a) b)
c) d)
a) b)
c) d)
 
Figure 34 Photomicrographs taken using EDIC/EF of ME7 scrapie infected tissue sections 
(n=6/concentration) fluorescently labelled with increasing concentrations of BTA 1: a) 500 
pM, b) 1 nM, c) 50 nM & d) 500  M. Arrows indicated prion associated amyloid deposits. 
Scale bar: 20  m. 
 
a) b)
c) d)
a) b)
c) d)
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e) f)
g) h)
e) f)
g) h)
 
Figure 35 Fluorescent labelling of prion associated amyloid deposits in ME7 scrapie 
infected brain [n=6; images a), b), c) & d)] and naïve brain sections [n=6; images e), f), g) 
& h)] utilising a BTA 1 concentration of 50 nM with an exposure time of 45 mins. Images 
a), c), e) & g) demonstrate EDIC/EF images with b), d), f) & h) displaying the 
corresponding surface plot. Arrows indicate areas of prion associated amyloid deposition.                  
Scale bar: 20  m. 
 
7.3.2. Screening of Thiazole Analogues for the Ability to Detect Amyloid in ME7 
Scrapie Infected Tissue 
 
Each analogue was assessed for their ability to fluorescently label prion associated 
amyloid in hippocampal sections of ME7 scrapie brain tissue. Amyloid was clearly visible 
in these sections following staining with both Thioflavin T and BTA 1 (Figure 36). 
Assessment was carried out in triplicate using the previously optimised protocols 
established for BTA 1 and Thioflavin T. Selection of the most suitable protocol was based 
on the structural relationship of the compound to either precursor.  
     136   
a) b)
c) d)
e) f)
a) b)
c) d)
e) f)
 
Figure 36 Prion associated amyloid deposits in ME7 [a), b), d) & e)] and naïve brain [c) & 
f)]  sections fluorescently labelled with Thioflavin T [n=6; images a), b) & c)] and BTA 1 
[n=6; images d), e) & f)]. Arrows indicate prion associated amyloid deposition.           
Scale bar: 20  m   
 
Each BTA 1 analogue was evaluated at both 100 nM and 50 nM working 
concentrations. An arbitrary score was attributed to each analogue by four volunteers as a 
measure of the compounds ability to bind to and identify amyloid from naïve brain tissue 
relative to their structural precursor in regions of the brain known to display large 
concentrations of plaque deposition (Table 11 and Figure 37).  Representative images of 
several of the analogues applied to ME7 scrapie infected tissue are shown in Figure 38. 
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Table 12 Mean scores attributed to BTA 1 and Thioflavin T analogues  
assessing their ability to fluorescently label prion associated amyloid. 
 
 
 
 
 
 
aResponse to 340 – 380 nm excitation. 
bResponse to 405 – 455 nm  
excitation.
*indicates analogue was incompletely soluble in 0.1 M HCl 
 
BTA 1 analogues  Thioflavin T analogues 
Chemistry 
Assessment 
scores
a 
Chemistry 
Assessment 
scores
b 
BTA 1  ￿￿￿￿￿  Thioflavin T  ￿￿￿￿￿ 
28c   ￿  30a*  ￿ 
31d   ￿  31a  x 
28d   ￿￿￿￿  31b  ￿ 
30b  x  31c  ￿ 
33b  x  33a*  x 
33c  ￿  29e*  ￿￿ 
33d  x  28a  x 
42b  x  28b*  x 
41h  x  29d*  x 
43  x  29b*  x 
42c  x  29g  ￿ 
42a  ￿  29h*  x 
41c  ￿  29f  x 
41e  x  29c*  ￿ 
41a  ￿     
41d  x     
41g  x     
41f  x     
41i  x     
44  ￿     
41b  x         138   
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Figure 37 Graphical representation of the scored assessment of each thiazole analogue 
relative to their precursor upon staining of ME7 scrapie brain tissue sections 
(n=3/analogue). A score of 0 is equivalent to x and 5 = ￿￿￿￿￿. 
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a) b)
c) d)
e) f)
a) b)
c) d)
e) f)
a) a) b) b)
c) c) d) d)
e) e) f) f)
 
Figure 38 Representative photomicrographs of ME7 scrapie infected brain sections 
(n=3/analogue) fluorescently labelled with the thiazole analogues: a) 41d, b) 41g, c) 28d, 
d) 29e, e) 31b & f) 31a. White arrow indicate positive staining of prion amyloid in a tissue 
section. Red arrows indicate autofluorescent lipofucin. Scale bar: 20  m. 
 
Screening of the thiazole analogues identified a Thioflavin T and BTA 1 derivative, 
designated 29e and 28d, respectively, as compounds of interest. Comparison with naïve 
brain sections stained in parallel with ME7 tissue confirmed the remaining compounds as 
being ineffective amyloid fluorophores. Faint autofluorescent lipofucin, visible as gold and 
blue deposits approximately 2  m in diameter under BTA 1 and Thioflavin T EDIC/EF 
filters, respectively, was identified in both scrapie infected and naïve brain sections (Figure 
38). Further tissue section staining was performed using 29e and 28d analogues relative to     140   
their precursors. This permitted the exclusion of the Thioflavin T analogue 29e for 
subsequent analysis based on poor reproducibility of initial results, potentially due to its 
incomplete solubilisation in HCl (Table 11). Conversely, the analogue 2 (4’ 
Dimethylaminophenyl) 6 methyloxybenzothiazole or 28d demonstrated intense 
fluorescence upon binding to deposits morphologically similar to prion associated amyloid 
plaques at both 100 nM and 50 nM working concentrations.  
 
7.3.3. Analysis of the Binding Sensitivity of BTA 1 and 28d Using 
Immunohistochemistry 
 
To further assess the binding sensitivity of BTA 1 and 28d, both fluorophores were 
used to fluorescently label prion associated amyloid in 263K scrapie infected tissue 
sections. Their fluorescent signal upon binding to prion amyloid was overlaid with the 
primary antibody 6H4, recognising the prion protein amino acids 144 – 152, to confirm 
binding sensitivity. Negative controls performed in parallel with 263K scrapie infected 
tissue sections confirmed the loss of PrP
c through the three step degradation process (data 
not shown). 
Co localisation of fluorescent signal from both BTA 1 and 28d was observed. 
Moreover, the fluorescent signal from both fluorophores was demonstrated to overlap with 
that of both diffuse and more concentrated prion associated amyloid identified by 6H4 
(Figure 39).  
 
7.3.4. Analysis of 28d Binding Specificity Using EDIC/EF 
 
  Analysis of 28d binding specificity was performed. Positive, amyloid plaque bound 
fluorescence of both BTA 1 and 28d (n=10/compound) was analysed against the 
fluorescence upon binding to naïve brain tissue. Amyloid plaques of similar dimensions 
were selected and analysis performed at a constant exposure. A high signal to background 
ratio corresponded to a greater difference between positive, amyloid bound and 
background fluorescence.  Consequently, a degree of specificity for each compound can be 
calculated. 
Data obtained suggest that 28d demonstrates a greater specificity for prion 
associated amyloid relative to BTA 1 as a result of a larger difference between 
fluorescently labelled prion associated amyloid plaques and naïve brain tissue (Figure 40). 
Statistical analysis suggests a significant difference between the two data means               
(P = 0.0015) at the 95% confidence level.  
 
 
1
4
1
 
 
 
a
)
b
)
c
)
d
)
e
)
f
)
g
)
h
)
i
)
a
)
b
)
c
)
d
)
e
)
f
)
g
)
h
)
i
)
 
F
i
g
u
r
e
 
3
9
 
P
h
o
t
o
m
i
c
r
o
g
r
a
p
h
s
 
i
n
d
i
c
a
t
i
n
g
 
t
h
e
 
a
s
s
o
c
i
a
t
i
o
n
 
o
f
 
f
l
u
o
r
e
s
c
e
n
t
 
s
i
g
n
a
l
 
f
r
o
m
 
t
h
e
 
s
t
a
i
n
i
n
g
 
o
f
 
p
r
i
o
n
 
a
s
s
o
c
i
a
t
e
d
 
a
m
y
l
o
i
d
 
i
n
 
2
6
3
K
 
s
c
r
a
p
i
e
 
i
n
f
e
c
t
e
d
 
b
r
a
i
n
 
(
n
=
6
 
s
e
c
t
i
o
n
s
)
 
w
i
t
h
 
B
T
A
 
1
 
[
a
)
,
 
d
)
 
&
 
g
)
]
 
a
n
d
 
2
8
d
 
[
b
)
,
 
e
)
,
 
h
)
]
 
w
i
t
h
 
i
m
m
u
n
o
h
i
s
t
o
c
h
e
m
i
s
t
r
y
 
p
e
r
f
o
r
m
e
d
 
u
s
i
n
g
 
t
h
e
 
p
r
i
o
n
 
p
r
o
t
e
i
n
 
p
r
i
m
a
r
y
 
a
n
t
i
b
o
d
y
 
6
H
4
 
[
c
)
,
 
f
)
,
 
i
)
]
.
 
S
c
a
l
e
 
b
a
r
:
 
2
0
 
 
m
.    142   
Compound
BTA-1 28d
P
i
x
e
l
 
i
n
t
e
n
s
i
t
y
 
(
a
r
b
.
 
u
n
i
t
s
)
0
500
1000
1500
2000
 
Figure 40 Ratio of prion amyloid bound positive signal (n=10 amyloid plaques/staining 
procedure) to naïve tissue bound background intensity of the thiazole fluorophores BTA 1 and 
28d. 
 
7.3.5. Analysis of the Rate of Photobleaching of 28d Against BTA 1 
 
The rate of fluorescent signal loss or photobleaching was analysed. Amyloid plaques 
of similar dimensions were fluorescently labelled with either BTA 1 or 28d and the signal 
intensity was plotted at 10 sec intervals over a 10 min time course. A constant exposure was 
utilised throughout the experiment.  
Data suggest a significant increase in amyloid bound fluorescent signal stability 
relative to BTA 1 (Figure 41). The rate of fluorescent signal loss was markedly slower from 
amyloid plaques labelled with 28d comparative to BTA 1. At a time interval of 100 sec, 28d 
demonstrated an average signal intensity of 151.5 ± 3.4 relative to 96.7 ± 2.3 for BTA 1 at the 
same time period. This variation was demonstrated as statistically significant (P = 0.00177) at 
the 100 sec interval. However, at all time intervals, the plotted course of photobleaching was 
significantly different with an increased mean pixel intensity of amyloid bound 28d relative to 
BTA 1.   
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Figure 41 Loss of fluorescent signal intensity over a 10 minute time course for prion 
associated amyloid plaques (n=3/staining procedure) fluorescently labelled with either 28d or 
BTA 1.  
 
Significantly, both compounds displayed a comparable sigmoid pattern of fluorescent 
degradation. Critically, however, 28d demonstrates a much greater initial stability to signal 
degradation than BTA 1, resulting in a decreased overall rate of photobleaching. The 
fluorescent signal of 28d bound to amyloid is maintained at a constant level until 
approximately 40 sec, at which point the average fluorescent signal intensity of BTA 1 has 
decreased to 157.9 ± 2.02. 
   
 
7.4. DISCUSSION 
 
The amyloid flurophore 2 (4’ Methylaminophenyl) Benzothiazole or BTA 1 is a 
derivative of Thioflavin T. Studies have indicated that it possesses a high affinity for amyloid 
with high specificity towards amyloid plaques and neurofibrillary tangles in post mortem 
Alzheimer brain tissue and selectively binds amyloid in both murine and several human TSE     144   
strains (Ishikawa et al., 2004; Klunk et al., 2001; Klunk et al., 2003). Absence of the positive 
charge from the quaternary heterocylic nitrogen of the benzothiazolium group also results in 
efficient brain entry and passage through the blood brain barrier, unlike Thioflavin T. 
Consequently, BTA 1, when radio labelled with the positron emitting radionuclide carbon 11 
(
11C), represents a high quality tracer candidate for in vivo PET imaging (Klunk et al., 2003; 
Mathis et al., 2002; Neumaier et al., 2007). Furthermore, derivatives of BTA 1, such as N 
Methyl 
11C 2 (4' methylamino phenyl) 6 hydroxy benzothiazole
 (
11C 6 OH BTA 1; also 
known as "Pittsburgh Compound B" or 
11C PIB), have also demonstrated promising in vivo 
PET results in Alzheimer’s disease (Butters et al., 2008; Drzezga et al., 2008; Ng et al., 2007; 
Scheinin et al., 2007). Further studies into amyloid detection using compounds such as BTA 1 
and 
11C PIB may aid in the early diagnosis of Alzheimer’s disease, which is consequently 
critical for treatment considerations and disease management. In prion disease, amyloid 
fluorophores such as BTA 1 also possess the capacity to inhibit PrP
res formation in cellular 
models of TSE (Ishikawa et al., 2004). Whilst BTA 1 had no effect on disease course in 263K 
or Rocky Mountain Laboratory (RML) in vivo rodent models, intravenous injection of 1 mg of 
the Congo red derivative (trans, trans), 1 Bromo 2,5 bis (3 hydroxycarbonyl 4 
hydroxy)styrylbenzene
 (BSB) prolonged the incubation period in RML mice by 14 %. These 
data suggest that amyloid imaging probes may provide significant advances in in vitro and in 
vivo detection, in addition to therapeutic benefits in prion diseases and the amyloidoses.  
This study assessed the ability of thirty five analogues of Thioflavin T and BTA 1 to 
fluorescently label prion associated amyloid in vitro using the previously optimised protocol 
for their precursor. Initial study of the thiazole analogues was constrained by the total volume 
of each compound synthesised. However, the BTA 1 analogue 2 (4’ Dimethylaminophenyl) 
6 methyloxybenzothiazol or 28d was selected for further evaluation based on the compounds 
ability to identify amyloid in ME7 scrapie infected brain tissue. Structurally, 28d can be 
separated from BTA 1 due to the addition of a methoxyl group on the first ring and a methyl 
group, replacing a hydrogen atom, on the amine group (Figure 42). Interestingly, 28d also 
shares structural similarities with 
11C PIB (Ng et al., 2007).  
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Figure 42 Chemical structure of 28d relative to BTA 1 (inset). Red circles indicate structural 
changes associated with 28d relative to BTA 1. 
 
  Common to the thiazole compounds, 28d possesses an intact three ring structure. No 
functionality was observed in compounds where the three ring structure was disturbed such as 
30b or 31d, the latter possessing an identical empirical formula to 28d but structurally lacking 
a complete second ring. Compounds such as 28d, 
11C PIB and BTA 1 lack the positive charge 
of the quaternary heterocyclic nitrogen observed in Thioflavin T. Therefore, it can be assumed 
that loss of this charge is beneficial to the compound in terms of sensitivity and/or specificity, 
or at least has no positive effect in addition to permitting greater blood brain barrier 
permeability as previously described. Moreover, compounds displaying a greater structural 
divergence from that of BTA 1 were ineffective. The structural similarities between 28d and 
11C PIB suggest optimisation of the thiazole group of fluorescent amyloid labelling 
compounds is likely to lie close to that of BTA 1. As such, 28d may represent an optimised 
chemical structure for the thiazoles.  
Further analysis of 28d was performed to confirm the sensitivity of BTA 1 and 28d for 
amyloid. Positive fluorescent staining was overlayed with immunohistochemical labelled 
PrP
res using the primary antibody 6H4. A strong association was observed between 28d and 
BTA 1 fluorescence. Moreover, intense fluorescent signal, clearly distinguishable from 
surrounding tissue, strongly correlated with diffuse and concentrated PrP
res deposition as 
identified by 6H4. This suggests that the alteration in chemical structure of 28d from its 
precursor BTA 1 had no effect on the labelling of PrP
res. Data also demonstrate several 
advantageous features of 28d over its precursor. Firstly, positive, PrP
res fluorescence intensity 
was assessed relative to naïve tissue signal for both BTA 1 and 28d as a measure of compound 
specificity. The analogue 28d demonstrated a significantly greater difference in positively 
bound fluorescence compared with background fluorescence. Although this appeared to be a     146   
result of a reduction in background fluorescence rather than an increase in binding to amyloid, 
it is not clear whether this difference may be due to a reduction in binding to naïve tissue or as 
a result of a lower degree of fluorescence upon attachment compared to BTA 1. Moreover, 
28d also demonstrated greater signal stability relative to BTA 1. An important issue with 
regards to thiazole staining is the rate of signal degeneration which can be a major 
disadvantage compared to immunohistochemistry. With respect to its precursor Thioflavin T, 
BTA 1 is less stable under fluorescent light and any thiazole synthesis should aim to develop 
compounds with a slower rate of photobleaching. Conversely, 28d demonstrated a slower rate 
of fluorescent signal degradation over a 10 minute time course. At a 4 min time interval, the 
fluorescent signal of BTA 1 bound to PrP
res was indistinguishable from background 
fluorescence in contrast to 28d which was clearly visible. Critically, both BTA 1 and 28d 
display a weakening of signal through a similar path with an initial resistance to signal 
degeneration followed by a rapid loss of signal intensity which eventually begins to plateau 
after 3 minutes. However, 28d benefits from an increased stability when first exposed to 
fluorescent light which slows the time course of fluorescent signal degradation. 
  The implications for the identification of a novel thiazole compound capable of 
sensitively and specifically labelling prion associated amyloid range beyond in vitro 
identification and the prion diseases. Similarities in the morphology of amyloid fibrils and the 
universal high β sheet content common to all amyloid means that fluorophores are applicable 
and transferable between many of the amyloidoses such as prion, Alzheimer’s, Parkinson’s 
and Huntington’s disease, unlike immunohistochemical techniques (Merlini & Bellotti, 2003). 
Moreover, techniques such as PET utilise amyloid fluorophores for in vivo detection in 
Alzheimer’s disease and may be applicable to other diseases where amyloid deposition is a 
common event in the CNS or extraneural tissues. Data also suggest a potential therapeutic 
application for thiazole analogues (Ishikawa et al., 2004; Ishikawa et al., 2006). 
Unfortunately, evaluation of potential therapeutic benefit was beyond the scope of this study 
despite initial aims to perform such experiments. However, crucially, 28d represents a highly 
promising compound which may further enhance both in vitro and in vivo detection of 
amyloid disease. Preliminary evaluation suggests 28d to be both highly sensitive and specific 
for prion associated amyloid and a more stable fluorophore, relative to BTA 1. Further tests 
are required to establish binding affinity data, brain permeability and toxicity. However, 28d 
represents a novel compound with potential as a therapeutic and in vivo imaging probe, in 
addition to increasing in vitro amyloid detection which may better correlate with infectivity in 
prion disease.     147   
 
 
 
 
 
 
 
 
CHAPTER 8 
 
 
 
FINAL DISCUSSION AND FUTURE WORK 
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  This project was undertaken in order to improve methods of instrument 
decontamination in light of the risk of iatrogenic transmission of CJD to patients undergoing 
surgical procedures. Specifically, this project aimed to assess current decontamination 
procedures rather than the development of novel technologies or chemistries. It remained 
critical throughout this work that results and conclusions, as a consequence of these studies, 
were both applicable and translational to prion decontamination in an SSD setting.  
  An evaluation of current hospital decontamination procedures suggested that a 
significant concentration of proteinaceous contamination was accumulating on surgical 
instruments over their life cycle. Previous studies have also demonstrated significant residual 
contamination on surgical devices at the point of use (Lipscomb et al., 2006a; Lipscomb et al., 
2006b; Murdoch et al., 2006; Smith et al., 2005). However, these studies did not evaluate the 
effectiveness of the preceding decontamination process which is the most likely rationale for 
heavily soiled instruments. In this case, the cleaning and sterilisation procedure was confirmed 
as highly effective suggesting that instrument surface integrity is critical to the success of 
decontamination. As such it is clear that a standardised instrument life cycle must be 
employed across all SSDs whereby instruments of a certain age are withdrawn from 
circulation prior to the accumulation of significant levels of surface damage and 
contamination. This would significantly decrease the risk to a patient undergoing surgery due 
to instrument breakage or heavy soiling. However, this study also identified an exogenous 
source of proteinaceous instrument contamination other than that acquired during surgery. 
Handling by staff within the clean room during instrument inspection was demonstrated to 
apply significant concentrations of protein onto the surface of surgical instruments, which is 
then fixed to the surface through high temperature autoclave treatment (Howlin et al., 2009; 
Appendix B). Whilst this protein is unlikely to cause a direct risk to patient health itself, it will 
have an impact on the efficiency of subsequent decontamination processes over time. 
Critically, this work strongly suggests that gloves must be employed throughout all SSDs for 
staff handling instruments in order to remove this source of unnecessary contamination.  
  For the laboratory assessment of prion decontamination Chapter 4 utilised simulated 
washer disinfector cycles. The data generated highlights the importance of the analysis of 
entire decontamination cycles rather than individual chemistries (Howlin et al., 2010; 
Appendix C). Whilst infectivity assays were not available for the study, this new protocol for 
the analysis of decontamination techniques can be utilised with the animal bioassay as it 
employs the same carrier surface as standard methods for the evaluation of prion infectivity 
(Fichet et al., 2004; Fichet et al., 2007b; Fichet et al., 2007c; Jackson et al., 2005; Peretz et     149   
al., 2006).  Moreover, it suggests that current decontamination methods, combined with the 
prevention of soil drying, represent the best safe guard against iatrogenic CJD transmission, 
which is in agreement with other reports (Fichet et al., 2007a). However, stringent validation 
procedures are required and it is proposed that these utilise rapid and highly sensitive 
techniques, such as EDIC/EF analysis, rather than current methods, such as the Ninhydrin 
tests, which are clearly too insensitive (Lipscomb et al., 2006a). 
  As a consequence of the association of instrument surface scarring with protein 
contamination, it was proposed that infectivity assays should better represent a worst case 
scenario of surface contamination. Consequently, stainless steel wires were degraded with 
sodium hydroxide treatment prior to inoculation and implantation into the rodent host. This 
produced a surface which was demonstrated to be heavily scarred and damaged relative to 
standard stainless steel wires, adding to reports on the poor compatibility of WHO 
recommended guidelines with stainless steel instruments (Brown et al., 2005). Analysis of the 
degree of surface attachment of a 10 % (w/v) scrapie infected brain homogenate by EDIC/EF 
and the dual stain method suggested a significantly higher concentration of non amyloid, 
proteinaceous contamination bound to the degraded surface, compared with standard wires. 
Critically, therefore, this adjusted carrier surface does indeed represent a worst case scenario 
of surface contamination. This is important, as the wire implant model can not reproduce the 
complexity of an instrument surface. As such, the more difficult surface contamination and 
removal is made for a decontamination process, the more translational the conclusions about 
the efficacy of a given chemistry are for the SSDs. It is hoped that advances in cell culture 
techniques may permit more complex surfaces to be introduced into infectivity studies 
(Edgeworth et al. 2009). However, this draw back in the methodology of the animal bioassay 
is counter acted by the fact that the wires are left in situ, embedded in the CNS of the rodents 
throughout the experiment which may last up to a year, therefore prolonging the exposure 
surrounding tissue to the potentially infected surface. This is in contrast to the relatively brief 
contact patient tissues have with instruments during surgery and, consequently, prion material 
bound to the wire surface can be confirmed as fully inactivated or removed. Interestingly, 
initial results suggest that a degraded surface may possess the capacity to extend disease 
incubation time. Previous data on the reproducibility of this animal model argue against an 
inherent variability in the test method (Fichet et al., 2007c). It is possible that the extended 
incubation time is a consequence of the increase in surrounding proteinaceous contamination, 
thereby reducing contact of the infectious agent to surrounding host tissues. Whilst the 
prolonged incubation period was only statistically significant in one case, it can be assumed     150   
that this may be a consequence of either the lack of complexity of the wire surface or 
potentially that the extent of the initial degradation of the surface was not sufficient to exert 
maximal effects. It is proposed that subsequent experiments be undertaken to confirm these 
initial findings, whereby the wire surface is exposed to multiple treatments with sodium 
hydroxide to observe whether further degradation can extend incubation periods.  
  In order to improve methods of prion decontamination, this project also aimed to 
critically assess the assays used to evaluate and confirm the efficacy of prion inactivation and 
removal. Routinely, these involve identification of PrP
res by Western blot and infectivity using 
the animal bioassay. The newly developed EDIC/EF dual stain to identify both total protein 
and prion associated amyloid as a disease marker has demonstrated increased sensitivity 
relative to Western blot in both this project and published studies (Hervè et al., 2009; 
Lipscomb et al., 2007a). However, uncertainty over the size and nature of the infectious agent 
in prion diseases creates significant doubt over the validity of methods used to identify and 
evaluate decontamination processes. Sufficient data exists to suggest that infectivity associates 
with mature amyloid, PrP
res and smaller β oligomers to varying degrees (Castilla et al., 2005a; 
Novitskaya et al., 2007; Redecke et al., 2007; Silveira et al., 2005). This project represents the 
first assessment of the identification methods used to assess prion decontamination techniques, 
as well as the first correlation of the EDIC/EF dual stain with infectivity. Surface Western 
blots demonstrated, not only a reduced sensitivity relative to EDIC/EF amyloid detection, but 
also poor correlation with infectivity, which has also been demonstrated in other studies 
(Fichet et al., 2004). Importantly, whilst the EDIC/EF dual stain displayed increased 
sensitivity for prion identification, relative to both surface and suspension Western blot, only 
the Western blots carried out in suspension demonstrated a 100 % correlation with infectious 
disease. Consequently, whilst EDIC/EF detection of amyloid is more sensitive that Western 
blot detection of PrP
res, the latter method is more specific for infectious disease. However, 
given the capacity of Thioflavin T to detect oligomeric molecules in both prion and 
Alzheimer’s Disease it is likely that a significant degree of infectivity resides within these 
protein sub species (Maezawa et al., 2008; Simoneau et al., 2007).  
Given the close association of suspension Western blots with infectivity, further 
evaluation was performed to identify a correlation between structural alteration in PrP
res with 
infectivity. Primary antibodies were targetted to the N  and C terminals of the prion protein, 
the OR region, with several directed to the central core of the prion protein; one encompassing 
Helix 1 which has previously been identified as a potentially important structure in the prion 
conversion process (Vorberg et al., 2001). However, none of the six epitopes demonstrated     151   
any link with infectious disease. This could be due to several reasons. Firstly, the 
decontamination process may have removed or modified the antibody binding epitope. 
Secondly, smaller structural changes may be sufficient to remove the capacity of the prion 
protein to transmit disease. Both the NaOH and Alkaline 1 treatment rendered both the OR 
region and central core residues PK sensitive which may also affect the ability of the protein 
to transmit disease. Thirdly, it can not be excluded that infectivity resides within another 
epitope or, potentially, a smaller oligomeric PrP molecule undetected by Western blot 
analysis. However, it is clear that both EDIC/EF detection of amyloid and Western blot 
identification of PrP
res are not sufficient to confirm removal of the infectious agent alone and 
that they must be performed in combination with animal bioassays.  
The final chapter of this project focused on the evaluation of other amyloid 
fluorophores in an effort to improve the sensitivity and specificity of EDIC/EF dual stain, and 
therefore improve in situ detection of prions. Previous reports have demonstrated the increased 
sensitivity of BTA 1 relative to its precursor Thioflavin T (Mathis et al., 2002; Mathis et al., 
2003). A BTA 1 protocol for the fluorescent detection of prion associated amyloid has been 
optimised. Moreover, this project has isolated an entirely novel fluorphore, designated 28d, 
which demonstrates enhanced specificity and a slower rate of photobleaching relative to  
BTA 1. Work is underway to develop an EDIC/EF dual stain incorporating both BTA 1 or 
28d to improve the sensitivity of detection. However, additional work is required to further 
evaluate this novel compound. In addition to improving the in vitro and in situ detection of 
amyloid using fluorescent microscope techniques, these compounds have the capacity to 
replace existing compounds such as Thioflavin T in fibril formation studies and enhance in 
vivo PET imaging thereby improving their sensitivity. Moreover, amyloid flurophores have 
also been demonstrated to posses therapeutic effects in prion disease (Ishikawa et al., 2004). It 
is hoped that 28d can be evaluated in future studies to assess its potential therapeutic effect to 
attenuate the onset of clinical symptoms upon treatment at several time points post infection.  
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OVERVIEW OF THE ROUTES OF SYSNTHESIS AND CHEMICAL STRUCTURES 
OF THIOFLAVIN T AND BTA 1 ANALOGUES 
 
Two general routes of synthesis were utilized in this study. The choice of method was 
influenced by the availability of starting materials and the desired final product. The first of 
these is shown in Figure 43 and the resultant products shown in Table 12. 
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Figure 43 Route utilised in the synthesis of thiazole analogues 
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Table  13  Melting  point  and  yield  for  thiazole  analogues  and  several  intermediary 
precursors synthesised by the route described in Figure 43. 
Compound  R  R’  Melting point (°C)  Yield (%) 
30a 
α  CH3  N(CH3)2  152 153  84 
30b 
α  CH3  OCH3  142 146  68 
30c 
α  CH3  Br     89 
30d 
α  OCH3  N(CH3)2  178 179  66 
31a 
β  CH3  N(CH3)2     38 
31b 
γ  CH3  OCH3     77 
31c 
δ  CH3  Br  180 185  90 
31d 
δ  OCH3  N(CH3)2     87 
28a 
α  CH3  N(CH3)2  202 204  82 
28b
 α  CH3  OCH3  161 165  68 
28c
 α  CH3  Br  194 197  63 
28d
 α  OCH3  N(CH3)2  168 171  46 
33a 
α  H  N(CH3)2  170 172  75 
33b
 α  H  OCH3  100 102  62 
33c
 α  H  Br  110 113  51 
33d
 α  Br  H  110 113  56 
29b
 ε  CH3  OCH3  207 208  76 
29c
 ε  CH3  Br  212 213  37 
29d
 ε  OCH3  N(CH3)2  179 180  29 
29e
 ε  H  N(CH3)2  +250  78 
29f
 ε  H  OCH3  186 189  68 
29g
 ε  H  Br  204 207  27 
29h
 ε  Br  H  204 207  35 
α = recrystallised from hot MeOH.; β = columned in EtoAc/Hex (30%).; γ = pure product 
precipitated from solution.; δ = product precipitated from solution.; ε = recrystallised from hot 
CHCl3. 
 
In addition, the synthesis of a series of compounds was performed by an alternative 
route using the method demonstrated in Figure 44 and the products are listed in Table 13. 
Here, the chain between the second and third aromatic ring was varied, introducing a variety 
of chemical groups.      193   
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Figure 44 An additional route for the synthesis of a series of thiazole analogues 
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Table  14  Compound  and  corresponding  melting  points  of  thiazole  analogues  and 
intermediary precursors synthesised by the route described in Figure 44. 
Compound  R  R’  R’’  Melting point (
oC) 
41a  CH3  N(CH3)2  H  182 188 
41b  CH3  Br  H  +250 
41c  O(CH3)  N(CH3)2  H  186 193 
41d  H  N(CH3)2  H  207 208 
41e  CH3  N(CH3)2  Br  160 167 
41f  H  Br  H  227 230 
41g  H  OCH3  H  156 160 
41h           128 
41i  CH3  OCH3  H  206 210 
42a  H  N(CH3)2  H    
42b  CH3  NH2  H  +250 
42c  OCH3  N(CH3)2  H  207 208 
42d  H  40  H  118 120 
43  CH3  S(O)2Ph  H  +250 
44  CH3  N(CH3)2  Br  121 122 
 
All reactions proceeded as predicted with the exception of one which generated an unexpected 
compound.  The  coupling  of  40  (see  Figure  44)  to  dimethyamino  benzoic  acid  using 
benzotriazol 1 yl oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) as a coupling 
reagent resulted in the synthesis of 41h possibly due to the strong affinity between the two 
compounds (Figure 45). 
N
N
N
O
O
N
41h  
Figure  45  Product  from  attempted  coupling  of  dimethylamino  benzoic  acid  and  amino 
benzothiazole using PyBOP. 
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